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AbStract 
A modified Ellman method using acetylthiocholine as substrata has 
been used to reliably measure erythrocyte AChE activity (CV=7%). 
Reliable immunological quantitation of this enzyme (CV=7%) was 
achieved using monoclonal antisera to AChE (AE-1 and AE-2) in a 
fluid phase homogeneous enzyme-linked antiglobulin test (ELAT). 
AChE activity and antigen levels were similar for both adult male 
and female samples. Cord samples at term measured 60% of the 
adult value and reached lOO% within 5 months. 
An overall increase in AChE activity was observed as pregnancy 
progresses with patients 1 to 3 days post delivery showing 
significantly elevated levels of activity and antigen. 
Investigation of haematological disorders revealed cases of 
reduced levels of activity and antigen in a variety of 
conditions. 
An essay of plasma ChE activity using butyrylthiocholine as 
substrata has been developed using a microplate Ellman technique 
(CV=S%). An enzyme linked immunosorbent method (ELISA) using 
monoclonal antibodies MAb2-l and 2-4 (CV=S%) provided a sensitive 
and reliable means of quantitation together with the capability 
of handling a large number of samples. 
Normal Gaussian distribution curves were obtained for both 
activity and antigen levels for E~uE 1 u, E1uE1a and E1aE 8a individual~. The approximate amount that each of the genes E1 , E1a and E~ contribute to the ChE activity and antigen levels is presented allowing the effective efficiency (EE) of the gene 
product to be calculated. Immunological measurements have aided 
in the segregation of the silent gene variants representing zero, 
very low, low and high levels of immunoreactive protein and the 
identification of a new gene, E1x. Family studies have confirmed 
the existence of this gene. Anal~sis of activity and 
immunological data suggest that the E1 and E1t gene could be identical. 
A significant decrease in ChE activity occurs during pregnancy 
with even lower levels presenting during the first 2 to 3 days 
post delivery. Immunological measurements indicate similar 
reductions in the amount of ChE protein during these periods. 
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Introduction 
Hunt and Taveaux (1906) produced evidence for the involvement 
of acetylcholine (ACh) and other choline esters in 
neurotransmission and Dale (1914) proposed that ACh was rapidly 
split into acetic acid and choline by an esterase. The enzyme 
found in horse serum (Stedman et al., 1932) was called 
cholinesterase and was later identified in particulate form 
within the erythrocyte membrane (Stedman and Stedman, 1935). 
Alles and Hawes (1940) indicated that the serum and cell enzymes 
from human blood were qualitatively different. The serum enzyme 
hydrolyses butyrylcholine or propionylcholine faster than 
acetylcholine, whereas the cell bound enzyme preferentially acts 
on acetylcholine at low substrate concentration ( Mendel and 
Rudney, 1943). The serum enzyme was originally called 
'nonspecific' or 'pseudocholinesterase' while the erythrocyte 
membrane was believed to contain the specific or true 
cholinesterase, the latter being the same type of enzyme as 
present in nerve and muscle tissue (Nachmansohn and Rothenberg, 
1945), Augustinsson and Nachmansohn (1949) introduced the term 
acetylcholinesterase (AChE) for this enzyme and restricted the 
term cholinesterase (ChE) to the 'nonspecific' enzyme, also 
referred to as butyrylcholinesterase, propionylcholinesterase or 
plasma cholinesterase. 
The Enzyme Commission have given AChE and ChE the systematic 
names acetylcholine acetylhydrolase (E.C. 3.1.1.7.) and 
acylcholine acylhydrolase (E.C. 3.1.1.8.) respectively. 
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Erythrocyte Acetylcholinesterase 
Although, AChE was first detected in the human erythrocyte in 
1928 (Galehr and Plattner, 1928) its function in red cells 
remains unclear. The enzyme is also found in platelets (Zajicek, 
1957), lymphocytes (Szelenyi et al., 1982) and possibly 
granulocytes (Zajicek, 1957). 
Approximately 13% of AChE from the human erythrocyte consists 
of carbohydrate (Niday et al., 1977). This corresponds to a 
carbohydrate/protein ratio of 0.16 with glucose (22%), galactose 
(38%), mannose (11%), glucosamine (16%), galactosamine (11%) and 
sialic acid (2%) as the sugar components. 
Lipid, phosphorus and fatty acid analysis indicate 
phosphatidylserine and cholesterol as the major lipid components. 
Roberts and Rosenberry (1985) demonstrated that red cell AChE 
contains at least 10 different fatty acids, the majority (70%) 
present in the hydrophobic domain. Palmitate (16:0) is the most 
abundant (37%) with stearate (18:0) (11%), oleate (18:1) (12%), 
docosatetraenoate (22:4) (14%) anddocosapentaenoate (22:5) (10%) 
as the other major constituents. Two moles of fatty acid are 
present per mole of catalytic subunit with saturated and 
unsaturated fatty acids present in equimolar amounts. 
Human erythrocyte AChE is characterized by the presence of all 
the common amino-acids (Table.!). The N-terminal amino acid is 
blocked. Chhajlani et al. (1989) have analysed five tryptic 
peptides to determine the amino acid sequences. These showed no 
homology to those for human serum and brain butyrylcholinesterase 
or Torpedo californica acetylcholinesterase. 
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Figure 1 Diagrammatic representation of AChE 
from human erythrocyte membranes anchored in 
the lipid bilayer (Weitz et al., 1984). 
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Table 1 Amino Acid Composition of Human Serum Cholinesterase 
and Human Erythrocyte Acetylcholinesterase 
Amino Acid Percentage 
AChE1 
Alanine 9.7 
Arginine 6.8 
Aspartic acid 7.4 
Cysteine 1.0 
Glutamic acid 9.7 
Glycine 9.9 
Histidine 2.3 
Isoleucine 2.1 
Leucine 10.1 
Lysine 1.7 
Methionine 2.2 
Phenylalanine 4.9 
Proline 7.8 
Serine 5.8 
Threonine 4.5 
Tryptophan 1.9 
Tyrosine 3.4 
Valine 8.6 
1 Rosenberry and Scoggin (1984) 
2 Lockridge et al. (1987) 
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of total Amino Acids 
ChE2 
5.9 
4.0 
4.2 
1.4 
6.4 
8.0 
1.4 
4.7 
8.7 
6.1 
1.9 
6.8 
5.2 
6.4 
6.1 
3. 1 
3. 5 
5.6 
Structure 
The enzyme is an integral part of the red cell membrane 
extending to the outside surface (Heller and Hanahan, 1972). 
This was confirmed by the agglutination of human red cells by 
monospecific antiserum to AChE (Niday et al., 1977). The basic 
functional form is a dimer of molecular weight 160,000 containing 
a single intersubunit disulphide bond (Rosenberry and Scoggin, 
1984). Approximately 700-800 AChE dimers per erythrocyte have 
been estimated, corresponding to 40pg/ml of membrane volume (Ott 
et al., 1982). 
Erythrocyte AChE is a globular protein (G2) (fig.1). It has a 
high lateral mobility within the membrane and shows little or no 
interaction with the cytoskeletal network (Weitz et al., 1982). 
It is an amphipathic protein, each subunit having a large 
hydrophilic domain orientated towards the outside of the membrane 
and a smaller hydrophobic domain (less than 10 kD) localized at 
the carboxy terminus anchoring the enzyme into the lipid bilayer 
of the red cell membrane (Dutta-Choudhury and Rosenberry, 1984). 
Evidence by Haas et al. ( 1986) indicated that the membrane-
binding domain is a covalently linked glycolipid at the C-
termini of the subunits and has the sequence HIS-GLY-
ethanolamine-Z, where ethanolamine is in amide linkage to glycine 
and Z is a partially characterized structure containing 
carbohydrate and fatty acids. The lack of hydrophobic amino acids 
indicate that other components are responsible for the 
hydrophobicity of the membrane-binding domain of red cell AChE. 
Virtually all of the fatty acids which are covalently linked to 
red cell AChE are localized in the hydrophobic domain fragment 
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and participate in the membrane attachment of the enzyme. The 
current structure proposed indicates that Z consists of 
phosphatidylinositol (Ptdins) which is attached via a glycosidic 
linkage to a glucosamine residue which is attached to an 
oligoglycan. This oligoglycan is linked to the ethanolamine 
residue. Studies have shown a reduced expression of Ptdins-
anchored proteins in the rare acquired haemolytic disorder 
paroxysmal nocturnal haemoglobinuria (PNH) (Low, 1987), 
EnzYme Activity 
AChE catalyzes the hydrolysis of acetylcholine to choline and 
acetic acid. 
( CH 3 ) 3N+C2H40-CO-CH3 + H20 -- > ( CH 3 ) 3WC2H40H + CH 3COOH 
acetylcholine choline acetic acid 
The interaction between ACh (Beveridge et al., 1971) and AChE 
(Nolte et al., 1980) is one between two highly polar reactants. 
However, extensive non-polar hydrophobic areas (Kabachnik et 
al., 1970; Narayanan and Balaram, 1981) channel the ACh molecules 
towards the active centre, which is comprised of an anionic and 
esteratic site. Once within range the electrostatic attraction 
between the onium head of ACh and the anionic site takes over 
resulting in their binding followed by interaction by hydrogen 
bonding of the ether-oxygen of ACh with the acid group of AChE 
(fig.2) (Beckett and Albadr, 1975). The nucleophilic serine 
residue at the esteratic site reacts covalently with ACh allowing 
hydrolysis to proceed. 
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Interaction with the anionic subsites of the active centre 
involves only two of the three N-methyl groups of ACh and 
possibly theN-methylene group as well (fig.2). The acid group 
of AChE is located 3-4A away from the centre of the anionic site 
in a three dimensional structure to which the ACh molecule can 
be attached (Ngiam and Go., 1987). Evidence has also been 
provided for the existence of peripheral anionic sites (P1, P2, 
P3 and P4) on AChE that may regulate activity at the catalytic 
site (Changeaux 1966). 
H 
CH:t ,._""- - ""'" 
\ 
•H H• 
.; . , 
,. / ... . ---- .. ' 
// /N"-. ... - ...... 
I ,,--~ .. , t'CHa ..... , 
' 
, CH3 / ... ,• 
\ . .,., - ~---'~--~- ---
' - , 
' 
' \ 
.; 
I , 
I 
AS 
Figure 2 Model 
(Ngiam and Go, 
is made up of 
acid group. 
of AChE/substrate interaction 
1987). AS= anionic site which 
three anionic subsi tes; AG = 
16 
Factors Affecting Erythrocyte AChE Activity 
Alterations in AChE activity have been noted to parallel 
changes in lipid content in human erythrocytes (Kamber et al., 
1984). There is a decrease in the cholesterol:phospholipid ratio 
as the cell ages and this is followed by a decrease in the 
activities of membrane bound enzymes, including AChE. 
AChE activity appears to be dependent on the surface pressure 
of the surrounding bilayer. Drugs have been shown to inhibit the 
activity of membrane-bound AChE. Lignocaine is a lipophilic local 
anaesthetic that reversibly inhibits AChE activity of erythrocyte 
membranes possibly by increasing the lipid fluidity of the 
membrane (Laity and Whittaker, 1971). 
Variation in Cellular Activity 
AChE has been studied in the erythroid cells of human bone 
marrow (Keyhani and Maigne, 1981). The enzyme has been found by 
a cytochemical method in human basophilic and polychromatophilic 
erythroblasts, in which it occurs in the nuclear membrane, 
endoplasmic reticulum and golgi structures. In more mature 
orthochromatophilic erythroblasts the enzyme was found only in 
the storage compartment (the golgi apparatus), suggesting the end 
of its biosynthesis at this stage of maturation. 
Reticulocytes which appear during the physiological response 
following acute blood loss have an elevated erythrocyte AChE 
activity while those present in pathological reticulocytosis 
occuring in leukaemia, Hodgkins disease, multiple myeloma and 
myelofibrosis, show decreased red blood cell AChE activity 
(Sabine, 1965). Reticulocytes of the former type contain 
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approximately three times as much AChE as mature erythrocytes 
with a progressive fall in enzyme activity with increasing age 
(Sabine, 1965). 
Burman (1960) recorded the mean cord blood AChE activity to 
be 53% of the adult mean which was in general agreement, although 
slightly lower than that reported by other workers (Sabine, 1955; 
Pritchard and Weismann, 1956). The adult blood level appears to 
be reached between 3 and 5 months of age. Lower levels of AChE 
in the neonates may be . explained by the phenomenon of stress 
reticul~cytosis, in which foetal erythropoiesis is accelerated 
close to term. It has been suggested that normoblasts 'skip' a 
generation, perhaps at the stage when most AChE is synthesized 
(Lawson and Barr, 1987). The possibility of accelerated enzyme 
inactivation has not been eliminated (Herz and Kaplan, 1973). 
Electrophoretic patterns of adult and cord red cell AChE 
indicate more anodal migration of the foetal band. Neuraminidase 
treatment, which removes sialic acid, reduces the migration of 
both adult and foetal enzymes, which become electrophoretically 
identical. This treatment however, did not influence the 
catalytic activity. The electrophoretic difference was confirmed 
by isoelectric focusing where the pi of the adult enzyme was 4.80 
while the foetal enzyme was 4.62 (Garre et al., 1980). The pi of 
cord and adult AChE following neuraminidase treatment was 5.67. 
These observations indicated that the amount of sialic acid in 
these bloods was not identical. 
AChE is also found on human T cells (Topilko and Caillou, 1985) 
and cultured human leukaemia/lymphoma cell lines (Ajmar et al., 
1983; Rubinstein et al., 1984). These observations aid the 
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characterization of lymphocytes, since B cells have no detectable 
AChE activity. 
In mice, AChE is a specific and early marker of the 
thrombocytic series and is a constituent of the platelet membrane 
(Paulus et al., 1981). The release of AChE, by maturing 
megakaryocytes and platelets, may establish a feedback inhibition 
loop whereby the level of acetylcholine available to precursor 
cells depends on megakaryocyte age and/or numbers. The level of 
AChE could therefore control megakaryocytopoeisis by a similar 
regulatory role in human erythropoiesis ( Keyhani and Maigne, 
1981). 
ErYthrocyte AChE in Clinical Conditions 
Shanor et al. (1961) reported no variation in erythrocyte AChE 
due to the age (after 3-5 months) or sex of an individual. 
However, AChE is increased in the red cells in hereditary 
spherocytosis, in which molecules appear more fully exposed at 
the cell surface, probably related to the physical state of the 
lipid environment (Frenkel et al., 1980; Streichman et al., 1983) 
and a change in the membrane surface pressure. 
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired 
haemolytic disorder in which clones of red cells exhibit 
increased susceptibility to complement-mediated lysis and a 
deficiency of AChE activity ( Dacie, 1967; Rosse and Parker, 
1985). Patients with PNH generally have a population of 
apparently normal cells (PNH I cells, which have normal amounts 
of AChE and are resistant to the haemolytic action of complement) 
that coexist with a population of complement sensitive cells (PNH 
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III cells, which lack AChE). Another population of cells, called 
PNH II cells, may be present along with or instead of the PNH III 
clone. PNH II cells show only intermediate sensitivity to 
complement, but also lack AChE. Radioimmunoassay, 
radioimmunoprecipitation (Chow et al., 1985) and 
immunodisplacement techniques (Brimijoin et al., 1986) employing 
monoclonal antibodies indicate that AChE is absent from 
complement sensitive PNH cells and present in complement 
insensitive PNH cells. Clonal cultures of bone marrow from two 
patients with PNH have shown dual populations of erythroid 
'bursts' ( BFU-E) ( Rotol i et al. , 1984). Normal colonies were 
seen as well as complement sensitive colonies, the latter being 
deficient in AChE. This deficiency seems only to be a marker for 
the disease. 
In most cases of ABO haemolytic disease of the newborn the red 
cell AChE activity is below normal (Herz et al., 1972; 1973). 
Kaplan et al. (1964) showed that the AChE activity of red cells 
in ABO disease are significantly lower than those in rhesus 
disease and in normal newborns. 
Erythrocytes coated with IgG 'warm' antibodies with or without 
complement, in auto immune haemolytic anaemia ( AHA), are more 
likely to have reduced AChE activity than red cells sensitized 
by complement binding cold antibodies (Sirchia et al., 1970). 
Some decrease of AChE may also occur in disordered 
erythropoiesis such as myelofibrosis with myeloid metaplasia, 
erythroleukaemia and refractory anaemia (Herz and Kaplan, 1973). 
AChE has also been reported to be decreased in Down's syndrome 
(Kedziora et al., 1982), 
20 
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Plasma Cholinesterase 
Human ChE hydrolyses many choline and non-choline esters, its 
optimal substrate being butyrylcholine and unlike AChE it 
hydrolyzes benzoylcholine. The enzyme is found in plasma and in 
most tissues, but not in human erythrocytes. 
Plasma ChE is of clinical importance in the hydrolysis of many 
muscle relaxants (Kalow and Genest, 1957; Brown. et al., 1981), 
ester-type local anaesthetics and certain other drugs (La Du, 
1971). The genetic variants of human serum ChE were discovered 
after succinylcholine gained widespread use as a muscle relaxant. 
Succinylcholine or suxamethonium is the dicholine ester of 
succinic acid and has a short duration of action due to its rapid 
enzymic destruction by plasma cholinesterase. About 95% of an 
intravenous injection is hydrolyzed in the blood before reaching 
the patient's muscle. It was noticed that 1 in 2000 patients with 
lower levels of cholinesterase activity developed a prolonged 
apnoea after a standard dose of the drug (Kalow and Gunn, 1959). 
Evidence indicated the low enzymic activity to be inherited and 
a significant number of the healthy relatives had reduced levels 
of activity suggesting a serum protein polymorphism. It was 
tentatively proposed that the sensitive individuals were 
homozygous for an abnormal gene and that the inheritance was 
recessive (Lehmann and Ryan, 1956). Evidence by Stovner (1955) 
using a variety of substrates and inhibitors indicated that the 
cholinesterase of suxamethonium sensitive individuals appeared 
to be qualitatively different from normals and was called 
atypical. 
Two genetically independent loci, the first involving four 
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allelic genes have been linked to alterations in serum 
cholinesterase activity (Whittaker, 1980). Currently, four main 
systems of nomenclature for the first locus are in use (Table 2). 
The classification of Motulsky has been widely applied and has 
been adopted in this thesis. 
Table 2 
Motulsky 
(1964) 
El UEl u 
El•El• 
E fE t 1 1 
El.Ela 
EluEla 
E UE f 1 1 
El UE18 
E •E t 1 1 
El•El• 
E fE • 1 1 
Alternative Nomenclature for the Genetic Variants 
of human plasma cholinesterase coded for by the 
four alleles at locus 1 
Genotype Phenotype 
Goedde Lehmann Shows Motulsky Goedde 
and and et al (1964) and 
Baisch Liddell (1979) Baisch 
(1964) (1965) (1964) 
Ch uch u 1 1 NN CHE1*U/CHE1*U u u Ch1(UU) 
ChlDChlD DD CHE1*A/CHE1*A A A Ch1(DD) 
Ch 'eh ' 1 1 FF CHE1*F/CHE1*F F F Ch1(FF) 
Ch 8Ch 8 1 1 ss CHE1*S/CHE1*S s s Ch1(SS) 
Chl uchlo ND CHE1*U/CHE1*A UA I Ch1(UD) 
Ch uch r 1 1 NF CHE1*U/CHE1*F UF UF Chl(UF) 
Chluchls NS CHE1*U/CHEl*QO us u Chl(US) 
Ch °Ch ' 1 1 DF CHEl*A/CHE1*F AF AF Ch1(DF) 
eh °Ch s 1 1 DS CHEl*A/CHE1*QO AS A Chl(DS) 
Ch 'Ch s 1 1 FS CHEl*F/CHE1*QO FS F Chl(FS) 
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Plasma Cholinesterase Variants 
E.1a gene 
Kalow and Genest (1957) showed that the inhibition 
characteristics of the enzyme with dibucaine differed in 
sensitive and non-sensitive individuals. A fixed concentration 
of dibucaine ( 10-5M) was used and the percentage inhibition 
measured using 5*10-5M benzoylcholine as substrate was defined 
as the dibucaine number (ON) under standard conditions of 
temperature and pH. Two allelic genes were postulated. The E1u 
gene is responsible for the biosynthesis of the usual form and 
the E1a gene for the atypical form of the enzyme. Sensitive 
individuals E1aE 1a have a ON about 20, E1uE 1u have a ON about 80 
and some relatives of the sensitive patients were identified as 
E1uEt with a ON about 60 (Table 3). Maximum rates of hydrolysis 
of choline esters by the usual enzyme were two to four times 
greater than those obtained with the atypical enzyme (Oavies et 
al., 1960). All Michaelis constants for the normal enzyme were 
lower than those for the atypical enzyme . 
.E,1 f gene 
The fluoride resistant gene E1f was recognised by using sodium 
fluoride as differential inhibitor (Harris and Whittaker, 1961). 
The fluoride number (FN) was defined as the percentage inhibition 
by 5*10-5 M sodium fluoride of the rate of hydrolysis of 5*10-5 M 
benzoylcholine under standard conditions (temperature, pH etc). 
The E1f gene is allelic with the usual and atypical genes. 
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Silent Genes 
Further studies in the 1960's indicated the existence of a 
silent gene where no 
demonstrated (Liddell et 
cholinesterase activity could be 
al. , 1962; Hart and Hi tchell, 1962) . 
These individuals were homozygous E19 E18 , the silent gene being 
allelic with the usual gene (Simpson and Kalow, 1964). 
Goedde et al. (1965) described two silent gene sera showing 
2% activity with benzoylcholine as substrate and immunological 
reactivity was demonstrated using rabbit antisera to the usual 
human plasma cholinesterase. A structural alteration of the 
enzyme protein was assumed. Five other cases studied by Goedde 
et al. (1965, 1968) showed that 2 had no detectable enzymic or 
immunological activity. 
A large number of silent homozygotes were found among the 
Eskimoes of Western Alaska (Gutsche et al., 1967; Scott and 
Wright, 1967). One group (Type I) was found to have about 1% and 
the other group (Type II) about 3% of the usual activity. 
Acrylamide gel electrophoresis showed that Type I sera produced 
two bands of activity, one faster than any found in the usual 
enzyme, whereas Type II sera had five bands of activity, all 
corresponding to those found in the usual enzyme (Rubinstein et 
al., 1970). No reaction was detected with Type I sera when tested 
with an antisera to usual cholinesterase, whereas Type II did 
react with the antibodies. These workers concluded that the Type 
I serum cholinesterase is quantitatively and qualitatively 
different from both usual and Type II cholinesterase, whereas 
Type II and usual cholinesterase differ only quantitatively. Type 
I (E19 ) and Type II (E 1t) silent genes are allelic with each other 
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and with the E1u gene. 
A third type of serum cholinesterase deficiency has been 
reported in Eskimoes having less than 10% of usual cholinesterase 
activity with a major band that migrates slightly faster than the 
major band of usual cholinesterase following starch gel 
electrophoresis at pH 5, 3. This variant is allelic to the E1 
locus and the gene has been designated E{ ( Scott and Wright, 
1976). An individual with genotype E1rE 19 or E1rE 1t has less than 
10% of usual cholinesterase activity. 
Considerable confusion still exists over the heterogeneity of 
sera showing little or no cholinesterase activity, Further 
evaluation of these sera comparing enzymic and immunological 
reactivity should provide further insight and clarity into the 
characterization of these variants. 
E1J and E 1~ 
Garry et al. (1976) reported anomalous dibucaine numbers 
obtained with some sera which led to the postulate of a new gene, 
E1j. The E1aE1J heterozygotes can be detected by inhibitors, but 
the other E1J variants can only be identified by genetic 
analysis. It was proposed that the usual enzyme, as produced by 
the E1u gene, was still being produced in these phenotypes, but 
the level of the circulating enzyme was reduced by about 66% 
(Rubinstein et al., 1976). 
Using the inhibitor R02 0683 (dimethylcarbamate of (2-hydroxy-
5-phenyl(benzyl)-trimethyl-ammonium bromide) Evans and Wardell 
( 1984) concluded that the E1J gene is probably rare in the 
general Caucasian population and that the similarity of DN and 
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FN values for E1aE1J and E1aE/ could lead to confusion in 
genotyping using only dibucaine and fluoride as differential 
inhibitors. 
Rubinstein et al. (1978) described another variant E1k in two 
families, segregating for the E1a allele, from unusual dibucaine 
numbers. Evans and Wardell (1984) found the genotype E1aE 1k to be 
relatively common amoungst Caucasians, but the possibility 
existed for many to be incorrectly phenotyped as E1uE 1a. In 
addition, at present it is impossible to separate E1uE 111: and E11<E1k 
from the usual homozygote E1uE 1u, or from the heterozygote E1uE1' 
by R02 inhibition. Rubinstein et al. (1978) indicated that the 
E1k gene causes a reduction in enzymic and immunological activity 
of about 33% which could therefore be used to discriminate these 
genotypes. However, a more recent survey found E1uE 111: genotypes to 
have an average of 91% of the activity of the usual homozygote 
(Whittaker and Britten, 1985) and the flat Gaussian distribution 
curve of enzymic activities for the E1uE 1k heterozygote is not 
clearly separated from the similar distribution curve for the 
usual homozygote. Until the genotypes E1uE 1J, E1uE 1k and E1JE 1k can 
be resolved from E1uE1u the genetics of the E1J gene, as well as 
the E1k gene, will present problems. Some workers have observed 
enzyme activities within the normal range for some E1uE 1 j 
genotypes (Whittaker and Britten, 1989). 
27 
E h 
-1-
Whittaker and Britten (1987) reported unusual inhibition 
characteristics in two unrelated suxamethonium sensitive 
individuals. The dibucaine and fluoride numbers suggested the 
phenotype E1•E1•, but multiple estimations of the R02 number were 
unique. In addition, enzymic activity such as that found in some 
of the silent genes were noted (Whittaker, 1986). Since the 
latter are not known to exhibit unusual inhibition 
characteristics a new allele E1h was proposed. 
Table 3 Activity and Inhibition Numbers of the Genotypic 
Variants of Serum Cholinesterase 
Genotype Relative DN FN Frequency 
Enzymic 
Activity1 
EluElu 100 77-83 56-66 96" 
EluEls 50 77-83 56-68 1 in 190 
E UE f 1 1 86 70-83 46-54 1 in 200 
EluEl• 77 48-69 44-54 1 in 25 
El.Elt 59 45-59 28-39 1 in 20,000 
E 'E t 1 1 74 64-69 34-43 1 in 154,000 
El 'El a 37 64-69 34-43 1 in 150,000 
ElaEl• 43 8-28 10-28 1 in 2000 
El a El s 22 8-28 10-28 1 in 29,000 
ElsEla Activity too low to measure 1 in 100,000 
1 Benzoylcholine as substrate 
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Electrophoresis 
Human serum cholinesterase exists in multiple molecular forms. 
Four bands may be demonstrated in fresh plasma, using starch gel 
or polyacrylamide electrophoresis at alkaline pH with 
u-naphthylacetate as substrate and about 90% of the activity is 
present in the C4 band. LaMotta et al. (1965) showed that the 
isoenzymes are interconvertible and that the multiple forms of 
plasma cholinesterase are molecular aggregates. It was found that 
the C4 enzyme is a tetramer whose subunits are equal in size and 
charge with a molecular weight comparable to the Cl component of 
the native enzyme. 
An extra slow migrating cholinesterase band (C5) may be 
demonstrated in some Caucasians following starch gel 
electrophoresis at pH6 and its presence, C5+ phenotype, was shown 
to result in 30% more cholinesterase activity than with the C5-
phenotype. The gene coding for this band, designated the E2+ 
gene (its allele is called the E2- gene), is located at the 
second locus for cholinesterase and is not allelic to the El 
locus (Table 4 ) . The Cs+ phenotype has been found only in 
association with the El UEl u and EluEla genotypes suggesting the 
extra band is a hybrid or complex of the enzyme protein from the 
E1 locus with a second complementary protein from the E2 locus 
(Scott and Powers, 1974; Huensch et al., 1978). 
The recorded studies of the E2 allele indicate that some 
children have shown the E2+ phenotype even when both parents were 
E2- (Harris et al., 1963; Ashton and Simpson, 1966; Goedde et 
al., 1973). 
Nei tl ich (1966) reported four family members with 
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cholinesterase activities several times normal, an extra slow 
migrating band being present on starch gel electrophoresis. This 
variant was slower than the C5+ band coded for at the E2 locus. 
It was named Cynthiana after its place of origin. 
An unusual patient with leiomyoma has also been described, 
sensitive to suxamethonium and exhibiting only 2% normal 
cholinesterase activity, but after six months, activity slowly 
increased with an increase in the slow migrating bands on PAGE 
until the usual major band was observed after about a year, It 
is believed that initially the serum contained two factors, one 
a neuraminidase-like enzyme responsible for altering the 
electrophoretic mobility of cholinesterase by cleaving various 
amounts of sialic acid and the other a proteolytic enzyme for 
reducing the cholinesterase activity. The proposed mechanism was 
called the 'epigenetic modification' hypothesis (Ogita, 1975). 
The neuraminidase-like enzyme is believed to be genetically 
controlled, but not expressed except under appropriate 
physiological or pathological conditions by a gene called N8 • Its 
allele, Nu is associated with its absence. 
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Table 4 Alternative nomenclature for the electrophoretic 
variants of human plasma cholinesterase coded 
for by two common alleles at locus 2 
Genotype 
Harris e t al Motuls ky Shows et al 
(1963) (1964) (1979) 
Cs- Ez- CHE2*C5-
Cs+ Ez+ CHE2*C5+ 
Chromosome Assignments 
Genetic linkage studies suggest that the first locus of 
cho l inesterase, El is situated on t h e long arm of chromosome 3 
(Arias et al., 1985), at location 3q21-q26 (Huerre et al., 1984), 
by linkage with the caeruloplasmin gene and the transferrin 
receptor gene (Kidd and Gusella, 1985). Studies have shown that 
there are three i n trons at nucleotides 93 , 1433 and 1600 ( Kott 
198 7) . The first of these is in front of the leader peptide 
sequence, while the other two are near the 3' terminus of the 
c oding region . 
Genetic linkage studies have suggested a ~ossib l e linkage 
between the E2 gene and the a-haptoglobin gene (Lovrien et al . , 
1978) , which maps in a region on chromosome 16 , distal to the 
fragile site 16q22 (Simmers et al., 1986). Howeve r, recent 
evidence (Eiberg et al. , 1988) indicates tight linkage of the E2 
loc us to the gamma-crystallin gene cluster ( CRYG) locus located 
quite distally on chromosome 2 long arm (2q33-q35). 
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Possible Role of Plasma Cholinesterase 
The physiological function of cholinesterase is unknown, but 
may include a role in the transmission of slow nerve conduction 
( Bergmann and Wurzel, 1954), a protective role by removal of 
choline esters which would inhibit acetylcholinesterase (Lehmann 
and Silk, 1953; Mezincesco and Ghetie, 1974), involvement in 
lipid or phospholipid metabolism (Clitherow et al., 1963; Kutty, 
1980), regulatory involvement of choline homeostasis in plasma 
(Funnell and Oliver, 1965) and involvement in permeability 
control and transport of sodium and other ions across membranes 
(Duncan, 1967), 
Composition and Structure 
Plasma cholinesterase is biosynthesized in the liver, but its 
concentration there is low because it is released into the plasma 
immediately following synthesis. The enzyme is a glycoprotein. 
Nine carbohydrate chains appear to be attached to each asparagine 
residue at positions 17, 56, 106, 241, 256, 341, 455, 481 and 486 
(Lockridge et al., 1987) consistent with the report by Haupt et 
al. (1966) that 23.9% of the weight of human serum cholinesterase 
is due to carbohydrate. These chains are the complex type 
terminating in sialic acid. The amino acid composition of the 
purified enzyme (usual phenotype) has been determined (Muensch 
et al., 1976; Soreq and Gnatt, 1987; Lockridge et al., 1987) 
(Table 1). In addition, the complete amino acid sequence has been 
reported by Lockridge et al. (1987). 
Atypical serum cholinesterase has been shown to be due to a 
point mutation in the gene which changes aspartate 70 to glycine 
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(McG.uire et al., 1989}. The mutation occuring in nucleotide base 
209, which changes codon 70 from GAT to CGT, was detected in all 
five atypical cholinesterase families examined. This mutation 
(acidic to neutral amino acid substitution} accounts for the 
reduced affinity of atypical cholinesterase for choline esters, 
indicating that Asp 70 must be an important component of the 
usual cholinesterase anionic site. 
Lockridge et al. (1979) showed that highly purified usual human 
cholinesterase is a tetramer of molecular weight about 340,000 
with identical subunits approximately 85,500 in molecular weight 
(Lockridge et al., 1987). The molecule consists of a dimer of 
dimers (Lockridge et al., 1979} with each dimer containing only 
one interchain disulphide bond between two subunits and 3-5 pairs 
of intrachain disulphide bonds found in each subunit. The four 
subunits are held together by non-covalent bonds located near the 
surface of the molecule when the interchain disulphide bonds are 
broken. Human plasma cholinesterase consists of 574 amino acids 
per subunit, with each subunit containing one active centre. 
As with acetylcholinesterase there are two active sites, the 
anionic and the esteratic active site. The amino acid sequence 
of the esteratic site for E18 E18 , E18 E18 and E1uE 1u was found to be 
Gly-Glu-Ser-Ala-Gly-Ala-Ser-Ala-Val-Ser-Leu ( Lockridge and La Du, 
1986). The catalytically active serine residue underlined is the 
198th residue from the amino terminus (Lockridge et al., 1987}. 
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Cholinesterase levels in the Plasma 
Apart from pregnancy and iatrogenic causes plasma 
cholinesterase activity in heal thy adults varies very little 
over long periods of time. 
physiological factors such 
However, activity can vary with 
as age and sex and with other 
parameters such as body fat, plasma lipids or lipoprotein 
fractions. Males have higher cholinesterase activities than 
females (Propert and Brackenridge, 1976). 
At birth, levels are approximately 30-50% of adult values 
(Zsigmond and Robbins, 1972), there being a significant increase 
from the. first week of life to 4 months. This rapidly increases 
during the first 3-5 years of childhood and subsequently falls 
to the adult levels at puberty (Hutchinson and Widdowson, 1954). 
The half life of cholinesterase appears to be in the range 
2-16 days (Neitlich, 1966; Hall et al., 1984). 
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Cholinesterase in Clinical Conditions 
Decreased ChE Activity 
Plasma ChE activity decreases, sometimes substantially, in 
acute hepatitis, 
determination of 
prognosis. 
cancer 
activity 
and 
can 
burns 
be an 
patients. 
index of 
Sequential 
a patients 
"There is a rapid decrease in cholinesterase activity of about 
30% during the first trimester of pregnancy which is maintained 
until delivery. A further decrease in enzymic activity occurs 
during the early peurperium reaching a minimum at about the third 
day, after which the activity returns to normal after 3-6 weeks 
post-partum (Robson et al., 1986). Several alternate patterns of 
change during pregnancy have also been reported (Evans et al., 
1988). Interestingly, oral contraceptives containing oestrogen 
may also decrease plasma cholinesterase activity by 50% and 
modify the cholinesterase isoenzymes (Whittaker et al., 1971). 
This is reversible on withdrawal of the contraceptive. Redderson 
(1973) has suggested that the effects are caused by a 
steroid-induced 
biosynthesis. 
Glucocorticoids 
depression of 
and oestrogens 
hepatic cholinesterase 
also lower the plasma 
cholinesterase activity. Prednisone treatment may produce a 
decrease of 50% activity (Foldes et al., 1974), while oestrogen 
treatment for cancer of the prostate may reduce cholinesterase 
activity to 20% normal (Archer and Janowsky 1978). Plasmapheresis 
(Wood and Hall 1978) and haemodilution cardiopulmonary bypass 
(Viby Mogensen 1982) produces a dramatic fall in cholinesterase. 
Many drugs can reduce the cholinesterase activity in vivo. Most 
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of these are inhibitors, but others may reduce the biosynthesis 
of the protein in the liver. 
Inhibitors are classified as reversible or irreversible. The 
irreversible group are long lasting and normal enzymic levels are 
restored a few weeks after withdrawing the drug, when the liver 
has synthesized enough enzyme to give normal cholinesterase 
activity. This includes cytotoxic compounds (Wang and Ross, 1963; 
Zsigmond and Robins, 1972) and cyclophosphamide used in cancer 
treatment (Walker et al. , 1972), echothiopate iodide used in 
treatment of glaucoma (McGavin,· 1965) and the organophosphorous 
insecticides (Barnes and Davies, 1951). 
Reversible anticholinesterases include edrophonium, neostigmine 
and pyridostigmine (Barrow and Johnson, 1966; Foldes and Smith, 
1966). Other drugs are used as muscle relaxants either alone or 
by potentiating the action of suxamethonium using the inhibitory 
property of the drug on plasma cholinesterase. Vercuronium 
(Whittaker and Britten, 1981), propanidid (Doenicke et al., 
1968), pancuronium (Katz, 1971; Stovner et a'!., 1975), local 
anaesthetics and monoamine inhibitors (Bodley et al., 1969) can 
potentiate succinylcholine. 
The inhibitors which most frequently cause toxicological 
problems are the nerve gases, such as Tabun and Sarin and the 
systemic insecticides (eg. 
these potent inhibitors 
parathion and marathion). Many of 
are either organophosphates or 
carbamates. The pharmocological effects of these agents are due 
to inhibition of acetylcholinesterase in membrane structures of 
the nervous system. Most of these substances inhibit both 
acetylcholinesterase and plasma cholinesterase. In general, the 
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plasma enzyme is more susceptible to inhibition than the red cell 
enzyme and this has been used as a biochemical indicator for the 
presence of some types of inhibitors. A substantial decrease in 
the activities of both enzymes below normal values is indicative 
of an environmental effect, such as irreversible organophosphate 
inhibition. 
The rate of binding of the organophosphates to the enzyme 
varies greatly. It is usually fast following exposure to a high 
concentration of nerve gas 1 but slower with the insecticides 
which often require metabolic activation by the liver before 
becoming powerful cholinesterase inhibitors. 
There is considerable interperson variability 
vulnerability to cholinesterase inhibition. In many 
in the 
glaucoma 
patients using ecothiopate iodide as eyedrops the cholinesterase 
activity is not much depressed, whereas in others on exactly the 
same treatment plasma cholinesterase may be completely inhibited. 
Increased ChE ActivitY 
E2+ variants have on average 30% higher activity than the E2-
phenotypes. Other examples of genetically determined high 
activity have been reported in the Cynthiana variant (Neitlich 
1966). In addition, 20% increase in enzymic activity has been 
reported in thyrotoxicosis ( Thompson and Whit taker, 1965; Vincent 
et al., 1973). Treatment restores the mean esterase level. 
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Methods of AssaY of Acetylcholinesterase and Cholinesterase 
Activity 
Enzyme activity can be measured by a wide variety of techniques 
(Augustinsson, 1971; Whittaker, 1984), based on the measurement 
of the rate of hydrolysis of an ester, catalysed by 
cholinesterase. The enzyme should be demonstrated by low 
concentrations (10-5M) of specific inhibitors for both AChE and 
ChE such as eserine, or by specific inhibitors such as E600 
(diethyl-4-nitrophenyl phosphate) and quinidine sulphate (2 * 
10-5M) for ChE and 3116CT (bis(3-dimethylamino-5-hydroxyphenoxy) 
1,3-propane dimethiodide) for AChE. 
Acylthiocholines are hydrolyzed by ChE to the corresponding 
fatty acid and thiocholine. The rate of formation of the 
thiocholine can be monitored by the continuous reaction of the 
thiol group with 5-5'-dithio-2-nitrobenzoate and other products. 
The rate of formation of the yellow anion can be measured 
spectrophotometrically at 410nm (Ellman et al., 1961). 
(a) 
(b) 
( CH 3 ) 3N•cH 2CH 2SCOR + 
Acyl thiocholine 
H20 --- > RCOOH + ( CH 3 hWCH 2CH 2SH fatty acid thiocholine 
DTNB --> 5-thio-2-nitrobenzoate 
+ 
2-nitrobenzoate-
5-mercaptothiocholine 
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When reporting cholinesterase activity it is essential to state 
the substrate used, since the normal range is characteristic for 
each substrate. Benzoylcholine and butyrylthiocholine are 
probably the most commonly used substrates for ChE, with 
succinyl thiochol ine and propionyl thiochol ine having selected use. 
Currently, activity is recorded in ~mol of substrate hydrolysed 
per minute per ml of serum or plasma at 25'C. 
The calorimetric method of Okabe et al. (1977) using a choline 
oxidase/peroxidase procedure can be used (Panteghini and Bonora, 
1984) in conjunction with a centrifugal fast analyser. 
Chemiluminescent assays using luminal to detect hydrogen peroxide 
and fluorimetric methods (Pantel, 1981) provide sensitive 
determination of enzymes at low substrate concentration. 
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Enzyme Immunoassay 
Enzyme immunoassays were introduced about 20 years ago for the 
identification of precipitin lines obtained by immunodiffusion 
and electrophoresis (Nakane and Pierce, 1966, 1967; Avrameas and 
Uriel, 1966). The principles on which they are based are quite 
similar to those of immunofluorescence, where an antigen is 
specifically detected due to the discriminatory power of 
antibodies, and a marker attached to these antibodies indicates 
that such a reaction takes place. Enzymes are used as markers in 
enzyme immunoassays since they have, in contrast to fluorescent 
labels, the capacity of amplification .. Peroxidase was used as the 
enzyme, and thus techniques were known as immunoperoxidase 
procedures. 
An important advance was the use of various solid phases 
(originally plastics such as polystyrene) that have the capacity 
of binding antigens or antibodies in high concentrations under 
certain ionic conditions. These immunosorbants could then select 
the molecule to be detected from the test fluid which, in turn, 
could absorb an enzyme-labeled antibody (detector molecule). 
Application of this approach to the immunoperoxidase method 
simplified quantitative techniques, eliminating cross reaction 
in many instances. Automation of these systems also became 
viable. Development of monoclonal antibody production and 
auxiliary amplification molecules (avidin/biotin, streptavidin, 
protein A, lectins) all contributed to the rapidly expanding use 
of enzyme immunoassays. 
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Antibody Preparation 
It is practically impossible to make reproducible polyclonal 
reagents. Even antisera from the same animal taken at different 
times differ in their properties. In contrast, monoclonal 
antibodies have the same specificity and affinity, can be 
produced in virtually unlimited quantities and pure immunogen is 
not required for the immunization. However, a monoclonal antibody 
is unable to distinguish different antigens if they bear the same 
epitope, specificity may not be as high as expected, some may 
cross-react, which, in contrast to polyclonal antisera, cannot 
be removed with immunosorbents (Brodsky et al., 1979) and 
production is time consuming. 
Monoclonal antibodies may be much more sensitive to 
inactivation by freezing and thawing 1 changes in pH or other 
physical factors (Hosmann et al., 1980) important for their 
purification. The lower avidity of monoclonal antibodies and the 
small fraction of high-affinity antibodies (dominant in 
polyclonal sera) are the probable cause of their frequent lower 
detectability in enzyme immunoassay (EIA) when compared with 
polyclonal antisera and makes the selection of high-affinity 
monoclonal antibodies mandatory. Pooling of different monoclonal 
antibodies to gain avidity has given conflicting results (Ehrlich 
et al., 1982). Ultimately however, monoclonal antibodies make new 
designs of EIA possible. The most important advantage monoclonal 
antibodies offer for EIA is the possibility to standardize assay 
methods, the specificities, detectabilities and sensitivities. 
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Polyclonal Antibody Production 
The purpose of immunization is to obtain high-titred antisera 
with a high avidity. These may be increased by admixture of the 
immunogen with a suitable adjuvant (Freund's). Alternatively, 
protein stained with Coomassie blue m::~.y be cut as bands from 
polyacrylamide gels and used directly ( Buolard and Lecroisy, 
1982). It is also possible to use immune precipitate in agarose 
gels, eliminating contaminants which copurify with immunogen, but 
do net coprecipitate. One regime consists of injection of 25-50 
1!8/kg of immunogen once a month for up to 1 year. 
A 10-fold increase in titre may be achieved by immunoglobulin 
isolation using salt precipitation with saturated ammonium 
sulphate, ion-exchange chromatography (Levy and Sober, 1960), 
isolation on Protein A-Sepharose ( Langone, 1982), or by 
immunosorbents (Maze and Gray, 1980). 
Monoclonal Antibody Production 
Kohler and Milstein (1975) reported the successful fusion of 
normal mouse antibody-secreting lymphocytes with the cells of a 
myeloma cell line, thus producing a hybrid-myeloma which combined 
the properties of cell growth and antibody secretion. The hybrid 
cell could be grown in tissue culture and yield antibody in·the 
supernatants. The useful antibody secreting cell lines are 
selected by means of simple screening tests, such as ELISA, on 
the supernatants. The cell lines are purified by cloning and are 
stored in liquid nitrogen to guarantee quality and supply. 
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EnzYme Conjugation 
Enzymes most commonly used include horseradish peroxidase and 
alkaline phosphatase. Three different approaches for conjugation 
exist. Chemical labeling (Avrameas and Ternynck, 1971), 
immunological labeling (Mason and Sammons, 1978) and auxiliary 
nonimmune recognition systems (biotin/avidin, protein A, 
lectins). Preformed peroxidase-anti-peroxidase (PAP) complexes 
(Sternberger et al., 1970) may also be used. 
Avidin-Biotin Complex Methods 
Biotin a small, water soluble vitamin (m.wt. 244) can be easily 
conjugated to antibodies without damage to the antigen binding 
ability. Biotinylation does not impair horseradish peroxidase, 
but alkaline phosphatase activity is severely reduced. Avidin a 
glycoprotein (m.wt. 67,000) available from egg white has four 
active binding sites for biotin and since many biotin molecules 
can be bound to a protein this has a potential for amplification. 
Avidin, however binds in a non-specific manner to nuclear 
material and cell membranes and will react with other biological 
molecules such as lectins via the carbohydrate moiety. This has 
resulted in many workers substituting avidin with streptavidin. 
Streptavidin, a protein (m.wt. 60,000) with four high affinity 
sites for biotin, is isolated from the bacterium Streptomyces 
avidinii and does not exhibit non-specific binding. It is the 
strength of the interaction between biotin and streptavidin which 
enables the development of detection methods with short 
incubation times, while providing very high sensitivity and 
specifici ty. 'Spacer arms' between the biotin and the 
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macromolecule, allowing the binding between biotin and 
streptavidin to proceed unhindered are used to 
sensitivity. 
The Immobilization of immunoreactants on Solid Phase 
increase 
Microti tre plates have enjoyed considerable popularity as solid 
supports for both qualitative and quantitative enzyme 
immunoassays. It is desirable for the solid phase to have a high 
capacity for binding immunoreactants, to exhibit minimal 
dissociation, to incur negligi"ble denaturation of the immobilized 
molecule and to orientate the immobilized antibody with binding 
sites towards the solution and the Fe portion towards the solid 
phase. 
Plastic however, being immunoreactant-consumptive, with a low 
adsorption capacity per unit area, may not be suitable for large 
antigens due to spacial limitations, The resultant 
antibody-antigen interactions proceed much slower than in 
solution. Considerable inter-well variation in protein adsorption 
may exist, especially noticeable at the edges of the plate where 
an increased amount of protein attaches to the wells due to 
pronounced temperature differences across the plate ( Burt et al., 
1979), wells at the edges being several degrees hotter than those 
in the interior ( 'edge effect' ) . Thus, immunochemical and enzymic 
reactions in edge wells may proceed at a higher rate than those 
in cooler interior wells. 
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Nature of Protein-Plastic Interaction 
Non-covalent Attachment 
Protein adsorption to plastic is generally attributed to 
non-specific hydrophobic interactions and is independent of the 
net charge of the protein, although binding is different and 
characteristic for each protein (Cantarero et al., 1980). 
Non-covalently adsorbed antigen may be desorbed during the test 
(Engvall et al., 1971) and compete for the immunoreactant added, 
leading to decreased detectability and increased variability. 
This can be minimized by using the immobilized reactant at the 
appropriate concentration and washing extensively after 
immobilization and each subsequent step ( Cristensen et al., 
1978). With an excess of protein, multiple layers stack on the 
protein monolayer by protein-protein interactions. Such secondary 
interactions are not very stable and interfere in the EIA. 
The three most important variables for the adsorption of 
proteins on a 
concentration. The 
carbonate, pH 9.6. 
solid phase are temperature, time and 
most widely used coating buffer is 0. 05M 
Incubation is usually overnight at 4'C in a 
humid chamber, but may be shortened by increasing the temperature 
or the antigen concentration. The optimum coating concentration 
for purified IgG is 11lg/ml, and for antigens or antibodies 
between 1 and 1011g/ml ( Engvall, 1980), but at least 60min 
incubation at 37'C is required. The detectability with complete 
antiserum is about 4 times less than with purified IgG. Free 
spaces on the solid matrix may be blocked using an albumin 
solution. 
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Covalent Attachment 
A simple method is pretreatment of polystyrene with 
glutaraldehyde (GA) or ethylchloroformate (ECF) (Dobbins Place 
and Schroeder, 1982). Microtitre plates thus treated can be 
stored for at least 4 weeks. Pretreatment of antibodies with GA 
prior to coating can decrease their desorption and give a higher 
detectability in EIA. 
Attachment of Antigens or Antibodies to Plastic 
Heusser et al. (1981) have described methods to attach cells 
to the bottom of microti tre plates to form stable cell mono layers 
sui table to detect antibodies against cell surface antigens. 
Plates are either pretreated with a heterogenous population of 
antibodies ( IgG fraction) directed against cell surface 
components or with lectins, such as phytohaemaglutinin (PHA). 
Attached cells can be subsequently fixed with glutaraldehyde. 
Fixation of cells with glutaraldehyde in conjunction with 
poly-L-lysine (Heusser et al., 1981) coating ~f plates can also 
be used to prepare stable cell monolayers for solid phase assays. 
Under these conditions, cells remain firmly attached. Such cell 
layers can be used for both radioimmunoassay (RIA) and 
enzyme-linked immunosorbent assay (ELISA) to yield specific and 
reproducible results. Plates containing glutaraldehyde-fixed 
cells can be stored for several weeks without loss of cell 
membrane antigens. Nonspecific binding to reactive sites on the 
plate may be reduced by the use of 1% BSA, 0.1M glycine or 0.05% 
tween 20. 
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Design of Enzyme Immunoassays 
Two types of EIA can be distinguished, homogeneous (in 
solution), for the detection of small compounds and heterogeneous 
(one of the immunoreactants is anchored to a solid phase), for 
the detection of large compounds. Two differential type of assay 
have been developed (Kurstak et al., 1984; Tijssen, 1985) namely 
activity amplification (AA) and activity modulation (AM) assays. 
In the former the detector immunoreactant is used in large excess 
to detect the antigen and by the law of mass action, exceedingly 
small amounts of sample molecules can then be detected. 
Specificity of such methods may be poor. The contrary applies to 
AM methods where low concentrations of immunoreactants are used. 
Noncompetitive Solid-Phase Enzyme Immunoassays 
Both antigens and antibodies may be detected. The 
immunoreactant, complementary to the molecule to be detected, 
is immobilized on the solid phase. This sensitized solid phase 
serves to extract the target molecules from the sample fluid. 
This is followed by one or more steps with antibodies, which may 
be labeled with an enzyme. 
Competitive Solid-Phase Enzyme Immunoassays 
Competition always occurs in the second layer of solid phase 
reactions. The molecule to be detected competes either with the 
labeled species for the solid-phase immunoreactant or with the 
solid-phase immunoreactant for the labeled species. Either 
antigen or antibody can be labeled. 
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Homogeneous Noncompetitive Enzyme Immunoassays 
Two antibodies are labeled with two different enzymes, the 
product of one being the substrata of the other (eg. hydrogen 
peroxide produced by glucose oxidase is consumed by peroxidase). 
Homogeneous Competitive Assays 
Reaction of the antibody with the hapten attached to enzyme, 
substrate or cofactor may cause steric inhibition and thus modify 
the enzymic a~tivity or change the conformation of the enzyme 
resulting in a modulation of enzymic activity. Haptens present 
in the sample will bind with the antibody and thus prevent a 
proportional amount of antibody from reacting with the enzyme. 
This will decrease the enzyme modulation. 
Solid Phase Enzyme Immunoassays 
The molecules or complexes to be detected diluted in a suitable 
buffer are extracted with the appropriate receptor and detected 
by enzyme-labeled tracers. Nonspecific adsorption to the solid 
phase is avoided by adding a large excess of blocking agent such 
as a non-ionic detergent (tween 20, triton X-100) or an inert 
protein (gelatin or B.S.A. ). 
The ionic conditions should be such that specific antibody-
antigen interactions are not influenced, whereas nonspecific 
interactions are minimized. For this reason an isotonic buffer 
is usually chosen. Ionic interactions are the most frequent cause 
of background staining. The buffer may also influence the enzyme. 
PBS contains a high concentration of inorganic phosphate which 
is a strong competitive inhibitor of alkaline phosphatase and 
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Tris buffer is then advised for use with this enzyme. 
The optimal temperature, time and buffer solutions should be 
established in preliminary tests and checkerboard ti trations 
performed to determine the optimal dilution of the various 
components of the test. The conjugate dilution and incubation 
period is chosen giving 
antigen, but below 
maximum 
0.2 for 
absorbance with the 
the nonspecific 
specific 
samples. 
Alternatively, dilution will be sui table where the standard curve 
shows sufficient linearity of appropriate slope for that 
particular assay so that the majority of test samples can be 
evaluated. 
Increased sensitivities are possible with bridge methods using 
avidin-biotin, PAP and lectin. Immune reactions can also be 
accelerated considerably in the presence of polyethylene glycol 
(PEG) 6000 (Hellsing and Richter, 1974). Increasing PEG 6000 
concentration, both accelerates the reaction and increases 
.detectibility, however the background also increases. 
Processing of Data 
The standard deviation (SD) and coefficient of variation (CV) 
should be determined for each system developed and results 
presented accordingly. Computer programs have been designed to 
rapidly process EIA data taking these requirements into 
consideration. Intra and interassay variations of results need 
to be assessed to evaluate the precision and reproducibility of 
the system. Reproducibility is generally expressed by testing the 
samples in duplicate and the SD calculated by the equation 
SD = {~d2/2N in which d is the difference between duplicate 
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absorbances and N the number of paired samples. 
Results may be presented in a number of ways, In terms of a 
cut-off value to discriminate presence or absence of test 
antigen. This level may be 0.15 absorbance units (Halbert et 
al., 1983), two or three times the mean (Malvano et al., 1982), 
or the mean plus two or three standard deviations (Richardson et 
al., 1983). In addition visual inspection has frequently been 
used for rapid screening of enzyme immunoassays; this is quite 
subjective however, and difficult to distinguish positive from 
negative responses at the doubtful interval. 
Comparison of absorbance values obtained with that of a 
standard curve will present results either in arbitrary or 
relative units or in terms of concentration of the antigen or 
hapten, often in mg/ml. These dose-response curves which serve 
to estimate the antigen concentration are usually sigmoidal or 
hyperbolic. Precision of the standard curve can be considerably 
improved with suitable plotting systems. Plotting the absorbance 
data linearly or logarithmically against a logarithmic x-scale 
often facilitates the construction of a reliable standard curve, 
but may not always prove satisfactory. Curvilinear fitting may 
be performed by transforming one or both variables (from linear 
to square root, logarithm or inversion), by polynomial or other 
curvilinear regressions, or by transformations for proportions 
(Tijssen, 1985). 
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Immunochemistry of the Cholinesterases 
Modern immunology has opened new approaches to the 
identification of subtle structural differences in the apparently 
homogenous cholinesterases isolated from different sources. 
Particularly rapid progress has been made in applying 
immunochemistry, immunocytochemistry and immunoassay to the study 
of AChE and ChE (Brimijoin and Rakonczay, 1986}. 
Many polyclonal antibodies have been produced to AChE 
(Williams, 1969; Rieger et al., 1976; Gurari and Fuchs, 1974; 
Adamson, 1977; Zanetta et al., 1981) and plasma ChE (Hodkin et 
al., 1965; Rubinstein et.al., 1970, 1976, 1978; Eckerson et al., 
1983) providing useful information. Monoclonal antibodies now 
offer a means of gaining insight into the structure, function and 
biosynthesis of ChE's (Fambrough et al. 1 1982; Brimijoin et al., 
1983; Mintz and Brimijoin, 1985). 
Williams ( 1969) reported inhibition of non-neuronal AChE by 
polyclonal antisera. Niday et al. (1977) described an antibody 
to erythrocyte AChE which gave single precipitin lines with the 
enzyme on immunodiffusion and rocket, crossed and 
immunoelectrophoresis. The enzymic activity of purified AChE was 
partially inhibited by the antiserum, reaching only 35% 
inhibition even with excess amount of antibody, Results indicated 
competitive inhibition. Agglutination of human red blood cells 
by monospecific antiserum to AChE confirmed the localization of 
the enzyme on the outer surface of the erythrocyte membrane. 
Fambrough et al. (1982) reported the production of monoclonal 
antibodies to human erythrocyte AChE. The specificity of each 
antibody for human erythrocyte AChE was confirmed when each 
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antibody inte+acted with AChE in solution to form discrete 
complexes sedimenting more rapidly than free AChE. Isoelectric 
focusing and SOS polacrylamide gel electrophoresis of the 
purified immunoglobulin indicated that all the monoclonal 
antibodies were unique, thus defining at least four antigenic 
sites on the AChE molecule. The monoclonal antibodies with 
similar cross-species reactivity (AE-1 and AE-2) were shown to 
bind to different sites on the ChE molecule by velocity 
sedimentation techniques. Hybridomas AE-1 and AE-2 were _donated 
to the American Type Culture Collection. 
Brimijoin et al. (1983) described the production of several 
monoclonal antibodies to human AChE and ChE. A solid. phase 
immunoadsorbance assay was used to screen and characterize the 
antibodies. No cross-reactivity of the AChE antibodies with ChE 
nor ChE antibodies with AChE was reported. Moreover, none of the 
antibodies bound to the catalytic active site of AChE or ChE, 
since neither enzyme was inactivated. 
Further studies have been done with the aid of anti-human AChE 
monoclonal antibodies, fluorscein-isothiocyanate labelled second 
antibodies with a fluorescence-activated cell sorter (Brimijoin 
et al., 1986; Dockter and Morrison, 1986). This system has been 
used to identify separate populations of AChE-positive and AChE-
negative red cells in the blood of patients with PNH 
corresponding to PNH I and PNH II cells respectively (Brimijoin 
etal., 1986). 
Hangaard et al. ( 1984) reported an immunological method for 
measuring AChE in different body fluids. A polyclonal antibody 
was produced in rabbits and bound to the wells of a microtitre 
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plate. The enzyme was quantitated by its own enzymic activity. 
This technique forms the basis of an additional test to monitor 
potential neural tube defects ( NTD). In addition to elevated 
alpha-foetoprotein (AFP) in amniotic fluid and maternal serum, 
the concentration of AChE is also raised in most cases of NTD. 
Sorensen et al. (1986) reported AE-2 inhibited the AChE enzymic 
activity. The epitope resided on the individual subunits. The 
rate of phosphorylation of the enzyme by 
diisopropylfluorophosphate was not affected by the antibody, 
indicating it does not affect the esteratic site. However, 
inhibitors directed towards the anionic site(s) competed with 
antibody binding, suggesting that one of these is the epitope. 
Further results suggested that interaction between enzyme and 
antibody took place, not by binding directly to the anionic site 
itself, but rather inducing an allosteric long distance 
interaction between the antibody binding site and the anionic 
site. The titration with antibody is biphasic and yields about 
80% inhibition even in the presence of a large excess· of 
antibody, Inhibition is fully reversible upon dilution in a time 
dependent manner. AE-2 was also found to inhibit human adult and 
foetal brain AChE. ChE showed no reactivity towards the antibody. 
Brimijoin et al. (1987) described a radiometric assay for human 
AChE using a 125 I-labeled antibody against AChE with a detection 
1 imi t near lOOpg. An AChE enzyme-! inked immunosorbent assay 
(ELISA) using a biotinylated second antibody detected by alkaline 
phosphatase conjugated avidin was also described with a 
sensitivity similar to that of the radiometric assay (Brimijoin 
et al., 1987). 
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The development of an enzyme immunoassay system for erythrocyte 
AChE has been relatively slow probably due to the number of other 
methods of assay currently available. These include colorimetric 
(Whittaker, 1984), fluorometric (Brimijoin et al., 1986) and 
radiometric (Brimijoin et al., 1987) assays. The colorimetric 
assay presents results in terms of enzyme activity, while the 
radiometric and fluorometric procedures, although quantitating 
amount of enzymic protein, require elaborate and expensive 
equipment. 
A number of methods for the quantitation of proteins on the 
surface of erythrocytes have emerged over the last few years and 
these methods have been adapted and compared in an attempt to 
provide a set of simple yet accurate and reproducible protocols 
for the characterisation of erythrocyte AChE. These techniques 
involve the quantitation of AChE in situ on the intact red cell, 
precluding the laborious extraction of this enzyme molecule using 
gel filtration (Froman et al., 1980) and centrifugation (Steck 
et al., 1970) techniques. 
It is of interest to know whether the inherited variants of 
human ChE can be immunologically distinguished. This does not 
appear to be possible at the moment. Tests with antibodies 
(Eckerson et al., 1983; Brimijoin et al., 1983) demonstrated 
immunological similarity between the 'atypical' and 'usual' form 
of ChE. 
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Aims of Proposed Work 
The established method of immunological quantitation of plasma 
cholinesterase is 
polyclonal antisera. 
by rocket 
The method 
immunoelectrophoresis using 
however is unsuitable for 
measuring low levels of protein (below 10% of usual). The 
introduction of enzyme linked immunological techniques in recent 
years with the increased availability of high quality monoclonal 
and polyclonal antibodies, make these procedures ideal for the 
development of a more suitable quantitative assay for the 
cholinesterases. In addition, the use of a battery of monoclonal 
antibodies defining different antigenic regions of the molecule 
will provide a further level of characterization. The genetic 
variants of plasma cholinesterase will be investigated by ELISA 
to give greater insight into the relationships which they have 
with each other and with the usual form of the enzyme. Of 
particular interest is the group of 
degree of confusion appears to 
'silent' variants where a 
exist at present. The 
implementation of immunological measurements on these samples may 
provide further classification of the group. 
The variation seen in plasma cholinesterase in certain 
conditions will also be investigated using these immunological 
techniques. An interpretation of the observed decrease in plasma 
cholinesterase activity which occurs during pregnancy and 
continues during the early puerperium could be provided by 
monitoring the changes in molar concentration of the plasma 
enzyme which occur during this period. 
The adoption of microplate techniques has the added advantage 
of relatively fast mass screening capability with a sensitivity 
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appropriate to the enzyme under investigation. Several ELISA 
protocols using different monoclonal and polyclonal antibodies 
will be used for evaluation and comparison. 
in terms of accuracy, reproducibility, 
applicability will be presented. 
The best procedure 
sensitivity and 
Acetylcholinesterase, also, is well suited for enzyme linked 
immunological assay since the enzyme is located an the outer 
surface of the membrane. Both liquid and solid phase techniques 
will be investigated for the most appropriate assay system. 
Changes in erythrocyte acetylcholinesterase activity and in the 
physical properties of the enzyme have b~en reported in several 
haemolytic conditions such as paroxysmal nocturnal 
haemoglobinuria. Enzyme linked techniques will again be used to 
determine whether the observed catalytic changes are functions 
of the molar concentrations of the enzyme located in the 
erythrocyte membrane. Progress in this field will probably be 
slower than for the plasma enzyme, since acetylcholinesterase is 
less stable and the relevant pathological and physiological 
conditions are rare. 
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Methods 
The compositions of buffer, substrate and antibody solutions 
used are given in Appendix I. 
ErYthrocyte Acetylcholinesterase 
Erythrocyte AChE Activity 
The basis of the method is the hydrolysis of acetylthiocholine 
to acetic acid and thiocholine ( Ellman et al., 1961). The 
catalytic activity is measured by following the increase of the 
yellow anion, 5-thio-2-nitrobenzoate, produced when thiocholine 
reacts with 5.5'-dithio-bis-2-nitrobenzoic acid (DTNB). It is 
necessary to confirm a linear relationship of the assay procedure 
at the selected temperature (fig 3). 
A reagent blank to estimate the non-enzymatic hydrolysis of the 
substrate was prepared by substituting phosphate buffer solution 
in place of the sample. 3ml of phosphate buffer were pipetted 
into a glass tube to which 20~1 of washed (*3 with 0.9X NaCl) 
packed cells were added. 20~1 of acetylthiocholine solution (ATI) 
(Aldrich Chemical Co.) were added, the reagents mixed and 
incubated at 22·c for 2min. Following centrifugation at 1000*g 
for 30sec, 1ml of supernatant were removed to which 33~1 of DTNB 
(Aldrich Chemical Co.) were added. 200~1 of reaction mixture were 
transferred to a microplate and the absorbance measured at 405nm. 
Triplicate testing indicated a CV of 7%. 
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Figure 3 
The effect of increasing time of 
incubation of ATI with adult erythrocytes 
on absorbance (20 samples tested). 
A range of activities were calculated for 30 healthy adult 
males and test results were presented in terms of arbitrary units 
(AU) relative to the mean of that range. Alternatively, activity 
was calculated using equation 1. 
Equation 1 
AChE activity = ~ * ~ 
* b ,6t 
1000 * 
13600 
where a = total volume; b=sample volume 
1 1,1mole/min/ml 
1 packed cells 
b.A = change in absorbance; .6.t = change in time 
1 = depth of light path on the microplate 
Molecular extinction coefficient of the 
yellow anion = 13600 
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For 20~1 of packed cells + 3ml of phosphate buffer + 
20~1 of acetylthiocholine 
Dilution = _lQ_ 
3040 
and for 1ml of supernatant + 33~1 DTNB 
Total dilution = _lQ_ * 
3040 
Total dilution = 0.006369 
1QQQ. = 
1033 
~ = = lJl1 
b 0.006369 
sample volume 
total volume 
For 200~1 of reagent the depth of the light path = 0.780cm 
Enzyme units for the SI system are based on moles/second rather 
than ~moles/min. The unit of enzyme activity corresponding to the 
conversion of 1mole/sec of substrate is the katal. To convert U 
( ~moles/min) to katal (mole/ sec) multiply ~moles by 1 o-6 to 
obtain moles and divide minutes by 60 to obtain seconds. 
1 U = 1~mole/min = 1 * 10-6 mole/sec 
60 
= 16.67 * 10-9 katal 
Since 10-9 katal = 1 nanokatal 
1 U = 16.67 nanokatal 
Enzyme activity is expressed as ~kat, nkat or pkat per litre to 
obtain convenient units. 
Interference in the assay technique due to uneven sampling of 
the suspended red cells will result in poor reproducibility in 
duplicate samples. 
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Immunological Quantitation of Erythrocyte AChE 
Haemagglutination Method 
50~1 of AE-1 and AE-2 (Bristol Blood Transfusion Centre) were 
incubated with 50~1 of a 2% red cell suspension (in LISS) for 
20min in a 37•c water bath. Cells were washed 4 times in isotonic 
saline and 50~1 of rabbit anti-mouse immunoglobulin (DAKO) 
reagent added. Cells were centrifuged 1000*g for 20sec and 
examined over a light box for agglutination. Reaction with 
anti-mouse immunoglobulin produced positivity with slight 
prozoning, AE-1 showing a titre of 1/128, AE-2 1/512. However, 
agglutinates were weak and easily disrupted. 
Microplate Antiglobulin Test 
A rigid polystyrene 'U' well microplate was primed with 100~1 
of UBS/BSA. 100~1 of a 20% red cell suspension were aliquoted 
into each well and the microplate centrifuged at lOOO*g for 2min. 
The supernatant was discarded and the cells resuspended in 135~1 
UBS/BSA giving a final concentration of approximately 2%. 25~1 
aliquots from the master tray were transferred to a dilution 
microplate ( 'U' well) and resuspended in 135~1 UBS/BSA giving an 
approximate concentration of 0.2%. 25~1 of diluted antiserum (AE-
2 diluted 1/100 in UBS/BSA) and 25~1 of red cell suspension were 
added to a 'V' well microplate and incubated for 1hr at 37·c. The 
plate was washed 4 times with UBS/BSA/tween, the cells being 
packed hard by centrifugation (1000*g for 2min) after the last 
wash. 25~1 of 1/1000 diluted anti - IgG was added to each well and 
incubated for at least 15min at room temperature and centrifuged 
1000*g for lmin. The microplate was then examined using an angled 
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light box. Positive reactions result in the red cells remaining 
at the bottom of the well, negatives stream down the side of the 
microwell. 
The optimum dilution for the rabbit anti-mouse immunoglobulin 
was 1/1000 for a 1/100 dilution of AE- 2 (table 5). This method 
has the potential for high volume testing of samples and c an 
therefore be used as a convenient screening procedure. 
Table 5 
AE-2 
1/32 
1/64 
1/128 
1/256 
1/512 
1/1024 
1/2048 
Checkerboard titre of AE-2 in the 
Microplate Antiglobulin Test 
Rabbit anti-mouse immunoglobulin dilution 
1/50 1/100 1/200 1/400 1/800 1/1600 1/3200 1/6400 
+ + + + + + + 
+ + + + + + + + 
+ + + + + + + 
+ + + + + + 
+ + + + + 
+ 
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Solid Phase Microplate Monolayer Method 
(1) Liquid Phase Sensitization 
A 2% erythrocyte suspension was sensitized with the 
antibodies AE-1 and AE-2 by incubation in liquid phase for 20min 
at 37'C. Microwells were coated with rabbit anti-mouse 
immunoglobulin by incubating overnight at 4'C at pH9.6 in 0.1M 
carbonate buffer. 50pl of a 0.1% suspension of sensitized 
erythrocytes were added to the microwells, incubated for 30min 
at 2 2 • C and .centrifuged at 1 OOO*g for 2min. M icrowells were 
examined for monolayering. 
Both monoclonals exhibited prozoning and results are presented 
on an arbitrary scale of 0-10 (reaction strength : O=negative and 
1 O=maximal positivi ty) (fig. 4). This technique was unable to 
differentiate levels of AChE from normal adult, cord and PNH 
eryrthrocytes. 
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Figure 4 
Effect of increasing dilution of AE-1 
and AE-2 on the degree of monolayering 
obtained with normal adult 
erythrocytes using liquid phase 
sensitization. 
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(2) Solid Phase Sensitization 
Microplates were coated with rabbit anti-mouse immunoglobulin 
b y incubating overnight at 4 ' C at pH9 . 6 in 0.1M c arbonate buffer. 
100~1 aliquots of serially diluted AE-1 and AE-2 in PBS pH7.2 
were added to each microwell and incubated at 37 ' C for 1hr 
( fig.5). Wells were washed thrice with PBS tween. 50~1 of a 0.1% 
suspension of washed erythrocytes were added to the microwells 
and incubated for 30min at 22'C and centrifuged at 1000*g for 
2min . Microwells were examined for monolayering. 
Again, no differentiation was observed between adult and cord 
samples and no improvement was observed when using ammonium 
sulphate precipitated AE-1 and AE-2. 
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Figure 5 
Effect of increasing dilution of AE-1 and 
AE-2 on the degree of monolayering 
obtained with normal adult erythrocytes 
using solid phase sensitization. 
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( 3) Poly-L-lysine and Said Phase Sensitization 
High molecular weight (>400,000) poly-L-lysine is highly 
positively charged. Incubation of this reagent in the wells of 
a microplate, which carry a negative charge, results in the wells 
becoming coated with a positive layer. Incubation of erythrocytes 
followed by centrifugation results in a fine monolayer of cells 
coating the well bottom. These cells may then be lysed using 
distilled water with the 'ghosted' cell membranes remaining on 
the well surface. Some workers use a glutaraldehyde solution to 
fix the cells to the well surface, but this may result in an 
altering of antigenicity. 
100~1 of po1y-L-lysine (BDH) 3~g/ml in PBS (optimum between 3 
and 30~g/ml, concentrations higher and lower than these show a 
marked decline in coating conditions) were added to each well and 
incubated for lhr at 37'C. After this time the wells were washed 
· 3 times in PBS/tween 20. 100111 of a 0.25% (in PBS/tween) cell 
suspension were added to each well and allowed to stand for 5min, 
after which time the plate was centrifuged for 1000*g for lmin. 
Again the plate was washed 3 times in PBS tween. The wells were 
then flooded with distilled water and allowed to stand for 2min 
at room temperature and washed once in distilled water. 100111 of 
0.25% glutaraldehyde in PBS/tween pH 7 . 2 were added, incubated 
for 5min at room temperature and washed 3 times in PBS/tween. 
100111 of primary antibody for the particular red cell membrane 
antigen under test was added and incubated for lhr at room 
temperature. Plates were again washed 3 times in PBS/tween. 100~1 
of 1/200 dilution (PBS/tween) of rabbit anti-mouse-HRP conjugate 
(DAKO) was added and incubated for 2hr at room temperature. After 
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this time the plate was washed 3 times in PBS/tween. Peroxidase 
substrate (OPD) was added and the reaction stopped after 15min 
using 1M H2 S04 • 
Monoclonal anti-A and anti-B produced good positive 
absorbances. Thirty routine grouping samples were tested in this 
way and ABO groupings agreed with normal haemagglutination 
methods. Various subgroups of A were evaluated to see if 
absorbance values were related to the number of group A antigen 
sites on the red cell surface (table 6) providing a means of 
quantitation. 
Table 6 Absorbances obtained with A subgroups using 
solid phase techniques 
A subtype Absorbance No. of A sites 
At 1. 565 1 *106 
Az 1 .192 2.5*105 
A1B 1.324 6 *10 5 
A3 (high grade) 0.845 5 *104 
A 3 (low grade) 0.349 3. 5*104 
Ax 0 4.8*103 
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Thus, an antigen density in excess of 30, 000 sites per 
erythrocyte is required for detection by this method. Since there 
are approximately 800 AC hE dimers per erythrocyte (Ott et al., 
1982), this technique is not sensitive enough for this antigen. 
This was confirmed by the extremely weak reactivity produced with 
AE-2 while AE-1 produced no reaction. 
To quanti tate smaller numbers of antigen on the red cell 
surface biotinylated and avidin/streptavidin conjugated reagents 
(DAKO) were used at appropriate concentrations a nd incubation 
times. This involved the use of the substrate 
3,3' ,5,5'-tetramethylbenzidine (TMB) (Dynatech). Unlike OPD, TMB 
is non-carcinogenic, non-mutagenic and is not susceptible to 
1 ight, producing an intense blue colour with a maximum absorption 
peak at 655nm. Inhibition of reactivity with lM sulphuric acid 
c hanges t he colour of the reaction mi xture from blue to bright 
yellow wit h a two fold increase in colour intensity at 450nm. 
Unfortunately, using avidin extremely high absorbances were 
observed in the negative wells. The cause of this very h igh 
background was due to reactivity between the avidin and PLL and 
reaction was potentiated by biotin. Only gelatin gave any useful 
blocking of the non-specific reactivity, but was unable to 
prevent non-specific reaction occuring between avidin and the red 
cel l membrane. Performance of the avidin/biotin assay system with 
AE-1 and AE-2 has thus been poor. To overcome these problems the 
use of streptavidin (SA) has been investigated. 
Both streptavidin peroxidase conjugate and biotinylated 
anti-mouse Ig were used from a stock concentration of 500 ~g/ml. 
AE-2 at a dilution of 1/4, streptavidin peroxidase 1/1600 and 
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biotinylated anti-mouse IgG at 1/200 were found to be appropriate 
(fig.6). Although better results were obtained with the AE-1 and 
AE-2 monoclonal antibodies using the SA/biotin system there was 
not a sufficient difference in absorbance between tests to 
provide a detectable decrease in AChE in the relevant disorders 
under investigation. Adult and cord cells investigated using this 
system showed no difference . Solid phase techniques are thus not 
yet sensitive enough to detect the differences in erythrocyte 
AChE levels that occur between adult and cord samples. 
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Comparison of AE-1 and AE-2 using HRP 
conjugated and SA/biotin conjugated 
antisera using solid phase techniques. 
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Enzyme Linked Antiglobulin Test (ELAT) 
This is a modification of the technique described by Postoway 
et al. (1985) to quantitate small numbers of human antibody on 
the surface of red cell membranes. Antibodies attached to 
specific antigen on the surface of the erythrocyte are detected 
using an alkaline phosphatase conjugated antibody of high 
specific activity for the primary antibody. Phosphatase substrate 
is added and colour development is proportional to the number of 
antigen sites present on the cell membrane. Alkaline phosphatase 
is used as the conjugated enzyme since peroxidase activity is 
endogeneous to the red cell and would give false positive results 
when HRP is used. Unbuffered saline must be used in the enzyme 
substrate reaction, since inorganic phosphate is an inhibitor of 
alkaline phosphatase. 
Glass test tubes were filled with PBS/BSA and emptied after a 
few minutes. 500~1 aliquots of primary antibody AE-1 and AE-2 
diluted to 5mg/l and 1 . 5mg/l respectively in LISS/BSA, were added 
to the pre-wetted tubes, followed by 500~1 of a 2% red cell 
suspension in LISS/BSA (fig.7). The cells had been previously 
washed twice with PBS/BSA and once with LISS/BSA. The tubes were 
mixed, covered with paraf ilm and incubated for 15min at 3 7 • C 
prior to centrifugation (1000*g for 30sec) The supernatant 
containing the antibody was discarded and the compacted red cells 
carefully washed 3 times in PBS/BSA. 200~1 of alkaline 
phosphatase rabbit anti-mouse antibody (1/100 dilution in 
PBS/BSA) (fig.8) was added. The tubes were again mixed, covered 
with parafilm and incubated for lhr at 37'C. After this period 
the c ells were washed 3 times in PBS/BSA and 1ml of UBS/BSA was 
68 
added to the red cell button, mixed and the cell suspension 
transferred to new tubes pre-wetted with UBS/BSA. The tubes were 
filled with UBS/BSA, centrifuged at lOOO*g for lmin and the 
supernatant discarded. The red cells were mixed with 200ul 
UBS/ BSA and 200ul of p - nitrophenyl phosphate substrate added. 
Tubes were incubated at 37'C for 20min (fig.9), centrifuged at 
lOOO*g for 30sec after which the supernatant was transferred to 
a further tube and neutralized by 25ul of 3M NaOH. lOOul of 
coloured product, diluted (1:3) with UBS/BSA, was transferred to 
a microplate and the absorbance read at 405nm. A control using 
LISS/BSA in place of AE-2 was included as an indicator of 
haemolysis. 
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The effect of increasing % e rythrocyte 
suspension on absorbance obtained us i ng 
AE-2 i n the ELAT. 
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The effect of increasing dilut ion of 
alkaline phosphatase ( AP) . conjugated 
anti-mouse immunoglobulin on the 
absorbance obtained using AE-1 and AE-2 
in the ELAT. 
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Figure 9 
Absorbances obtained at given time 
intervals after addition of substrate 
with adult and cord erythrocytes in the 
ELAT. 
Comparison was made between adult and cord cells using AE-1 
(fig.10) and AE-2 (fig.l1). Co njugate dilution was 1/100 . 
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Figure 10 
Effect of increasing dilution of AE-1 
on absorbance using adult and cord 
erythrocytes in the ELAT. 
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Figure 11 
Effect of increasing dilut i on of AE-2 
on the absorbance obtained with adult 
and cord erythrocytes in the ELAT. 
The enzyme linked antiglobul in test has given reliable results. 
Duplicate testing indicating a CV for this assay s ystem of 7%. 
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Antibody Consumption Test to Quantitate the Number of IgG 
Molecules on the Surface of Erythrocytes after Incubation with 
At least 150 molecules of IgG per erythrocyte are required to 
cause agglutination (Stratton et al., 1983) and between 500 and 
2000 molecules of IgG per erythrocyte are required for maximal 
agglutination (Merry et al., 1984). The number of immunoglobulin 
molecules (AE-2) attached per erythrocyte during the incubation 
stage of AE-2 with erythrocytes was estimated using an antibody 
consumption test to compare the sensitivity of ELAT with the 
haemagglutination test. 
It would be extremely difficult to quantitate the number of 
immunoglobulin molecules on each erythrocyte directly and so an 
indirect method of quantitation was devised. An ELISA was used 
to estimate from a standard curve the amount of immunoglobulin 
in the antibody solution before and after adsorption. The 
difference between these two values indicates the amount adsorbed 
on the erythrocytes. The number of IgG molecules adsorbed per red 
cell can then be calculated from the equation: 
Number of IgG 
molecules per 
red cell 
= amt IgG adsorbed(g) * Avogadro's constant 
m.wt. IgG Number of RBC 
Using an ELISA to quanti tate mouse immunoglobulin IgG the 
absorbances obtained for serial dilutions of AE-2 are indicated 
(fig.12). Serial dilutions of AE-2 previously incubated with an 
equivalent volume of 2% erythrocytes were quantitated in 
parallel. The curves only diverge when the AE-2 dilution is 
greater than 1/32 indicating the amount adsorbed by the 
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erythrocytes only becomes detectable at this dilution. 
This technique cannot, therefore, be performed at the 1/2 
dilution of AE-2 (1.5mg/l) normally used in the ELAT. The 
dilution of AE-2 would have to be greater than 1/32 and therefore 
a 1/100 dilution of AE-2 was chosen. Using the above equation 100 
molecules of AE-2 were calculated to be adsorbed onto the surface 
of each erythrocyte after 15min incubation for a 1/100 dilution 
of AE-2. Using the standard curve of dilution of AE-2 against 
absorbance obtained during the ELAT (fig . 13), if 100 molecules 
are adsorbed per erythrocyte for a 1/100 dilution of AE~2 then 
assuming a linear axis, 270 molecules of AE-2 would be adsorbed 
for a 1/2 dilution of AE-2. The linearity of the axis can be 
proven by using a second dilution ( >1/32) of AE-2 suspension. 
Al. though, it is accepted that this is an assumption, it does 
indicate the method to be twice as sensitive as the 
haemagglutination technique, while providing an objective method 
of quantitation. 
300vl of a 1/100 dilution of AE2 was incubated with 300vl of 
a 2% erythrocyte suspension in LISS at 37'C for specific time 
intervals up to 90min. The cells were centrifuged 1000*g for 
30sec and 100vl of supernatant added to microtitre wells 
precoated with rabbit anti-mouse immunoglobulin (RAMI). After 
1 hour at room temperature the plate was washed 4 times using 
PBS/tween and 100vl of 1/200 dilution RAMI-HRP conjugate added 
and incubated for 1 hour at room temperature. The plate was 
washed 5 times in PBST and lOOvl of OPD substrate added. After 
3min reaction was stopped by adding lOOvl of 1M H2S04 • Absorbance 
was measured at 492nm. 
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Figure 13 
Effect of dilution of AE-2 in the ELAT. 
The number of IgG molecules adsorbed 
per red cell are extrapolated from the 
value obtained with a 1/100 dilution of 
AE-2. A linear axis is assumed. 
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Figure 14 Effect of dilution of AE-2 on 
absorbance obtained in the ELAT. 
If one compares absorbances obtained by the ELAT with doubling 
dilutions of AE-2, the 1/2 dilution used in this technique 
approaches saturating levels (fig.14). The number of 
immunoglobulin molecules bound per erythrocyte reaches a maximum 
at 15min incubation wi th a 2% red cell suspension and then 
decreases progressively with time (fig . 15). 
75 
HU!I)e'"" of IQ ,., I ecu 1 e'J!I per reo ce 11 
1ro.-----~----~-----------------------, 
100 ······-···-- ···-··-·-····-·-·-·-······- ·········-·······-····-···-···········-··············-··--····-·· 
90 ---···-·---····· ---···-···~---------------·-············-··········-··-·····-··-········ 
60 - ·---··-·····-···- ···-·-·-···--·······-·--·········· ········---·······-···-···-····-····-
20 ···-···········-·····-········-··············-····-·-·---········---··---·····-·-······-····-··-·····-
oL-----~------~------~------~----~ 
0 ro ~ ~ ~ 100 
Time or l ncuoatlon ( ml n) 
Figure 15 
Effect of incubation time of a 1/100 
dilution of AE-2 on the number of 
immunoglobulin molecules adsorbed 
per red cell using a 2X cell 
suspension. 
The results are presented in terms of activity using the Ellman 
reaction with acetylthiocholine as substrate and antigen level 
using t he ELAT with p-nitrophenol phosphate as substrate. 
Samples were tested over a number of days (table 7). A gradual 
reduction in AChE was observed. For future testing samples older 
than 8 days were not used. 
Table 7 
AChE 
Activity 
Antigen 
Effect of Age of Sample on Activity and 
Immunological Measurements of ErYthrocyte AChE 
Percentage decrease of original value 
dayO day2 day5 day7 dayS day10 
0 3 .9 4.0 6.0 6.0 7.2 
0 3.6 5.3 5.5 5.2 6.8 
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Units for AChE ActivitY and Antigen Levels 
In addition to results given in terms of vmole of substrate 
hydrolysed per min per ml these are also presented on an 
Arbitrary Unit (AU) scale. The mean absorbance for the adult male 
reference range is regarded as 100% and values for the other 
ranges are presented relative to this. For 30 adult male samples 
the mean absorbance for activity and antigen levels were 1 . 18 and 
1.20 respectively. 
Relationship Between Units of Measurement of AChE 
Activity 
AU = test absorbance 
1. 18 * 
100 
Using equation 1 in the methods section: 
7.39 
* 
test absorbance = ____ vmole/min/ml 
0.0871 
* 
AU = ____ vmole/min/ml 
Antigen level 
AU = test absorbance 
1. 20 * 
100 
77 
Plasma Cholinesterase 
Plasma ChE Activity (Modified Ellman) 
A pool of 5 E1uE1u donors was used as the standard solution of 
plasma ChE. 100111 of diluted test serum and diluted standard ( 1/8 
to 1/128 in 0.01M phosphate buffer pH 7.2) were added to each 
well of a microplate and 100111 of BTI/DTNB (1:9) substrate added 
using an 8 channel micropipette. A reagent blank was included to 
monitor non-enzymic hydrolysis of the substrate. For a 1/16 
dilution of plasma the change in absorbance at 405nm with time 
using a substrate concentration of 0.3mg/ml was linear (figs.16 
and 17). This dilution of test serum was regarded as the optimum. 
Activity was calculated as the change in absorbance at 405nm per 
minute and values read off the standard curve. Results were 
reported in terms of arbitrary units (AU) (ie. activity relative 
to the standard pool). 
The use of microplates and the linkup of the ELISA reader to 
a microcomputer enables 48 duplicate tests to be performed in an 
extremely short space of time. The CV was 5%. 
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Figure 16 Effect of substrate incubation 
time on the absorbance obtained with 
various of dilutions of pooled plasma. 
Substrate concentration 0~3mg/ml. 
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Figure 17 Effect of substrate incubation 
time on the absorbance obtained with 
varying subs tra te concentration. Plasma 
diluted 1/16. 
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Immunological Quantitation of Plasma ChE 
Rocket Immunoelectrophoresis 
Agarose gels were prepared as 1% solutions (0.12g in 12ml) in 
Tris-veronal {barbitone) buffer pH 8. 7 by incubating in a boiling 
water bath. 10~1 of anti-cholinesterase (DAKO) were added to the 
molten agarose prior to pouring onto a glass plate covered with 
gel bond film . Gels must be cast on the hydrophilic surface of 
the film. 5~1 of sera were added to wells (4mm) cut in the solid 
agarose gel and subjected to immunoelec trophoresis at 
2V/cm/plate. 
Plates were pressed under filter paper soaked with distilled 
water for 15min and washed for 15min in O.lM NaCl and for 2*15min 
in water, pressed as before and dried in a stream of air at room 
temperature. 
Gels were incubated in the a-naphthyl acetate (Sigma)/fast red 
(GURR) substrate at 37•c for 10min and observed for staining. 
a-naphthyl acetate used under these conditions is a specific 
substrate for serum cholinesterase. 50%, 25% and 10% standards 
were used and tests were diluted 1 in 4. Cholinesterase can not 
be seen with protein staining alone. 
Superior precipitation rockets were obtained using the Plymouth 
antibodies, 288 (picture 1) being slightly better than 188 and 
the DAKO, BCL and SSI antibodies being better than the B'ham 
anti-ChE. The latter antibody produced diffuse precipitates which 
were difficult to measure. 
Triplicate testing indicated a CV of 12% using this technique. 
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Electrophoresis using Enzyme Amplification 
On completion of electrophoresis as described above the plate 
was washed 3*30min in 0 .1M NaCl. The plate was incubated for 
10min in 5% swine serum (DAKO) diluted in PBS pH 7.2 and for 
45min in peroxidase labeled swine anti-rabbit immunoglobulin 
( DAKO) diluted 1/50 in 5% swine serum in PBS. This antibody 
provides the amplification stage by combining with the rabbit 
anti-ChE in the precipitation rockets. After pressing and washing 
3*30min in 0 .1M NaCl the plate was incubated for 15min in 
substrate, rinsed w~th water, dried in air and the peak heights 
measured. 
This technique, although well established for quanti tating 
other proteins such as alpha foetal protein (Kjrervig and Ingild, 
1983}, did not produce reliable results for plasma 
cholinesterase, probably due to the specific activity of the 
antibodies used. Other drawbacks of this technique are the length 
of time of assay and the limited number of samples handled. 
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Enzyme Immunoassay 
The enzyme immunoassay involved immunological quanti tat ion 
using the enzymic activity of plasma cholinesterase itself. Four 
antisera DAKO, Plymouth 188, 288, and B'ham anti-ChE were 
evaluated for reactivity using this technique. 
100~1 of a 1/500 dilution of primary antibody were incubated 
at 37'C for 1hr, RT for 6hr or 4'C overnight (fig.18). For 
convenience any of these conditions may be used. Plates were 
washed thrice with buffer, 100~1 of diluted plasma ( 10%-100%) 
added to each well and the plates incubated for 2hr at 37'C. 
Plates were washed 4 times with buffer and 100~1 of BTI/DTNB 
substrate added. Absorbances were measured at 405nm after 30min. 
A standard curve can be plotted and results calculated. 
0.1M carbonate buffer pH9.6 in the coating stage and phosphate 
buffer 0.01M pH7.2 in the diluting and washing stages produced 
no results with any of the antibodies. Increasing substrate 
concentration did not improve matters. Increasing the pH of the 
buffers when using the DAKO antibody produced reactivity. 
Carbonate buffer pH9.6 gave the highest absorbance (fig.19). 
However, in spite of concentrated effort using this technique 
the coefficient of variation was high, in many cases reaching t'he 
40%. This is probably a function of the quality of the antiserum 
being used. 
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composition 
the enzyme 
Enzyme Linked Immunosorbent Assay (ELISA) 
1001-11 of anti-cholinesterase , diluted 1/1000 in carbonate 
buffer ( 0 .1M pH9. 6), was added to each well of a microti tre 
plate. The plate was covered with plastic film then incubated at 
4 • C overnight or at 37 · C for 1 hour. The residual liquid was 
discarded and the plate washed thrice with the phosphate buffered 
saline . The plate was tapped dry at each stage. 1001-11 aliquots 
of sera and standards diluted in PBS/tween were added to each 
well, then incubated at room temperature for 2 hours. The plate 
was washed as above and 1001-11 of conjugated antibody, diluted jn 
1/300 in PBS/tween, was added to each well. The covered plate was 
incubated at room temperature for 1 hour prior to washing 4 times 
with PBS/tween. 1001-11 of peroxidase substrate, TMB, was added to 
each well and the initial blue colour development was terminated 
after 2min by addition of 1001-11 sulphuric acid (1M) when the 
colour changed to deep yellow. 
The standard curve can either be plotted on semilogarithmic 
paper with Absorbance at 450nm as ordinate and 
concentration of standard as abscissa, or best of line curve fits 
may be employed directly to results input into a computer. 
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Polyclonal Antisera 
Although this technique worked well using the established DAKO 
ELISA antibodies for C-reactive protein (CRP), performance with 
the DAKO antisera for plasma ChE proved disappointing. Using 
anti-IgG-HRP conjugate both the anti-ChE and anti-CRP were shown 
to coat the microwell to the same extent (fig.20), proving the 
difference in performance was not due to well coating. 
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Figure 20. Mean absorbances at different 
rows along a microplate, using anti-
rabbit IgG HRP conjugate to detect anti-
ChE and -CRP (mean of 3 assays). 
Varying the experimental conditions revealed optimum dilutions 
of the HRP-conjugated (fig.21) and the primary anti-ChE (fig.22) 
antibody to be 1/50 a nd 1/1000 respectively. This dilution of 
conjugate is unrealistic due to the amount available and 
financial restrictions. 
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absorbance. 
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When PEG ( polyethyleneglycol) 6000 was used to improve the 
performance of the system, a large increase in colour 
development, both background and test was observed when both 
antigen and antibody were diluted in 3% PEG. Neither 1% nor 3% 
bovine serum albumin were able to block this high background 
absorbance. Thus PEG did not produce any significant improvement. 
The reducing agents dithiothreitol (OTT), 2-mercaptoethanol 
(2-ME) and iodoacetamide (IA) were used to investigate whether 
splitting the cholinesterase tetramer into its component monomers 
would enable better binding to the coating antibody. Use of the 
proteolytic enzymes papain and bomelain to break up the ChE 
molecule and hence expose the epitopes were also investigated. 
Plasmas treated in this way were subjected to PAGE to examine the 
ChE banding patterns. 
The use of papain in combination with the papain inhibitor E64 
after treatment of antigen, prior to addition to the plate 
produced no improvement over the normal assay method. 
: Use of OTT produced a large increase in colour production. 
However, E15 E15 genotypes, with no immunologically detectable 
protein by immunoelectrophoresis, still produced high absorbances 
indicating false positivity with this technique due to the 
precipitation coating the bottom of the well. Neither 2-ME or 
IA produced any significant improvement in performance. 
A number of test and standard samples were assayed by ELISA 
using DAKO antisera and quite a high CV% was obtained of the 
order of 15%. Correspondence with Dr. Agnette Ingild (DAKO) 
confirmed these findings, high background absorbances again being 
reported. 
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A combination of low dilution of the conjugate and relatively 
high CV% resulted in this antibody being used only as a backup 
to confirm results obtained with other antibody systems. 
It would seem that this particular antibody is more suited for 
immunoelectrophoretic techniques. 
When the Behring anti-ChE diluted 1/500 was used as the primary 
coating antibody a 1/100 dilution of the DAKO anti-ChE HRP 
conjugate was found to be the optimum. Unfortunately, Behring 
ceased production of anti-ChE and supplies became restricted so 
that further use of this antibody was prevented. 
The Plymouth anti-ChE, 188 and 288, were presented for use as 
unpurified rabbit plasma. Microplates were first coated with a 
swine anti-rabbi t-IgG ( DAKO 1/400). Checkerboard titres were 
performed on the anti-ChE diluted 1/20 to 1/200 in PBS/tween. 
These were complemented by dilutions of 1/50 to 1/800 of the DAKO 
anti-ChE-HRP conjugate. With antigen dilutions ranging from 50% 
to 10% no reactivity was observed. The B'ham anti-ChE-HRP 
c~ntained an extremely potent anti-rabbit immunoglobulin and so 
its use with the Plymouth rabbit antibodies would result in false 
positivity. These two rabbit antisera were not suitable for 
ELISA. 
When using the B'ham sheep anti-ChE checkerboard titres were 
performed between the conjugated and unconjugated antisera to 
find the optimum dilutions required, a standard 5% antigen 
concentration being used. Incubation at room temperature for 1h 
produced positive results even while using very high coating 
antibody dilutions. Optimum dilution of the conjugated antibody 
was 1/200. The method was extremely reproducible with low CV 
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(less than 5%). These are conditions associated with a good EL ISA 
based system. However, when used to analyse test samples unusual 
results were which did not correlate with activity or 
quantitation by rocket immunoelectrophoresis. This system was 
therefore rejected. 
Dilutions of antigen were incubated for 2hr at room temperature 
on microplates previously coated with B'ham anti-ChE (1/1000). 
Two-fold dilutions of biotinylated monoclonal anti-ChE (MAb 2-
1) were added. HRP conjugated streptavidin diluted 1/2000 was 
used as detector (fig.23). Optimum concentration of the MAb 2-
1 biotin conjugate was 1/4000. 
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Figure 23 Effect of dilution of plasma on 
absorbance obtained with B'ham anti-ChE 
as primary antibody and varying dilution 
of MAb 2-1 biotin conjugate. 
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When the SSI rabbit polyclonal anti-ChE was used as the primary 
coating antibody at a dilution of 1/5000, antigen dilutions from 
1/20 to 1/320 were incubated for 2hr at room temperature. 
Dilutions of monoclonal anti-ChE 2-1 (fig.24) and 2-4 (fig.25) 
were incubated for 1hr at room temperature and a 1/1000 dilution 
of DAKO rabbit anti-mouse- IgG HRP conjugate used as detector 
antibody. 
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Figure 24 Effect of dilution of plasma on 
absorbance obtained with ssr as primary 
antibody and varying dilutions of MAb2-
1. 
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Plasma ChE ELISA 
SSI antisera 
AbSorbance 192nn 2.-------------------------------------------, 
1 . 5 - ·-----·- - ·4·-···-··-· --- ········· 
·-····--·····-··;:=·········=········::::::::·-·····!:::::::-.. ····=····-···- ···:::.::.::::-······.:::::::············-···-······-······-···················-·-······-····· 
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Figure 25 Effect of dilution of plasma on 
absorbance obtained with SSI as primary 
antibody and varying dilutions of MAb2-
4 • 
Standard curves for both MAb2-1 and 2-4 using SSI as primary 
coating antibody were good, enabling very high dilutions of 
antisera to be used. 
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Monoclonal Anti-ChE: MAb 2-1; 2-2; 2-3; 2-4 
The four monoclonal antibodies to plasma ChE were incubated 
overnight at varying concentrations to establish the relative 
amount attached to the microwell using rabbit anti-mouse-IgG HRP 
conjugate (fig.26). 
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Figure 26 Effect of dilution of MAb's 2-
1, 2-2, 2-3, 2-4 on absorbance after 
incubation overnight at 4'C. Rabbit anti-
mouse-IgG HRP-conjugate was diluted 
1/500. 
ELISA's were performed using serial dilutions of MAb's to 
establish the optimum concentration of each as primary antibody 
(fig. 27). 
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Plasma ChE ELISA 
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Figure 27 Effect of dilution of 
MAb 1 s 2-1 1 2-21 2-3 and 
absorbance. 
100000 
primary 
2-4 on 
A 1/1000 dilution of MAb 1 s 2-1 1 2-2 and 2-4 and 1/400 dilution 
of MAb 2-3 were chosen for the primary coating antibodies. Using 
a 1/40 dilution of plasma the optimum dilution of B 1 ham anti-
ChE HRP conjugate was 1/300 (fig.28). Serial dilutions of plasma 
were used to plot standard curves (fig.29) with these antisera . 
MAb 1 s 2-1 and 2-4 were superior to MAb2-3 and MAb2-2. The latter 
proving unsuitable. 
Results using MAb 1 s with the DAKO anti-ChE HRP conjugate 
detector antibody were inferior to the B 1 ham conjugate 1 but could 
be used as a backup antibody for any confirmatory testing. 
Thus for the ELISA for plasma ChE, MAb's 2-1 and 2-4 were used 
in conjunction with sheep anti-ChE HRP conjugate as the detector 
antibody. This system involved the minimum number of steps and 
produced good standard curves with a CV of 5% . 
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Figure 28 Effect of dilution of B' ham 
anti-ChE HRP conjugate on absorbance with 
each of the primary MAb's. 
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Plasma ChE ELISA 
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Figure 29 Effect of dilution of plasma on 
absorbance using ELISA for ChE with MAb's 
as primary antisera and B'ham anti-ChE 
HRP conjugate diluted 1 /300. 
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Results 
Erythrocyte Acetylcholinesterase 
Reference Ranges for AChE Activity using acetylthiocholine as 
substrate and Antigen Levels by the ELAT technique 
Thirty normal adult male and female and normal cord samples 
were t ested to establish reference ranges for each (table 8). 
Ranges were calculated for activity and antigen levels for 30 
adult males . Results are presented relative to t he mean of these 
ranges on an arbitrary unit ( AU) scale. In addition , r esults are 
given in terms of ~mole of substrate hydrolysed per min per ml 
of packed cells. Data collected in this way allowed frequency 
distributions for heal thy male , female and cord samples t o be 
plotted (fig. 30- 32). 
Tab le 8 Reference ranges of Enzymatic and Immunological 
Activity for Er ythrocyte AChE (mean±SD) for 
populations of healthy males , females and cord 
bloods 
Category Number Activity Antigen 
tested ~mole/min/ml 1 AU2 AU2 
Adult male 30 8 . 71±1.39 100±16 100±14 
Adult female 30 8.54±1.22 98±14 100±15 
Cord 30 4.97±0.87 57±10 62±10 
1 packed cells 
2 AU relative to the mean for healthy adult males 
No significant difference was found between male and female 
values for either activity or antigen levels. Cord cells, 
however, averaged 60% of the healthy adult male value . 
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Table 9 Statistical comparison of AChE activity and 
antigen levels for adult male and cord 
erythrocytes 
Category Mean sn1 S.E. 2 T p 
mean 
Activity 
Adult male 100 16 2.92 
12.48 <0.001 
Cord 57 10 1. 83 
--------------------------------------------------
Antigen 
Adult male 
Cord 
Cord Cells 
Activity 
Anitgen 
100 
62 
57 
62 
1 Standard Deviation 
14 
10 
10 
10 
2 Standard Error of Mean 
2.56 
12.10 <0.001 
1. 83 
1. 83 
1. 94 0.116 
1. 83 
AChE activity and antigen levels for adult male and cord 
samples we re compared statistically to .establish whether each are 
separate populations (table 9) . 
98 
JC-95 36-90 9 1-95 96- 100 101-105 106-110 111-115 118-120 121-125 
Arbitrary Units- Adult male 
1111 AChE activity 1111 AChE ant lgen 
Figure 30 Frequency distribution of AChE 
activity and antigen levels for healthy 
adult males. 
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Figure 31 Frequency distribution of AChE 
activity and antigen levels for healthy 
adult females. 
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- AChE act ivi ty - AChE antigen 
Figure 32 Frequency. distribution of AChE 
activity and antigen levels for healthy 
cord samples. 
Relationship of Erythrocyte AChE with Age of Patient 
Erythrocyte AChE activity and antigen levels were evaluated for 
patients in a number of age groups, from gestational age (fig.33) 
through postnatal (fig.34) and adolesence (fig.35) to adulthood 
(fig.36). 
AChE activity and antigen levels rise sharply after birth 
reaching adult values within 5 months. Levels remain remarkably 
constant throughout the teenage and adult life, with a possible 
slight downward trend towards later life. 
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Figure 33 Effect of 
foetal erythrocyte 
antigen levels. 
--+-ACnE ant IQen 
gestational age 
AChE activ ity 
on 
and 
ArO i trary Unlt9 ( AU) 
120.-----~----~~--------------------------------~ 
100 
60 
<4 0 -······-----·-·-···-······--····-··········-··--··--··-····-··-··-·-····-··-···--········································ 
20 ·····-·-·--··········································-·················-························-····-····················-··········-···················· 
oL---~---L--~----L---~--~--~~--~---L--~~ 
0 2 6 8 10 12 H 16 18 20 
Postnata l age ( weeks) 
-·-· ACnE actI v Ity --+- ACnE ant lqen 
Figure 34 Effect of postnatal age (0 to 
20 weeks) on erythrocyte AChE activity 
and antigen levels. 
101 
ArOitrary untts 
12o.-----------------------------------------------, 
100 ____ ...... :..:... ··· -~·-·· ···-··=~~:::::····::··:_:::.:::···· ;· ···········-··;·······--·· ···············-······r· · ·· ··:.::;::::· 
80 - ------------------------------------ -------··················· ······-··-·----·-···-·-·-··-·-- -·--·-·· 
60 - ··---------·---·-·---················-·········-··········-················-··---·--·-···-·-···-·····-······-·· 
40 -·-·--·---·---------···-·-···--···-·····--·---······-----··------·--···----·---·-··· 
20 ···-···-··········-·-·-·--········-···--············---···--··········--···-······-····-······-·········-·-·········-··········· 
J 7 9 11 13 17 19 
Age (years) 
---- "cne activity 
Figure 35 Efect of age throughout 
adolesence on erythrocyte AChE activity 
and antigen levels. 
Ar!>ltrary u n l ts 
12o.-----------------------------------------------~ 
100 .::::::····::~ ··· ·~· .................. . . , ·······························-···· -:·- ····-···:;:··- -············· 
--------:,;------.. --- -·-·--~-- --:-- ----r-
80 f- ----·--------------·.: ................................................ .;. .... .' ...................................... :. ........................... .. 
60 r------·-····-·-·--····--··--·-·--·----·-·---------··--··---------···--·--·---·--·-·-····--··········-··--···---····--····· 
-'40 f-----.............................................................................................................................................................. .. 
20 r-·-······---··--··---·-·---··---···--·-·-·--·---····-···- ·-··----···--··--·-·--·-·····--···----·-········-····--···--··-·····----···----·· 
0~----~----~------~----~----~------~----~~ 
20 30 40 50 60 70 80 90 
Age (years) 
--· - · AChE !!Ctl v I ty -+- AChE ant l qen 
Figure 36 Effect of age throughout 
adulthood on erythrocyte AChE activity 
and antigen levels. 
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Relationship of Erythrocyte AChE with Mean Cell Volume (MCV) 
A number of samples were tested to establish whether AChE on 
the eryrthrocyte surface is related to the actual size (MCV) of 
the red cell. Samples of erythrocytes varying in MCV from 65 to 
100 were tested for AChE activity and antigen level (fig . 37). 
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Figure 37 The effect of decreasing mean 
cell volume on erythrocyte AChE activity 
and antigen levels in microcytic cells. 
It appears that there is an overall trend of increasing 
erythroc yte AChE activi ty and antigen level with decreasing cell 
size for erythrocytes of MCV in the range 65 to 85. 
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The levels of AChE on the surface of macrocytic erythrocytes 
(MCV 99 to 113) were also investigated (fig.38). These samples 
were selected from a number of patients showing varying degrees 
of vitamin B12 and folate deficiency. There appears to be a wide 
distribution of results with no apparent trend. 
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Figure 38 The effect of increasing mean 
cell volume on erythrocyte AChE activity 
and antigen levels in macrocytic cells. 
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Erythrocyte AChE activity and antigen levels during pregnancy 
Erythrocyte AChE was monitored at various stages of pregnancy 
in 93 women (fig.39). 
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Figure 39 The efect of gestational age on 
erythrocyte AChE activity during 
pregnancy. 
There appears to be an overall increase in AChE a c tivity as 
pregnancy progresses. Although AChE antig·en l evels were not 
monitored on all these patients, t ho se with high activity also 
presented with high antigen levels. Postnatal samples between one 
and three da ys were investigated to ascertain whether the level 
of this enzyme activ ity at deli very was affected (fig.40). 
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Figure 40 Frequency distribution of 
erythrocyte AChE activity and antigen 
levels measured 1 to 3 days postnatal. 
A wide distribution of both activity and antigen levels was 
observed postnatally (fig. 40), reflected in the mean and standard 
deviation (table 10 11). On average AChE was found to be 
increased with several samples presenting with very high 
activity. Samples later than 3 days postnatal were not available 
for testing. Statistical comparison of activity and immunological 
data between females 1 to 3 days postnatal and non-pregnant 
females was made (table 10 11) to establish whether the 
difference between the two was significant. 
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Table 10 Erythrocyte AChE activity in a number of 
patients 1 to 3 days postnatal (mean±SD) 
Category Number AChE Activity 
AU1 pmole/min/ml 2 
Postnatal 38 113±24 9.84±2.09 
(1 to 3 days) 
S.E. 
mean3 
3.89 
T p 
3.22 0.004 
Female 
non-pregnant 
30 98±14 8.54±1.22 2.56 
1 relative to the mean value for healthy adult males 
2 packed cells 
3 Standard error of the mean 
Table 11 Erythrocyte AChE antigen level in a number of 
patients 1 to 3 days postnatal (mean+SD) 
Category Number AChE antigen S.E T p 
AU1 mean2 
Postnatal 22 111±22 4.69 
( 1 to 3 days) 
2.03 0.102 
Female 30 100±15 2.74 
non-pregnant 
1 relative to the mean value for healthy adult males 
2 Standard error of the mean 
Erythrocyte AChE in Haematological Disorders 
A number of haematological disorders were investigated for AChE 
activity and antigen levels (table 12). 
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Table 12 Enzymic and antigenic activities of erythrocyte 
acetylcholinesterase in patients having 
haematological disorders . 
AChE Arbitrary Units 
Condition Activity1 Antigen1 Comment 
PNH 
PNH 
PNH 
ALL 
AML 
AML 
AML (M5) 
AML (M 5) 
CLL 
CLL 
CLL 
CMML 
NHL 
Cancer breast 
malaria 
Auto-immune IgG 
Auto-immune IgG+C3d 
ABO HDN day 0 
ABO HDN day 3 
MDPS 
PRV 
alcoholic cirrhosis 
Diabetes 
Iron def. anaemia 
Reticulocytosis 27% 
Reticulocytosis 42% 
HE 
HS 
73 
79 
62 
57 
79 
83 
87 
88 
96 
79 
102 
11 2 
88 
120 
62 
62 
86 
47 
50 
94 
97 
104 
92 
110 
115 
119 
105 
130 
76 
81 
72 
51 
84 
82 
89 
89 
104 
71 
100 
115 
95 
117 
72 
70 
88 
41 
47 
98 
93 
96 
92 
115 
91 
98 
low 
low 
low 
very low 
low 
low 
low end norm 
low end norm 
normal 
low 
normal 
h igh end 
normal 
high 
low 
low 
low end norm 
low 
low to norm 
normal 
normal 
normal 
normal 
high end norm 
high end norm 
high/normal 
normal 
high/norm 
1 AU relative to mean value for healthy adult males 
PNH 
ALL 
AML 
CLL 
CMML 
NHL 
HDN 
MDPS 
PRV 
HE 
HS 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
Paroxysmal Nocturnal Haemoglobinuria 
Acute Lymphoblastic Leukae mia 
Acute Myeloid Leukaemia 
Chronic Lymphoblastic Leukaemia 
Chronic Myelo-Monocytic Leukaemia 
Non-Hodgkins Lymphoma 
Haemolytic Disease of the Newborn 
Myelodysplastic Syndrome 
Polycythaemia Rubra Vera 
Hereditary Eliptocytosis 
Hereditary Spherocytosis 
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Plasma Cholinesterase 
The plasma ChE standard consisted of a pool of _5 E1uE 1u blood 
bank donor plasmas. These plasmas were frozen within 6 hours of 
collection and kept at -3o·c. The ChE activity and antigen levels 
for this standard were assigned 100 arbitrary units (AU). Values 
for the samples tested are presented relative to this standard. 
Statistical Comparison of Methodology 
(1) Plasma ChE Activity 
All activities using benzoylcholine as substrate were measured 
by the Cholinesterase Research Unit, Hammersmith Hospital, London 
W12 OHS , who also supplied DN, FN and R02 numbers to identify the 
genotypes. 170 E1uE 1u samples were assayed for plasma ChE activity 
using BzCh and BTI as substrate and statistical comparison was 
made between the results obtained for each (table 13-14). A graph 
showing linear regression was plotted (fig. 41) . 
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Table 13 Statistical analysis of Plasma ChE Activity using 
BzCh and BTI as substrates for 170 E1uE 1u samples 
Minimum value 0.79 100 
Maximum value 1. 66 222 
Mean 1. 02 138 
Standard Deviation (SD) 0.16 23 
Coefficient of Variation (CV%) 16 17 
1 ~mols/min/ml plasma 
2 AU relative to a standard of 5 E1uE1u donors 
Table 14 Regression Analysis of Results Obtained for Plasma 
ChE Activity for 170 E1uE 1u samples using BzCh and 
BTI as Substrates 
Regression Analysis 
Linear Polynomial 
Correlation Coefficient 0.889 0.889 
Standard Error 10.86 10.86 
Slope 1.266 
Y Intercept 8.217 
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Figure 41 Linear regression analysis showing 
relat ionship between the two substrates Bzch and BTI in 
the assay of plasma ChE activity . 
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(2) Plasma ChE Immunological Quantitation 
(i) Rocket Immunoelectrophoresis (288) and ELISA {MAb2-1) 
50 E1uE 1u samples were quantitated for plasma ChE levels by R. I. 
and ELISA. Statistical comparison was made between the results 
obtained by both techniques (table 15-16) and a graph of linear 
regression plotted (fig.42). 
Table 15 Statistical AnalYsis of Plasma ChE Quantitation 
by Rocket Immunoelectrophoresis and ELISA for 
QJL..E1 uE 1 u samples 
Minimum value 85 100 
Maximum value 190 190 
Mean 137 139 
Standard Deviation (SD) 35 26 
Coefficient of Variation (CV%) 25 19 
1 AU relative to 5 E1uE1u donor standard (Plymouth 288) 2 AU relative to 5 E1uE 1u donor standard (MAb2-1) 
Table 16 Regression Analysis of Results Obtained for Plasma 
ChE Quantitation by Rocket Immunoelectrophoresis 
and EL ISA for 50 E1 uE1 u samples 
Regression Analysis 
Linear Polynomial 
Correlation Coefficient 0.740 0.741 
Standard Error 18.05 18.10 
Slope 0.574 
Y Intercept 59.98 
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Figure 42 Linear regression analysis showing 
relationship between rocket immunoelectrophoresis and 
ELISA in the quantitation of plasma ChE. 
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(ii) ELISA Using MAb2-1 and MAb2-4 as primary antibodies 
170 E1uE 1u samples were quanti tated for plasma ChE levels by 
ELISA using MAb2-1 and MAb2-4 and statistical comparison was 
made between the results obtained with each antibody (table 17-
18) and a graph of linear regression was plotted (fig. 43). 
Table 17 
Minimum 
Maximum 
Mean 
Standard 
Statistical Analysis of Plasma ChE Quantitation 
by ELISA using MAb2-1 and MAb2-4 for 170 E 1uE 1~ 
samples 
MAb2-1 1 MAb2-4 1 
value 100 98 
value 230 230 
136 144 
Deviation (SD) 25 26 
Coefficient of Variation (CV%} 18 18 
1 AU relative to a standard of 5 El UEl u donors 
Table 18 Regression Analysis of Results Obtained for Plasma 
ChE Quantitation by ELISA using MAb2-1 and 
MAb2-4 for 170 E1uE 1u samples 
Regression Analysis 
Linear Polynomial 
Correlation Coefficient 0.815 0.815 
Standard Error 15.36 15.39 
Slope 0.868 
Y Intercept 26.06 
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Figure 43 Linear regression analysis showing the 
relationship between the monoclonal antibodies MAb2-1 and 
2-4 used in ELISA for the quantitation of plasma ChE. 
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Analvsis of Genotypic Variants for Plasma Cholinesterase 
Data obtained for enzymic activity with butyrylthiocholine and 
benzoylcholine as substrate and for antigen levels as measured 
by ELISA, using MAb2-1 and MAb2-4 for a number of genetic 
variants of plasma cholinesterase (table 19) has enabled 
to be plotted (fig. 44-46). Calculations of the ratios of 
(table 20) indicates a statistical distinction between these 
genotypes. 
Table 19 Cumulative activity and immunological data for 
genotypic variants of plasma ChE. 
Results are presented as mean ± SD 
Genotype Activity R . I. z MAb 
Number BzCh1 BTIZ 2-1 z 2-4 2 
EluE1 u 170 1.02±.16 138±23 137±35 136±25 1-14±26 
El uEla 60 0 . 77±.15 104±23 122±33 118±27 122±25 
ElaEla 56 0.46±.09 57±13 86±30 90±28 90±27 
EluEls 7 0.57±.10 81±13 90±25 84±15 79±12 
E1aE1s 11 0 . 25±.10 33±14 55±24 48±14 45±12 
E aE k 1 1 20 0.56±.08 74±12 82±25 88±22 89±21 
1 lJmols/mi n/ml plasma 
z AU relative to a standard of 5 E1uE1u donors 
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Table 20 
Genotype 
Comparison of activity and immunological data 
for the usual and atypical variants of plasma ChE. 
Results are presented as mean + SO 
Activity MAb Ratio 
Number BTI 1 2-1 1 2-4 1 BTI/2-1 BTI/2-4 
EluEl u 170 138±23 136±25 144±26 1.02±.08 0.96±.08 
EluEla 60 104±23 118±27 122±25 0.88±.08 0.85±.08 
ElaEla 56 57±13 90±28 90±27 0.63:.t.07 0.63±.07 
1 AU relative to a standard of 5 E1uE 1u donors 
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Table 21 
Genotypes 
BTilHAb2-1 
El UElu 
El uEla 
Statistical comparison of the ratios of 
activity to immunological protein for the usual 
and atypical genotypes using the students 't' 
test. 
mean SD S.E. 1 T p 
mean 
1.02 0.08 0.0061 
11.65 <0.001 
0.88 0.08 0.01 
-------------------------------------------------------
EluEla 0.88 0.08 0.01 
17.86 <0.001 
ElaEla 0 . 63 0.07 0.0094 
-------------------------------------------------------
EluElu 1. 02 0.08 0.0061 
32 . 59 <0.001 
ElaEla 0.63 0.07 0.0094 
BTilHAb2-4 
EluEl u 0.96 0.08 0.0061 
9.16 <0.001 
EluEla 0.85 0.08 0.01 
-------------------------------------------------------
El uEla 0.85 0.08 0.01 
15.72 <0.001 
ElaEla 0.63 0.07 0.0094 
0.96 0.08 0.0061 
27.58 <0.001 
0.63 0.07 0.0094 
1 Standard Error of Mean 
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Figure 44 
u u 
Frequency distribution of E 1 E 1 individuals for enzymic activity 
using (a)benzoylcholine and (b)butyrylthiocholine and 
immunological quantitation using (c)MAb2-1 and (d)MAb2- 4. 
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Figure 45 
Frequency distribution of E ~ E ~ individuals for enzymic activity 
using (a)benzoylcholine and (b)butyrylthiocholine and 
immunological quantitation using (c)MAb2-1 and (d)MAb2-4. 
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a a 
Frequency distribution of E 1 E 1 individuals for enzymic activity 
using (a)benzoylcholine and (b)butyrylthiocholine and 
immunological quantitation using (c)MAb2-1 and (d)MAb2-4. 
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Investigation of heterogeneity of the silent gene for plasma ChE 
ELISA using MAb's 2-1 and 2-4 was used to quantitate the enzyme 
protein in 43 apparently 'silent' homozygotes with little or no 
catalytic activity (table 22). The ELISA estimates are expressed 
as the percentage ratio of the binding of each sample compared 
with the binding observed for a pool of 5 E1uE 1u plasmas. 
Rocket immunoelectrophoresis ( R. I.) was performed using the 
'piggy-back' method. Rockets of the same height and staining 
intensity as the 25% standard do not contain any immunologically 
dete ctable c holinesterase prot~ in. Longer and weaker staining 
peaks are indicative of functionally inactive, but 
immunologically reactive cholinesterases, the amount being 
proportional to the difference in height of the rocket obtained 
for the test and the height of the 25% standard (picture 2). 
Results for R.I. (table 19 and 22) are expressed as a percentage 
of the 2 5% standard. All assays were at least duplicated. 
Cumulative data is given in table 23. 
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Table 22 Plasma cholinesterase activ ities and levels 
in 43 apparent silent gene homozygotes. 
Group Individual Activity R. I. 2 EL ISA MAb 
BzCh1 BTI 2 2-1 2 2-4 2 
1 I LM 0 0 0 0 0 
2 I IG 0 0 0 0 0 
3 I RR 0 0 0 0 0 
4 I TT 0.01 0 0 0 0 
5 I ss 0.02 0 0 0 0 
6 I LC 0.02 1 0 0 0 
7 I YW 0.02 1 0 0 0 
8 I AD 0 . 03 0 0 0 0 
9 I DF 0.03 0 0 0 0 
10 II AG 0 14 20 17 19 
11 II KJ 0 7 18 20 
12 II DE 0.06 3 20 11 24 
13 III CL 0 0 12 12 
14 III DD 0 0 0 2 2 
15 III MP 0 0 0 3 3 
16 III JV 0 0 0 2 0 
17 Ill MM 0 0 0 3 0 
18 III EE 0.01 4 15 4 5 
19 III YW 0.02 0 0 2 0 
20 Ill AB 0.02 1 3 1 
21 III SK 0.02 1 0 9 6 
22 Ill FK 0.02 0 10 3 0 
23 III KQ 0.02 2 10 7 4 
24 III AG 0.02 2 0 2 3 
25 III MH 0.03 11 18 7 8 
26 III SQ 0.04 0 2 4 
27 III MH 0.04 2 0 2 3 
28 III RC 0.06 6 7 7 
29 III QB 0.12 1 0 0 
30 IV YL 0 0 120 125 
31 IV MS 0 0 200 210 
32 IV GD 0 0 150 14 5 
33 IV AF 0 4 130 125 
34 IV AW 0 0 100 180 200 
35 IV JM 0 0 210 205 
36 IV VH 0 0 160 130 200 
37 IV KM 0 0 116 112 
38 IV CH 0.01 0 110 120 200 
39 IV PH 0.02 1 180 145 
40 IV DS 0.04 0 100 150 150 
41 pp 0.13 12 0 0 0 
42 VT 0.08 7 35 120 66 
43 JK 0.04 18 52 4 4 48 
1 ~mols/min/ml plasma 
2 AU relative to a standard of 5 EluElu donors 
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Table 23 Cumulative data for apparent silent gene 
homozygotes. 
Group Patient Activity R. I. 2 M Ab 
BzCh1 BTI 2 2-1 2 2-4 2 
I 1 - 9 0.01 0 0 0 0 
II 10 - 12 0.02 8 20 15±4 21:!:3 
III 13 - 29 0.03 2 4 4 4 
IV 30 
-
40 0.01 0 118±29 153±34 165±38· 
41 0.13 12 0 0 0 
42 0.08 7 35 120 66 
43 results discarded - probable 
pathological low activity 
1 ~mols/min/ml plasma 
2 AU relative to a standard of 5 E1uE1u donors 
Immunological studies of families segregating the silent gene 
for plasma cholinesterase 
Seven family groups segregating the silent gene for plasma ChE 
were investigated for enzymic activities using the two substrates 
BTI and Bzch with dibucaine and fluoride inhibition and for 
antigen levels using MAb2-1 and 2-4 (table 24). The pedigrees of 
these familes are shown (fig. 47). 
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Table 24 Biochemical data for individuals from seven 
families each segregating an apparently 'silent' 
homozygote (P =Propositus). 
Family Activity DN FN EL ISA MAb 
Individual BzCh1 BTI 2 2-1 2 2-4 2 
1 I-1 0.72 120 80 58 116 115 
I-2 0.63 104 80 60 85 87 
II-1 p 0 0 0 0 
II-2 0.99 140 81 59 118 118 
II-3 0.69 102 80 58 96 88 
2 I-1 0.55 76 82 62 80 80 
I-2 0.34 53 78 62 48 52 
II-1 p 0.03 2 3 3 
II-2 0.31 44 83 60 60 58 
II-2 0.34 54 83 60 60 52 
II-3 0.31 50 79 61 58 60 
II-3 0.18 25 79 61 25 22 
II-4 0.04 0 2 4 
II-5 1. 25 160 79 62 180 180 
III-1 0.53 65 80 57 78 82 
III-2 0.64 105 81 58 100 110 
3 I-1 0.21 32 79 65 37 41 
I-2 0.59 60 80 59 70 52 
II-1 0.71 82 80 58 84 70 
II-2 p 0.02 1 0 0 
II-3 0.02 1 3 1 
II-4 0.61 78 82 60 86 70 
II-5 o.2e 40 eo 57 35 52 
4 I-1 0.49 76 82 58 104 90 
II-1 p 0 0 12 12 
III-1 0.53 90 80 60 104 102 
III-2 0.29 50 79 62 60 50 
III-3 0.35 60 79 59 66 60 
III-4 0.70 110 82 59 108 110 
IV-1 0.23 40 80 61 52 48 
IV-2 0.22 42 81 62 65 60 
IV-3 0.27 48 79 58 61 54 
5 I-1 0.50 80 82 61 69 64 
II-1 p 0 0 116 112 
II-2 0 0 210 205 
6 I-1 0.57 67 81 63 205 152 
I-2 0.28 22 81 63 37 35 
II-1 0.02 1 180 145 
II-2 p 0.02 0 200 150 
7 I-1 0 0 200 210 
I-2 0 0 120 125 
I-3 p 0 0 150 150 
II-1 0.33 45 81 60 45 45 
II-2 0.43 65 82 61 58 58 
II-3 0.32 48 81 63 140 140 
II-4 0.46 70 81 61 140 150 
1 1Jmols/min/ml plasma j 2 AU relati ve to standard 
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Figure 47 Pedigrees of seven families segregating aJ2J2arentl;y 
'silent' homozygotes 
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Immunological Studies of families segregating the E 1h gene for 
Plasma Cholinesterase 
Plasma ChE activity and antigen levels were examined for 2 
families in which a new allele E1h was found to be segregating 
with the E1a gene (Whittaker and Britten, 1987) (table 25), This 
data enabled cumulative ranges for the heterozygous E1h variants 
within these families to be calculated (table 26). The family 
pedigrees are shown (fig.48) . 
Table 25 Plasma c holinesterase for the E1h families 
Family Activity DN FN R02N ELISA MAb Probable 
Individual BzCh1 BTI 2 2-1 2 2-4 2 Genotype 
1 I-1 0.77 108 64 48 73 108 88 E uE a 
I-2 0.57 100 78 56 100 106 105 lk 1h El El 
II-1 0.58 90 80 60 100 81 79 E UE h 1 1 
II-2 0.26 36 28 28 33 50 46 E aE h 1 1 
II-3 0.55 85 82 59 100 78 82 E1uElh 
II-4 p 0.24 30 27 26 30 40 48 E aE h 1 1 
II-5 0.59 96 80 58 100 94 88 EtuElh 
II-6 0.46 61 58 44 58 66 62 E1aElk 
II-7 0 .58 84 57 45 62 90 80 EtaElk 
II-8 0.96 130 82 59 100 112 130 E UE k l l 
II-9 0.26 34 29 28 34 60 54 E aE h 1 1 
II-10 0.25 34 28 27 35 44 45 E aE h 1 1 
II-11 0.63 108 78 57 100 110 104 E UE h 1 1 
III-1 0.53 82 79 57 100 80 62 E UE h l 1 
III-2 0.67 79 58 100 E UE h 1 l 
III-3 0.95 152 82 58 97 130 122 El UEl u 
III-4 0.98 140 79 59 94 134 148 E 1 UE 1 u 
III-5 0.94 140 80 58 96 134 140 EluElu 
III-6 0.87 130 81 59 97 125 105 E1uEl_u -
2 I-1 0.67 98 65 50 75 110 102 El uEl a 
I-2 0.60 96 78 56 94 105 95 E UE h 1 1 
II-1 p 0.30 28 25 32 E aE h 1 1 
II-2 0.32 55 29 27 28 78 72 E aE h 1 1 
III-1 0. 7 6 120 78 56 97 118 118 E UE h 1 1 
1 ~mols/min/ml plasma 
2 AU relative to a standard of 5 E1 uE1 u donors 
P = Propositus 
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Table 26 
Genotype 
El UElh 
E aE h 1 1 
E kE h 1 1 
E 1 UE 1 u 
ElaEla 
Cumulative data for the heterozvgotes of the 
genotypic variant E1h of plasma ChE compared 
with E 1~1u and E 1~1a individuals 
Number Activity EL ISA MAb 
Bzch1 BTI 2 2-1 z 2-4 2 
7 0.62±.07 97±12 95±15 90±17 
5 0.27±.03 39±10 54±14 53±10 
1 0.57 100 106 105 
170 1.02± . 16 138±23 139±23 147±32 
56 0.46±.09 57± 1 3 90±31 90±28 
1 pmo ls/min/ml plasma 
z AU relative to a standard of 5 E1uE1u donors 
Figure 48 
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Plasma Cholinesterase Levels throughout Pregnancy 
Two groups of women were studied. Group A consisted of 16 
healthy pregnant women who, at term, underwent spontaneous or 
induced labour with epidural analgesia followed by vaginal 
delivery. Patients with any complication of pregnancy or mothers 
of babies with any neonatal abnormality were no t studied. None 
of these patients h ad abnormal liver function or any major 
illness and none received general anaesthesia. Veneous blood 
samples were taken during pregnancy, prior to the administration 
o f epidural analgesia and subsequently during the puerpe r i urn 
(fig.49). The second group of six women (Group B) was studied to 
clarify the c hanges in c holinesterase which occurs during the 
first post partum week (fig. 50). All Group B patients were 
healthy and underwent obstetrically indicated elective caeserian 
sec t ion under epidural analgesia. Venous blood samples were 
obtained from them prior to delivery and on 1, 2 , 3, 4, 5 and 42 
days postpartum. 
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Figure 49 Plasma ChE levels throughout pregnancy 
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Figure 50 Plasma ChE levels up to 5 days post-delivery 
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Discussion 
AcetYlcholinesterase 
Traditional methods of assay of erythrocyte AChE involve 
electrometric (Michel 1949), radiometric (Augustinsson 1971) and 
calorimetric techniques (Whittaker 1984). Separate validation of 
the calorimetric method described is not required since it is not 
significantly changed from the protocol 
(Whit taker 1984) . The method based on the 
already 
Ell man 
reported 
reaction, 
provides a reliable method of measuring AChE activity. The 7% 
coefficient of variation for this technique (CV) is similar to 
that previously reported (Ellman et al., 1961). 
An AChE standard for both activity and antigen levels was 
unavailable due to the limited storage period of red cells. 
Activity values are therefore presented in arbitrary units (AU) 
relative to the mean of the normal range for healthy adult males 
and also as ~moles of substrate (acetylthiocholine iodide) 
hydrolysed per min per ml of packed cells~ A healthy male sample 
was always included in the batch as the control sample for the 
procedure. 
The substrate was always present in excess and the temperature 
was maintained at 22'C, A reaction blank prepared by substituting 
phosphate buffer solution in place of the sample is mandatory to 
measure the spontaneous hydrolysis of substrate. AChE activity 
is maximum between pH 7.5 and 9. At high pH there is considerable 
non-enzymatic hydrolysis of the substrate which would yield a 
high blank value. Phosphate buffer pH 7.2 was used in this assay 
to reduce the blank to negligible proportions. 
Erythrocytes are thoroughly washed before assay and 
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contamination due to plasma ChE is negligible and ChE inhibitors 
were not considered necessary in this instance. As indicated 
(fig.3), there is a linear relationship between length of time 
of incubation of substrate and absorbance at 405nm using the 
assay conditions described. 
The development of monoclonal antibodies for erythrocyte AChE 
(Fambrough et al, 1982) has enabled alternative methods of 
quantitation of this enzyme. The enzyme is located on the outer 
surface of the erythrocyte membrane and, in consequence, the 
epitope to which these antibodies are directed are available for 
reaction. This allows the adaptation of a number of serological 
techniques for the quantitation of erythrocyte AChE. 
Haemagglutination using the two monoclonal antibodies AE-1 or 
AE-2, directed against different epitopes on erythrocyte AChE, 
gave slightly weaker reactivity with red cells from a cord and 
PNH sample than with a sample from a normal heal thy adult. 
Agglutinates, however, were weak and easily disrupted. This 
method does not allow objective quantitation of AChE, since the 
number of AChE sites are insufficient for this procedure to be 
sensitive to· large percentage changes in the overall number of 
AChE molecules. It merely acts as a crude test to detect the 
presence of AChE on the surface of erythrocytes. 
The microplate antiglobulin test using AE-2, provides a method 
of large scale screening with relative ease. The use of weaker 
red cell suspensions in this method compared to the 
haemagglutination method requires greater dilution of AE-2, 
allowing increased sensitivity of reaction. This method merely 
discriminates and does not quantitate AChE. Results are either 
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positive or negative (table 5). 
Solid phase microplate methodology was investigated to ally the 
inherent handling advantages of microplates with a quantitative 
procedure. However, quantitation of AChE, even using the 
sensitive ELISA based reagents biotin and streptavidin in 
conjunction with erythrocytes coated with either AE-1 or AE-2 
monolayered onto microplate well surfaces, did not result in a 
method sensitive enough to detect the differences in the number 
of AChE sites on the surface of adult and cord erythrocytes. This 
is unfortunate since this method has a number pf advantages to 
recommend it; many samples can be tested with ease, antisera may 
be used with suitable economy and no transfer of reagents is 
required. With the advent of even more sensitive reagents, for 
example alkaline phosphatase/anti-alkaline phosphatase (APPAP) 
complexes, this method has real potential. The development 
of a fluid phase homogeneous enzyme linked antiglobulin test 
(ELAT) for erythrocyte AChE proved extremely successful, 
constantly providing reproducible results for both adult and cord 
samples (CV=7%). Samples may be reliably quantitated for as long 
as 8 days after venesection. 
An antibody ·consumption test indicated a maximum of 270 
molecules of AE-2 bound per erythrocyte when using AE-2 at a 
concentration of 1.5mg/l with a 2% cell suspension following 
15min incubation at 37'C. These conditions corresponded to a 
coloured product having an absorbance of approximately 1.2 units 
at 405nm (fig.11), which is a convenient location on the 
absorbance scale. Decreases in thP. number of AChE binding sites 
(which directly affects the number of AE-2 molecules bound) can 
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therefore be easily monitored. This can be illustrated in cord 
erythrocyt~s when an absorbance of about 0.7 is usually obtained 
(fig.11). Incubation of erythrocytes with AE-2 must not be longr 
than 15min as a decrease in the number of AE-2 molecules per 
erythrocyte (desorption) was observed after this time (fig.15). 
A minimum of 150 molecules of IgG per red cell are required for 
detection by the haemagglutination method ( Stratton et al., 
1983). This together with the requirement of between 500 to 2000 
molecules of IgG per erythrocyte for maximal agglutination (Merry 
et al., 1984) suggests that the ELAT is at least twice as 
sensitive as the haemagglutination method, while also providing 
an objective means of quantitation. Unfortunately the method is 
labour intensive and only six duplicate tests can be reliably 
performed per run. It would be of advantage if an automated or 
semi-automated procedure could be developed to overcome these 
difficulties. 
AChE results are presented in terms of activity for the Ellman 
method and antigen quantitation using the fluid phase ELAT. The 
mean value for the adult male is assigned 100 arbitrary units 
(AU) for both activity and antigen level, while values for the 
other groups of samples tested are presented relative to this. 
No difference was found between adult male and adult female 
values with both showing normal Gaussian frequency distributions 
(fig.30-31). 
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Relationship of Erythrocyte AChE with Age of Patient 
Cord blood erythrocytes were found to have a mean activity of 
57% of healthy adults, in general agreement with other workers 
(Sabine 1955; Burman 1960) and mean antigen level of 62% of 
healthy adults. The frequency distribution of AChE for cord red 
cells (fig.32) and statistical comparison (table 9) indicate the 
higher range of values for the antigen levels compared to the 
activity is fairly significant (p = 0.116). This suggests that 
although there is a smaller number of AChE molecules on the 
erythrocyte surface as defined by AE-2 these molecules may be of 
a slightly different conformation to the usual healthy adult AChE 
molecule resulting in an enzyme which is less efficient 
catalytically. This difference between activity and antigen 
levels becomes smaller when samples from babies 0 to 20 weeks 
old were tested (fig. 34). Insufficient numbers of samples were 
available to perform statistical comparison. 
Samples taken from pre-term foetuses and neonates indicate a 
steady rise in both erythrocyte AChE activity and antigen levels 
from 47% at 20 weeks to 60% of adult values at term, with the 
antigen levels rising slightly faster than activity (fig. 33). 
This upward trend is continued post-delivery, adult levels being 
reached within 5 months (fig.34). Levels remain remarkably 
constant throughout the teenage and adult period, while a slight 
downward trend occurs in later life (figs.35-36). 
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Relationship of ErYthrocyte AChE with Mean Cell Volume 
The normal range for adult erythrocyte volume (mean cell volume 
MCV) is quoted as 86±10fl (Dacie and Lewis, 1984). Erythrocytes 
decrease in cell volume in a number of haematological disorders 
such as iron deficiency anaemia and increase in conditions such 
as megaloblastic anaemia. Erythrocytes of reduced MCV have an 
overall trend of increasing AChE activity and antigen level with 
decrease in cell size. 
The 2% erythrocyte concentration used in the ELAT was 
determined using the haematocrit, measured with an automated 
Coulter cell counter and so more cells of smaller volume would 
be required for a 2% cell suspension. Results of the ELAT are in 
consequence presented per unit surface area rather than per 
erythrocyte. Three explanations may be given for erythrocytes of 
lower MCV resulting in higher antigen values: ( i) increased 
numbers of AChE molecules on the microcytic cell surface; ( ii) 
the same number of AChE molecules on the cell surface as on 
normal cells, which on a cell of smaller volume would result in 
a higher site density; (iii) an alteration in shape and/or 
location of the molecule in the cell membrane with easier access 
of the monoclonal antibodies to their epitopes. An additional 
survey of microcytic samples using red cell count (RBC) as the 
determinant of cell concentration could be used to exclude the 
first two possibilities. 
Results with macrocytic erythrocytes were confusing, activity 
and antigen levels are apparently unrelated to cell size 
(fig.38). This may be due to a number of factors. Two causes of 
macrocytosis are vitamin B12 and folate deficiency; both 
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substances are required for erythrocyte nuclear development. 
Reduced amounts of these will therefore impair protein and hence 
AChE synthesis. In addition, the circulating erythrocytes present 
in macrocytosis are immature compared to normal cells. The 
resultant AChE activity and antigen levels observed may be a 
combination of these factors. 
Relationship of ErYthrocyte AChE with Pregnancy 
An overall increase in AChE activity was observed as pregnancy 
progresses,' patients with high AChE activity presenting with high 
antigen levels (fig.39; table 10). Samples from patients 1 to 3 
days post delivery gave significantly elevated levels of activity 
(fig.40) when compared to healthy non-pregnant females (table 10 
- 11; p=0.004). Antigen level comparisons were less significant 
(p=0.102). None of the patients tested presented with microcytic 
values. This is in agreement with Pri tchard et al. ( 1956) who 
reported a steady rise in erythrocyte AChE during the first, 
second and third trimesters, remaining at a constant level at 
delivery and decreasing after 6 weeks post partum. These authors 
explained the increase by a progressive rise in the concentration 
of younger red cells (which contain greater amounts of AChE than 
older cells) circulating in the blood. This is due to the 
maintenance of the pre-pregnant haemoglobin levels with a 25 to 
35 per cent increase in plasma volume. The rate of erythrocyte 
product ion must exceed erythrocyte destruction and thus a greater 
proportion of the circulating red cells must have been released 
more recently from the bone marrow than in blood from the normal 
non-pregnant individual. In part agreement with th1s hypothesis 
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the statistcal values above indicate that while the numbers of 
AChE molecules are increased when compared to healthy non-
pregnant females (p=O .102) there is a more significant difference 
in activity between these two groups (p=0.004) suggesting in 
addition to an increase in the number of AChE molecules there may 
be a conformational difference in the AChE molecule allowing 
greater contact of the catalytic site with the substrate. As 
discussed later (reticulocytosis) this is indicative of the 
presence of younger red cells. It is also feasible that this 
increase in AChE in the cells could be caused by some hormonal 
effect on erythrocyte production or membrane structure. 
These observations are in contrast to those with plasma 
cholinesterase where a significant decrease in activity occurs 
during pregnancy ( Robertson, 1966), with even lower levels of 
activity reported during the first 2 to 3 days postpartum (Hazel 
and Monier, 1971; Robson et al., 1986). 
ErYthrocyte AChE Activity and Antigen Levels in Various 
Haematological Disorders 
Additional haematological disorders were investigated and 
categorised into three groups, determined by normal, lower or 
higher levels of AChE (table 12). No abnormality in AChE levels 
were observed in polycythaemia, myelodysplastic syndrome, non-
hodgkins lymphoma, and 2 out of three cases of chronic lymphatic 
leukaemia indicating this enzyme can not be used as a marker for 
these conditions. These results are surprising especially in the 
cases of polycythaemia and myelodysplasia, since malignant 
conditions affecting erythrocyte cell lines would be expected to 
139 
af feet their surface components, As has been previously reported 
( Abernathy et al., 1988) normal levels were found in a case of 
alcoholic cirrhosis with decreased plasma cholinesterase 
activity, in a case of insulin controlled diabetes mellitus 
(Suhail and Rizvi, 1989) and in hereditary elliptocytosis. In the 
latter condition the patient was diagnosed as a heterozygous 
trait with haemolysis being well compensated. Altered erythrocyte 
AChE activity may well be observed in the homozygous condition. 
Reduced levels of AChE activity and antigen level were observed 
in three cases of PNH not recently transfused. Brimijoin et al. 
(1986) using fluorescence activated cell sorting (FACS), reported 
a similar finding and concluded that the cholinesterase defect 
was dominated by enzyme loss rather than by structural 
abnormalities affecting enzyme function. Using this technique a 
fluorescent conjugate is used in place of an enzymic conjugate, 
but the principle remains the same as for the ELAT. The 
deficiency of this enzyme is a marker for PNH I cells (complement 
sensitive) and in consequence this particular method could be 
important when monitoring the prognosis of patients with PNH, 
since the relati~e proportions of AChE deficient and AChE 
containing cells could be established. 
All cases of acute leukaemia examined presented with low values 
for AChE, with one case of acute lymphoblastic leukaemia having 
particularly low levels. Two of the cases were newly diagnosed, 
while the rest were in relapse. This is in agreement with Scott 
et al. (1973) who reported low red cell AChE levels in patients 
in relapse and normal values when in remission. If one considers 
the common origins of blood cells it is not surprising that a 
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malignancy in the white cell line would p~esent with an 
abno~mally low level of AChE in the e~yth~oid cell line, but it 
is su~prising that low levels should appear in this type of 
leukaemia and not in the malignant conditions mentioned earlie~. 
The observation of patients with low ~ed cell AChE in patients 
in ~elapse becoming no~mal in remission is of impo~tant 
diagnostic value (Scott et al., 1973). It may well be that the 
drugs used in ~elapse, 
~emission, may be 
being mo~e powe~ful than those used 
di~ectly affecting AChE activity 
in 
on 
e~yth~ocytes. This would not appear to be the case, however, 
since immunological levels of the enzyme we~e also found to be 
low in ~elapse indicating a p~obable dec~ease in the numbers of 
AChE molecules in the e~yth~ocyte memb~ane. Toxic inhibit ion 
would be ~eflected by dec~eased enzyme activity, but no~mal 
immunological quantitation. The possibility exists that these 
cytotoxic d~ugs may be influencing the implanting of AChE in the 
erythrocyte membrane at the erythropoetic level in the bone 
mar~ow. A larger investigation with closer co~~elation to the 
patient's clinical condition, such as ~emission or ~elapse and 
emphasis on drug therapy or other treatment would be ~equi~ed to 
substantiate the use of erythrocyte AChE as a marke~ for acute 
leukaemia. The measu~ement of AChE activity and antigen levels 
on the white cell su~face would also be of value in these 
conditions. One case of CLL also gave low values of enzymic and 
antigenic activities, but it is not known whethe~ this patient 
was in relapse o~ whethe~ additional complications we~e involved. 
An interesting case of malaria gave ve~y low values of AChE 
enzymic and antigenic activity despite the patient p~esenting 
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with microcytic erythrocytes. The malarial parasite once inside 
the erythrocyte completely takes over, becoming fully competent 
for replication, protein synthesis and aerobic energy metabolism. 
The erythrocyte, however, has lost its nucleus, ribosomes and 
mitochondria and with them most of its energy supply, except for 
glycolysis. Maintenance of the integrity of the cell membrane 
therefore becomes increasingly difficult. However, since the 
malarial parasite is only detected in about 1% of the red cell 
population it is rather surprising that this alone would produce 
the AChE level seen in this patient and it is probable that it. 
is influenced by other factors. Additional patients are required 
to clarify these findings. 
Low AChE levels were observed in two cases of auto-immune 
haemolytic anaemia (AIHA) where the responsible antibody was IgG. 
Similar findings were reported by Scott and Rasbridge (1971) who 
concluded that IgG type antibodies are more likely to cause 
reduced AChE levels. Sirchia et al ( 1970) reported that AChE 
activity was significantly subnormal in the IgG and IgG + 
complement types of AIHA, while it was not significantly lower 
than normal where complement alone coated the red cells. 
Two cases of ABO haemolytic disease of the newborn (HDN) were 
found to have low levels of AChE. Similar cases were observed 
( Ferrone et al. , 1968; Herz et al. , 1968) in which low levels 
were reported for ABO HDN, but normal levels for Rhesus 
haemolytic disease. These results are confusing since both 
antibodies must be of the IgG type to cross the placental barrier 
to sensitize the foetal erythrocytes. Erythrocyte AChE is 
associated with the protein on which the AB( H) antigens are 
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located (band 3) and the binding of antibodies to these sites may 
disrupt this association. There are approximately 300,000 A or 
B sites per erythrocyte in the newborn and antibodies reacting 
with these structures may have a profound effect on the integrity 
of the membrane or simply mask the AChE catalytic and 
immunological binding sites. In contrast there are only 10 -
20,000 Rh(D) sites per erythrocyte and combination of antibodies 
with these structures probably would not have such an effect. 
A raised AChE activity, but with a normal antigen level, was 
:;p.. 
observed in ~cases of reticulocytosis. This seems to indicate 
a change in the orientation of the molecule in the cell membrane 
on reticulocytes allowing greater contact of the catalytic site 
with the substrate, whilst maintaining normal orientation of the 
epitope towards AE-2. 
A case of hereditary spherocytosis ( HS) similarly presented 
with increased AChE activity and normal antigen levels. This 
appears to be in agreement with Streichman et al ( 1983) who 
proposed that the AChE molecules appear more fully exposed at the 
cell surface in HS cells, possibly due to diminished hydrophobic 
interactions with neighbouring molecules in the membrane. This 
suggests a modified orientation of AChE in the erythrocyte 
membrane allowing greater enzymic activity, whilst the total 
number of molecules, as indicated by the ELAT, remains within the 
normal range. 
Elevated AChE levels were found in cases of chronic 
myelomonocytic leukaemia (CMML) and breast cancer, where it is 
possible that some drug therapy or iatrogenic involvement may 
affect the erythropoeitic system in some way. 
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The exact function of AChE in the erythrocyte membrane is 
unknown, but apart from a report of a single family with 
hereditary deficiency of erythrocyte AChE (Johns, 1962) and also 
a family with altered erythrocyte AChE (Coates and Simpson, 1972) 
the enzyme appears to be present on all erythrocyte samples 
tested. Additional analysis of disorders where AChE levels are 
altered may provide further insight into the function that this 
enzyme has in the erythrocyte membrane. The variation observed 
in certain disorders may be of diagnostic value in a number of 
conditions such as leukaemia. 
Recent reports ( Daniels 1989) have 1 inked the erythrocyte 
membrane protein OAF to the Cromer blood group system. In an 
effort to link AChE to a blood group system Herz et al (1972b) 
investigated AChE in En(a-) cells, but found normal activity. In 
addition, the blood groups Holley and Gregory have been 
discounted (B.G.R.L. unpublished data), although links with the 
Cartwright system cannot be excluded. It is hoped that a link 
between AChE and a blood group system, possibly through the 
identification of an AChE null phenotype, will be established in 
the near future. Monoclonal antisera and techniques similar to 
the ELAT will aid in this goal. 
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Plasma Cholinesterase 
The examination of cholinesterase activity using a combination 
of substrates and inhibitors (Whittaker, 19688 , 1968b; Whittaker 
et al., 1981, 1982; Whittaker and Britten, 1980) provide a 
particularly sound basis for characterization of the various 
genotypic variants of cholinesterase. 
An assay of plasma ChE activity using butyrylthiocholine (BTI) 
as substrate has been developed using a microplate Ellman 
technique. Butyrylthiocholine has an affinity for human plasma 
ChE twice that of acetylthiocholine, is more stable with respect 
to pH and temperature ( Szasz, 1968.) and is therefore the 
substrate of choice for human ChE using the Ellman method of 
assay. 
Although maximum activity of the enzyme is observed at pH 8.5 
- 9,0 (Silk et al., 1979) there is considerable non-enzymatic 
hydrolysis at this pH and in consequence phosphate buffer pH 7.2 
is used for the microplate assay. This reduces the non-enzymatic 
hydrolysis to negligible proportions and still allows the linear 
relationship of the assay procedures to be obtained (figs.16-
1 7) • 
In general, haemolyzed samples and heavily jaundiced samples 
were avoided since they were found to interfere with absorbances 
obtained. If plasma ChE activity was required on jaundiced 
samples, these were further diluted and results adjusted 
accordingly. A plasma blank was also used in these cases. All 
assay procedures were performed at 22'C, Das and Liddell (1970) 
have shown that temperature correction can be made by adding or 
subtracting 9% for each 1'C variation of the reaction mixture 
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from 25'C. 
The plasma ChE standard consisted of a pool of 5 E111E111 blood 
bank donor plasmas previously stored in plastic packs containing 
anticoagulant/preservative ( ci trate, 6g/l; phosphate, 0. 5g/l; 
dextrose, 5.8 g/1) and frozen at -30'C for approximately 8 months 
before use. The pool was divided into small aliquots and kept 
frozen until required. Each aliquot was used during a single day 
and then discarded. This pool provided the large volume of 
standard required for use throughout the study. Any continuity 
of standard would not have been possible using plasma from 
commercial sources. Supply of standard in such volumes would also 
have been prohibative on a cost basis. 
The ChE activity and antigen levels for the standard were 
assigned 100 arbitrary units (AU). Values for the samples tested 
are presented relative to this standard. The means for both ChE 
activity (138AU) and antigen (136AU and 144AU as defined by MAb2-
1 and 2-4 respectively) for 170 E111E111 individuals are 
considerably higher than activity ( 100AU) and antigen levels 
(100AU) for the standard (table 19), This is surprising as the 
standard is a pool of E111E111 samples. Additional pooled standards 
were examined and gave similar levels. The low values may, in 
part, be due to the presence of citrate, which has been shown to 
be a partial inhibitor of ChE (Whittaker, unpublished work), 
Alternatively, Ca2• and Mg 2• have been reported to activate ChE 
(Kobayashi et al., 1988) and the chelation of citrate with these 
ions would prevent this activation. The effect of these ions on 
the antigen levels is not known. Possibly a conformational change 
altering the epitope to which the antibody combines may be 
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involved. Comparison of plasma ChE activity using BzCh as 
substrate with the microplate Ellman method using BTI for 170 
E1uE 1u samples indicate a good linear relationship between the two 
techniques (correlation coefficient of 0. 889 fig. 41). The 
coefficients of variation for the E1uE 1u population tested for 
both substrates were similar (16% for BzCh and 17% for BTI; table 
13- 14). The microplate Ellman method using BTI as substrate is 
therefore a good alternative to BzCh when measuring plasma ChE 
activity. The use of microplates provides a convenient method of 
measuring large numbers of samples in a relatively short period 
of time. The coefficient of variation (CV) for this method (ME) 
was found to be 5%, which is comparable to that previously 
reported for the method using a cuvette (Whittaker, 1984). 
Quantitation of ChE has traditionally involved immunodiffusion 
and immunoelectrophoresis using precipitation, usually with 
polyclonal rabbit antisera. These techniques have been 
particularly useful in elucidating the heterogeneity of the 
silent gene phenotypes (Goedde et al., 1965; Rubinstein et al. 1 
1970). Optimum results were obtained with rocket immune-
electrophoresis, both by the normal and the 'piggy back' 
technique, with the Plymouth rabbit antisera. The method however 
is time consuming and therefore unsuitable for large numbers of 
samples. It involves subjective analysis with inherent 
inaccuracies, is unsuitable for measuring low levels of protein 
(below 10% of usual), and does not lend itself to direct computer 
manipulation. A comparison was made with the enzyme 1 inked 
immunosorbent techniques under development. Unfortunately, the 
enzyme immunoassay, which utilizes the enzyme activity of the 
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plasma ChE itself, using DAKO polyclonal antisera was discounted 
as unsuitable due to the very high CV%. The enzyme 1 inked 
immunosorbant assay (ELISA) using conjugated and unconjugated 
DAKO antisera also proved a disappointment, due to high 
background absorbances and CV ( 15%). Absorbance differences 
between buffer (blank) and E1uE 1u sera using these antibodies were 
small even using enhancers such as PEG. It would seem that the 
DAKO antibody is more suited to immunoelectrophoretic techniques 
than ELISA. 
Both Plymouth polyclonal antisera ( 188 and 288) were also 
unacceptable for ELISA, but produced very good results by 
immunoelectrophoresis and were especially useful in the 'piggy 
back' technique to evaluate 'silent'individuals for plasma ChE. 
The B'ham sheep polyclonal antisera (used both in primary and 
secondary conjugated stages) gave unusual results in the ELISA 
which did not correlate with ·those obtained from the other 
techniques. Possible cross-reaction with human IgG was discounted 
since the sheep anti-rabbit IgG had been absorbed out in one of 
the stages of preparation of the reagent by the Binding Site. 
A comparison of the DAKO (fig.21), SSI (fig.24), and B'ham 
anti-ChE (fig.29) polyclonal antisera as secondary detector 
antibodies with the monoclonal antibody MAb2-4 as primary coating 
antibody indicated optimum performance was obtained using the 
B'ham anti-ChE, HRP conjugated as the secondary antibody. 
The ELISA technique using the monoclonal and B'ham antibodies 
involves only 3 stages and with the use of pre-coated microplates 
results were easily obtained within 5 hours, In consequence, 
although plates may be coated by incubating the monoclonal 
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antibody in the wells at 37'C for 1 hour, coating overnight at 
4'C in a humid chamber proved more convenient. Although the 4 
monoclonal antibodies appeared to coat the microwell surface to 
the same degree (fig.26) when these antibodies were evaluated 
using standard plasma from an E1uE 1u donor pool with HRP-
conjugated B'ham anti-ChE as secondary antibody the performance 
of the antisera decreased in the order MAb2-4, 2-1, 2-3, 2-2 
(fig.27). The concentrations of each antisera as determined by 
the supplier (State Serum Institute) do not explain this 
difference ( MAb2-1, 2. 3mg/ml; MAb2-2, 1. 45mg/ml; MAb2-3, 
4.36mg/ml: MAb2-4, 2.46mg/ml). It can only be concluded that the 
relative affinity of the antibodies for plasma ChE also decreases 
in this order. MAb2-2 also gave high background absorbance. For 
this reason MAb2-1 and 2-4 were used routinely for the 
quantitaion of plasma ChE and MAb2-3 was used as a backup 
antibody when required. MAb2-2 with its relative poor performance 
was not used. ELISA using these antibodies produced good standard 
curves (fig.29) with a CV of 5%. 
Analysis of results obtained for the quantitation of plasma ChE 
of 50 E1uE 1u samples by rocket immunoelectrophoresis ( R. I.) and by 
ELISA (MAb2-1) showed the mean values for each range to be in 
close agreement (table 15). The coefficients of variation for the 
population, however, was greater for R.I. (25%) than for ELISA 
(19%) (table 15) probably indicating the former to be a less 
precise technique. A linear relationship exists between the two 
methods (fig. 42) with a correlation coefficient of 0.740 (table 
16). This fairly low correlation reflects the low precision of 
the immunoelectrophoretic technique. This is supported by the 
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high coefficient of variation for this technique (CV=12%). 
The mean values of the ranges for plasma ChE levels in 170 
E1uE 1u samples measured by ELISA was slightly higher using MAb2-
4 than 2-1 (table 17) possibly indicating easier access of the 
MAb2-1 epitope in the E1uE 1u pooled standard. The coefficient of 
variation for the population was the same for both antibodies 
(18%- table 17). Results obtained with MAb2-1 and 2-4 are 
linearly related (fig. 43) with a correlation coefficient of 
0.815. This correlation is surprisingly lower than expected and 
one which is difficult to explain because with many of the 
samples a correlation coefficient of 1 was observed. In spite of 
repeat assay some samples gave divergent values. Further work may 
resolve this problem. 
Characterization of plasma ChE was thus obtained by measuring 
activity using benzoylcholine and butyrylthiocholine, inhibtion 
characteristics using DN, FN and R02N as well as immunological 
quantitation by rocket immunoelectrophoresis and ELISA using the 
monoclonal antibodies 2-1 and 2-4 in conjunction with the B'ham 
anti-ChE-HRP conjugate. 
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Analysis of Genetic Variants for Plasma Cholinesterase 
Normal Gaussian distribution curves were obtained for both 
activity and antigen level determinations with E1uE 1u (fig.44), 
,-c..W>s 
genotypes. The ran-ges for 
cholinesterase activity and antigen levels are significantly 
different for each genotype (p<O.OOl in all cases- table 21). 
Results· presented below are in the order activity with BTI, and 
immunological levels of ChE as defined by MAb2-1 and 2-4 
respectively. All are given in arbitrary units relative to the 
Assuming each gene contributes equallly to the activity and 
antigenicity in the homozygotes, one can calculate the gene 
contributions to these values for the E1u and E18 genes. Using the 
values so obtained a theoretical value expected for the 
heterozygote, E1uE 18 can be calculated. 
Mean values (table 19) obtained with E1uE 1u individuals (138AU, 
136AU and 144AU) indicate the presence of the E1u gene results in 
the production of approximately 69AU of cholinesterase activity 
and 68AU and 72AU of immunological protein as defined by MAb2-
1 and MAb2-4 respectively (ie. each gene contributes half the 
value of the genotype). The values for the E1u gene should taly 
with those for the E1uE18 genotype if the E18 gene is truely 
silent. However, results for E1uE 19 individuals (81AU, 84AU and 
79AU) were slightly higher than expected, possibly due to the 
small number of samples tested or to the heterogeneity of the 
'silent' gene. 
Activity and immunological data (table 19) from E18 E18 samples 
(57AU, 90AU and 90AU) indi~ate the presence of the E18 gene cause 
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values to be decreased on average to 29AU, 45AU and 45AU. This 
represents a decrease of 58%, 34% and 37% respectively when 
compared to the E1u values. Confirmation of these values for the 
is truely silent, contributing neither to activity nor to 
immunological protein, the E18 gene gave values of 33AU, 48AU and 
45AU. These figures are in close agreement with the results 
obtained from the atypical homozygotes. 
Values for the E1u gene (69AU, 68AU and 72AU) and for the E18 
gene (29AU, 45AU and 45AU) would give expected theoretical values 
for the E1uE 18 genotype of 98AU, 113AU and 117AU. These are in 
close agrement with the actual values obtained with this genotype 
(104AU, 118AU and 122AU). 
Similar activity and immunological data obtained from E 8 E k 1 1 
individuals (74AU, 88AU and 89AU) and the calculated values for 
the E18 gene ( 29AU, 45AU and 45AU) indicate the E1k gene produces 
45AU of activity and immunological protein of 43AU and 44AU as 
defined by MAb2-1 and 2-4 respectively. 
These values are obtained from the mean of ranges for these 
genotypic variants and any individual may vary from values 
presented here. The mean contribution each gene makes towards the 
activity and antigen levels are shown (table 27). The effective 
efficiency (EE) of the activity of the cholinesterase produced 
by each genotypic variant was calculated using the immunological 
data in the equation: 
EE = Enzyme Activity (BTI as substrate) * 100% 
Immunological level (mean of MAb2-1 and 2-4) 
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Table 27 
Gene 
Elu 
E a 1 
Elk 
Contribution of the E 1~ .. L-!ha and E1k genes to 
enzyme activity and antigen levels. 
Contribution of each gene Effective Efficiency 
of gene product using 
MAb BTI as substrate 
BTI 1 2-1 1 2-4 1 (%age) 
69 68 72 99 
29 45 45 64 
45 43 44 103 
1 AU relative to standard donor plasma 
Atypical plasma cholinesterase differs qualitatively from usual 
cholinesterase due to a point mutation at position 70 on the 
amino acid chain (McGuire et al., 1989). This could explain the 
lower enzyme activity that this variant exhibits. However, a 
quantitative decrease, although much smaller than that observed 
with activity, also occurs. Consideration of activity values 
indicates that the Et gene product is only (29/69 *100%) 42% as 
active as the E1u gene product when butyrylthiocholine is used 
as the substrate (table 27). However, this assumes that the same 
number of molecules occur in each variant. Immunological data 
indicates that for the E1a gene (45/70 *100%) 64% of the number 
of cholinesterase molecules are present compared to the E1u 
individual (table 27). This indicates that the relative 
efficiency of the atypical cholinesterase molecule is 
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(42%/64% * 100%) 66% (and not 42%) compared with the usual form 
of the enzyme. A combination not only of a qualitative, but also 
a quantitative difference between atypical and usual forms of the 
enzyme is therefore indicated. 
This hypothesis is contrary to the findings of Rubinstein et 
al ( 1978) who compared the concentrations of immunologically 
reactive cholinesterase in a few atypical variants and concluded 
that the E18 allele results in the production of about the same 
number of immunopotent cholinesterase molecules as the E1u 
allele. The data presented here supports the conclusions of 
Eckerson et al (1983) who indicated the average concentration 
of enzyme protein as defined by a rabbit antiserum and enzymic 
activity at using either benzoylcholine or o-
ni trophenylbutyrate as substrate, was about 30% lower in the 
atypical compared with the usual enzyme. Eckerson et al (1983) 
therefore suggested that the atypical enzyme not only has altered 
catalytic properties ( K,), but also may be synthesized more 
slowly, or alternatively cleared more rapidly in vivo, than the 
usual enzyme. Our results clearly show that the dynamic ratio of 
synthesis and degradation of the two variant enzymes differ as 
well as their catalytic activity. 
Analysis of data from shows that the 
cholinesterase enzyme produced by the E1k gene has an efficiency 
of 103% compared to 99% for E1u. However, activity values 
obtained for this genotype were not consistant with accepted 
levels reported in the literature (Whittaker, 1986), but it must 
be emphasised that only a small number of samples were tested. 
Nevertheless, it appears that the resultant cholinesterase 
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activity observed in E1k individuals is due to a quantitative 
rather than a qualitative abnormality in agreement with 
Rubinstein et al (1978) who presented enzymic and immunological 
data indicating the 
molecules by 33%, 
E k 1 gene causes reduction 
Analysis of the Heterogeneity of the Silent Gene 
of usual E u 1 
It has been recognised . for many years that the so-called 
'silent gene' represents a heterogeneous complex· ( Goedde and 
Altland, 1968; Rubinstein et al., 1970), At present, 3 separate 
genes, E19 , E1 t and E1r, have been described (Scott, 1973; Scott 
and Wright, 1976). The relative affinities for different 
substrates (Altland and Goedde, 1970), electrophoresis 
(Rubinstein et al., 1970) as well as immunodiffusion (Goedde and 
Altland, 1968) have been used to differentiate the variants. 
Results obtained by ELISA and rocket immunoelectrophoresis are 
in close agreement (table 22). Moreover, it can be seen from this 
table that the majority (40) of the 43 samples can be separated 
into four groups leaving a heterogenous pool. 
The first section of patients (1-9) shows that an 
immunologically reactive cholinesterase cannot be detected with 
any of the monoclonal or polyclonal antisera by either technique. 
This group probably represents the E19 E15 homozygote, In all 9 
cases no detectable protein following electrophoresis, nor 
significant binding to monoclonal antibodies, nor activity with 
BTI as substrate were observed. Such observations could indicate 
the absence of protein synthesis by the E19 gene for plasma 
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cholinesterase. However, 0-3% of the normal enzyme activity was 
found in this group using benzoylcholine as substrate. It 
therefore seems more likely that a protein is synthesized in 
which the antigenic sites for the monoclonal antibodies are 
absent, disorientated or permanently blocked by an inhibitor. In 
addition, the catalytic site is disorientated or partially 
blocked. Goedde et al. (1965) suggested a qualitative difference 
between the silent. gene enzyme protein and the normal 
cholinesterase protein as the likely explanation of the absence 
of enzyme activity and antigen binding by immune-electrophoresis 
or double immunodiffusion tests in two silent homozygotes. A 
structural alteration of the enzyme protein was assumed to be 
more likely than a quantitative difference. Results presented in 
table 22 are not in variance with this hypothesis. 
The second group of patients (10-12), although showing 
diminished immunological reaction relative to the E1uE 1u genotype 
show increased immunological reaction relative to groups 1 and 
3 by the ELl SA technique as well as by rocket 
immunoelectrophoresis. The catalytic activity is also real, 
although not appreciable. It can be assumed that the structural 
modification or disorientation of the cholinesterase molecules 
in these individuals restricts the binding of the monoclonals to 
their antigenic sites. These findings of weaker than normal 
affinity of the antibodies support the observations of Rubinstein 
et al. (1970) and suggest that this group may be type II, which 
is controlled by the E t 1 gene, and probably represent the 
The third group of patients (13-29) show definite, but low 
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levels of immunoreactive protein- in fact, intermediate between 
our first and second groups of patients, The enzymic activity, 
by either substrate, in this third group is less than that found 
in our second group. Such findings are suggestive of a 
heterozygote, indicating that this third group could possibly be 
the heterozygote E15 E1t, This hypothesis requires confirmation by 
detailed family studies some of which are reported in the next 
section. 
The fourth group (30-40) shows appreciable binding of antibody, 
both by ELISA and by rocket immunoelectrophoresis, indicating 
that cholinesterase protein is present in all 11 samples. These 
values are much greater than those previously reported. There is, 
however, no enzymic activity using BTI and little activity with 
benzoylcholine (0-0.04%). This group may, therefore, represent 
a new gene, E1x. Evidence indicates that the antigenic sites at 
which the monoclonal antibodies react are not only intact, but 
may be more accessible for binding or alternatively more protein 
molecules may be synthesized. The low activity indicates that the 
catalytic site is disorientated or inhibited. 
Individual 41, who differs from all the others, may represent 
the third type of serum cholinesterase deficiency found in 
Eskimoes (Scott and Wright, 1976). This variant is reported to 
have about 10% of the normal cholinesterase activity and the gene 
has been designated E1r. No immunoreactive protein has been 
demonstrated by any of the monoclonals used in the ELISA. 
Individual 42 has appreciable immunoreactive protein but, 
unlike individuals in group 4, this patient has definite 
catalytic activity with both substrates. This individual may be 
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an E1rE 1x heterozygote, but this is a very tentative suggestion. 
Individual 43 is quite unique amongst the present group under 
investigation. This lady died shortly after the present sample 
was taken and it is possible that pathological involvement may 
be the explanation of the low activity found with benzoylcholine. 
The immunological studies certainly indicate the presence of 
immunoreactive protein. 
Immunological Studies of Families segregating the Silent Gene 
Seven family groups comprising apparently 'silent' homozygotes 
for plasma ChE and their relatives were screened by ELISA. All 
individuals in these families have the most common phenotype if 
one considers only the dibucaine and fluoride numbers. There is 
only one individual in these family studies who can be classified 
as a truely silent homozygote having the genotype E19 E19 • All 
biochemical parameters for individual II-1 in family 1 are zero 
(table 24) and in consequence it is mandatory that both parents 
must be segregating the E18 gene. Activity and immunological 
levels indicate that both these parents and the daughter II-3 
have the genotype E1uE 19 • The remaining daughter II-2 presents 
with normal activity and immunological levels together with 
normal inhibition characteristics and hence must be E1uE 1u. 
Three families 2, 3 and 4 appear to be segregating both the E19 
and E1 t genes in the propositus. One of them II-1 (family 2) has 
been phenotyped as E19 E1t (table 24) and one of his siblings II-
4 has the same phenotype. In this family the father I-1 is 
segregating a usual gene E1u, but it is difficult to assign the 
E19 gene to the father I-1 or to the mother I-2 for preference, 
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but it is probably the mother I-2 who has the genotype E1kE 1 t. 
Individuals II-2 and II-3 have similar biochemical parameters to 
their mother I-2 and therefore are of the genotype E 1kE 19 • The 
apparent diversity of results given in table 15 for individual 
II-3 in family 2 has interesting implications. The first sample 
was taken before marriage and the second after marriage when 
taking oral contraceptive. It has been observed that not only is 
the cholinesterase activity decreased by oral contraceptives, but 
that the isoenzyme pattern following electrophoresis is also 
changed (Whittaker et al., 1971). Both quickly return to normal 
on cessation of oral contraceptive. This is however, the first 
indication that the extent of immunobinding protein is also 
decreased by the use of oral contraceptives. It is therefore 
desirable that the possible influence of oral contraceptives on 
any low values of immunobinding protein in healthy young women 
should be eliminated prior to the assignment of the segregation 
of a rare gene. The two samples for the sister II-2 were also 
taken pre- and post- marriage, but this lady does not take oral 
contraceptives and the biochemical parameters in her case are 
very similar for both samples. In family 3, although the 
propositus II-2 has no detectable immunological protein using 
MAb2-1 and 2-4, he does have slight activity with both BTI and 
Bzch and therefore has the probable genotype E19 E1t. This is 
substantiated using data from his brother II-3 who exhibits the 
same amount of activity, while demonstrating detectable 
immunological protein. II-3 therefore, also has the genotype 
E1
5 E1 t. In this family the E 1k gene appears to be segregating with 
the father I-1 and is also present in the two sisters II-1 and 
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II-4 and the brother II-5. It is difficult to establish whether 
the E1s gene is segregating with the father or with the mother, 
but since both father and sister II-5 have the E1k gene and 
activity for the father is lower than II-5 it is assumed that the 
father is segregating the E1s gene and II-5 the E1 t gene. The 
father therefore has the genotype E1kE 1s and II-5 the genotype 
E/E1t. The mother of the propositus must therefore have the 
genotype E1uE 1t, II-1 and II-4 having the same values for activity 
and immunological protein with MAb2-1 and 2-4 have the genotype 
E1uE 1k, Family 4 is again unusual with the p['obable segregation of 
the E1k gene as E1kE 1s in two of the children III-2 and III-3 of 
the propositus II-1. It seems probable that the other children 
of II-1 ( III-1) and E UE t 1 I (III-4) 
respectively. There are problems in assigning suitable genotypes 
to the children IV-1, IV-2 and IV-3 of the sibling III-4. All the 
children have the same genotype and all must have inherited the 
E1t gene from their mother, but their low activities and low 
levels of immunological ChE protein is contrary to the 
inheritance of the E1u gene. The three children must have 
inherited a rare gene from their father. It is not the E1a gene, 
since their phenotype is usual and it seems likely that the E1k 
or even E1J may be segregating in the fourth generation of this 
family. Both genes are associated with diminished enzyme activity 
- 33% and 66% reduction of the usual E1u activity for E1k and E1j 
['espectively (Rubinstein et al., 1976; 1978). It is remarkable 
that the E1k gene appears to be segregating in the three families 
each having a propositus with the genotype E15 E1t. Although this 
is a striking result no significance can be attached to this 
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segregation within these families until more data is available. 
Two of the propositi in families 5, 6 and 7 appear to be 
segregating the new 'silent' gene E1x. The propositus 11-1 and 
her brother 11-2 in family 5 each show high immunological ChE 
protein with MAb2-1 and MAb2-4 and from this it may be deduced 
that the E1x gene is segregating in this family. However, the 
ELISA results for their mother 1-1 with either MAb2-l or MAb2-
4 are low and so it is extremely improbable that she is 
segregating the E1x gene. Thus, from the biochemical data it may 
be concluded that this lady has the genotype E1uE 19 • In this case, 
her children cannot be homozygote for the E1K gene, but must be 
heterozygote E1xE 19 • In family 6 the propositus 11-2 and his 
brother Il-l must have the same genotype, since their biochemical 
data are very similar and both are segregating the E1K gene. The 
father 1-1 has a high level of immunological ChE protein whereas 
the mother I-2 is definitely low. It can only be assumed that the 
father 1-1 is segregating the E1x gene and his enzymic activities 
with the two substrates are indicative of an E1uE 1x genotype, The 
genotype of the mother is suggestive of E1kE 15 • This means that 
their children Il-l and 11-2 are heterozygotes with ge:notype 
E19 E1x. Although there is considerable variation in the ELISA 
results obtained for the siblings 1-1 and 1-2 or the propositus 
I-3 in family 7, it is nevertheless apparent that the E1x gene is 
segr€gating throughout the generation. One may query whether the 
diverse results of 1-2 and 1-1 represent a heterozygote and the 
homozygote of E1x respectively. The children of 1-1 should 
resolve this problem, since if 1-1 is homozygous then all his 
children 11-1, 11-2 and 11-3 must segregate the E1x gene. But the 
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ELISA values for II-1 and II-2 are low and so we must assume that 
the E
1
x gene is not segregating in these children. In contrast, 
the high ELISA values for both monoclonal antibodies for II-3 
indicates that the E1x gene is segregating. I-1 must therefore be 
a heterozygote with a probable genotype E15 E1" with his children 
II-1, II-2 and II-3 having the genotype E1kE 15 , E 1uE 1
5 
and E1kE 1x 
respectively, since the low enzymic activities of II-1 and II-
3 probably indicate that the E1k gene is segregating within this 
family. The E1x gene is also segregating in individual II-4 and 
her genotype is probably E1uE 1x. 
Immunological Studies of families segregating the E1h gene for 
Plasma Cholinesterase 
Unusual inhibition characteristics in two unrelated 
suxamethonium sensitive individuals indicative of a new allele, 
E
1
h, segregating with the E18 gene was reported by Whittaker and 
Britten (1987). Both families w~re evaluated for activity with 
butyrylthiocholine as substrate and immunological quantitation 
as defined by MAb's 2-1 and 2-4. 
In the initial study 3 of the siblings (II-2, II-9 and II-10) 
in family 1 had identical inhibition characteristics to the 
propositus I-1. Activity and immunological data confirmed these 
findings, with similar results in all 4 cases (table 25). 
Immunological results fell within the ranges characteristic for 
E
1
8 E
1
5 • Siblings II-1, II-3, II-5, 11-11 and III-1 have been 
genotyped as E1uE 1h. Activity and immunological data for these 
individuals fall within the ranges for both E1uE 15 and E 1uE 1t, 
except II-11 who presents with slightly higher values, which fall 
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just outside the range for E 1uE 15 (table 19). 
Samples from the propositus in family 2 were not available for 
testing, but activity (Whittaker and Britten, 1987) is very 
similar to that of the sibling II-2. Activity and immunological 
levels for this sibling were slightly higher than expected, 
falling outside the higher end of the E18 E15 range. In addition, 
individual III-1 also exhibits high activity and immunological 
levels for an E1uE 111 • Since the parent I-2 has a level of 
cholinesterase within the range for an E1uE 111 the E111 gene cannot 
be the cause of this high activity observed in sibling III-1. The 
high activity must therefore be 
individual may therefore be C5'. 
due to the E u I gene. This 
The parents I-1 in family 1 and I-1 in family 2 fall within the· 
range for E1uE 18 , while I-2 in family 2 has typical values for 
E1uE 111 • However, values for I-2 in family 1 are far higher than 
would be expected for the genotype E1kE 111 and if it were not for 
the inhibition characteristics for I-1 and the results obtained 
with the rest of the family, I-2 could mistakenly have been typed 
Analysis of Cumulative ActivitY and Immunological Data for the 
'Silent' Variants 
Using cumulative data for activity and immunological le\"els 
obtained for the 'silent' (table 23) and E 111 (table 26) genes, 
mean values for the contibution of each of these genes may be 
calculated (table 28). The mean values for E 15 E 15 ( OAU, OAU and 
OAU) indicate the E15 gene contributes neither to activity nor to 
immunological protein. Data (table 23) obtained with the 
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homozygote E
1
tE 1t (8AU 1 15AU and 21AU) gives values for the E1t 
gene of 4AU 1 8AU and 11AU. Values for the genotype E1
5 E 1x ( OAU 1 
153AU and 165AU) are due to the Et" gene and for the genotype 
E
1
rE
1
5 ( 12AU 1 OAU and OAU) are due to the E1r gene since the E1
5 
gene is truely silent for both activity and immunological 
protein. Values for activity and immunological protein for the 
genotype E
1
aE 1h ( 39AU 1 54AU 1 53AU) and the estimated values for 
the E
1
a gene (29AU 1 45AU and 45AU) give values for the E1h gene of 
lOAU1 9AU and 8AU. If the same calculation is performed for the 
E
1
uE
1
h genotype then values for the E1h g,ene are much higher ( 28AU 1 
25AU and 16AU). The standard deviation for the ChE activity using 
BTI as substrate (table 19) for E1aE 1a individuals (13) is much 
smaller than for E1uE 1u individuals ( 23). In spite of the standard 
deviations for immunological quantitation of ChE protein being 
the same for both genotypes (table 19) due to the small numbers 
of samples tested it is assumed that the values for the E1aE 1h 
samples are more reliable in the assignment of values to the E1h 
gene. 
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Table 28 
Gene 
E u 1 
E r 1 
E s 1 
E X 1 
E t 1 
E h 1 
1 AU relative 
Contribution of the 'sil e nt', E 1h and E1: 
genes to enzymi c acti v ity and antigen l eve ls 
of plasma cholinesterase. 
Contribution of each gene 
M Ab 
BTI 1 2-1 1 2-4 1 
69 68 72 
12 0 0 
0 0 0 
0 153 165 
4 8 11 
10 9 8 
to standard donor plasma 
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Comparison of Plasma Cholinesterase Activity with Immunological 
Protein Levels in Genotypic Variants 
Results presented below are in the order ChE activity with BTI, 
and immunological levels of ChE as defined by MAb2-1 and 2-4 in 
arbitrary units. 
Cholinesterase activity and immunological protein levels for 
E15 , E1t and E1h genes combined with E1a and E1k genes (table 29) 
were evaluated and compared with results obtained earlier for 
these genes (table 27). Values for the E1aE 19 genotype ( 33AU, 49AU 
and 46AU) are due to the E1a gene, s i.nce ~he E19 gene does not 
contribute to any of these and are in close agreement with values 
calculated from the homozygote (29AU, 45AU, 45AU). 
Values for E/E19 individuals (46AU, 51AU and 52AU) and the E15 
gene (OAU, OAU, OAU) and E1kE 1t individuals (46AU, 51AU and 53AU) 
and the E1 t gene (4AU, BAU and llAU) indicate average values for 
the E1k gene of approximately 44AU, 47AU and 47AU. These values 
are in close agreement with those presented earlier for this gene 
(45AU, 43AU, 44AU) (table 27). 
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Table 29 
Genotype 
EluElu 
EluEls fam 
El uEl a 
E UE t 1 1 
E UE h 1 1 
E1uE1x 
E1aEla 
ElaE1s 
ElaElh 
E kE a 1 1 
E kE t 
lk lh 
El El 
E kE X 1 1 
Cholinesterase leve ls o f the 'silent' 
heterozygotes co mpa red to the u sua l a nd 
atypical homozygotes 
MAb 
Number BTI 1 2-1 1 2-4 1 
170 138 136 1 44 
7 81 84 79 
9 86 88 85 
3 93 93 91 
7 97 95 90 
2 69 174 151 
56 57 90 90 
11 33 49 46 
5 39 54 53 
7 46 51 52 
5 46 51 53 
1 10 0 106 105 
1 48 140 14 1 
1 AU relati ve to standard donor plasma 
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Comparison of Ratios of Enzyme Activity to Immunological Protein 
for Genotypic Variants of Plasma ChE 
Comparison of the ratios of cholinesterase activity to 
immunological protein (table 30) indicate that genotypes with 
ratios around 1.0 all have the E1u gene present, agreeing with 
Altland et al (1971) who reported a high correlation coefficient 
of enzyme activity with the corresponding amount of antigen. 
Evaluation of activity and immunological data of the genotypes 
presenting with ratios lower than 1.0 reveal that ratios decrease 
in the order E1k > E1a > E1x when these genes are present (table 
30) . 
The E1k gene only results in a slight decrease in the ratio. 
The E a 1 gene decreases the ratio of enzyme activty to 
immunological protein in combination with other genes in the 
order: E k 1 > > E s 1 > The higher amounts of 
immunological protein detected in the case of the E1a gene may 
indicate a mechanism whereby more ChE molecules are produced to 
compensate for the production of a qualitatively abnormal 
molecule. This hypothesis is supported by lower ratios than 
expected with the genotypes E1aE 1h and E1aE 1" where only 1 E1a gene 
is present. The E1s gene does not contribute and the E1h gene 
only contributes a negligible amount to both activity and 
immunological protein. Only the atypical gene contributes to the 
ChE production and an increased number of cholinesterase 
molecules are synthesized as a compensatory mechanism. 
Activity values for E1uE 1x are equivalent to those obtained with 
E1kE 1 t (table 29). The E1x gene would therefore appear to produce 
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greatl y inc r e ased a mounts of i mmunolog i c all y de tec t a bl e , but 
enzymi c all y d ysfunctionate pro tein e ve n in t he he te ro zygote . This 
ena ble s f a mil y stud i es to be performe d on these indiv iduals wi th 
ease. 
Table 30 
Genot ype 
E UE k 1 1 E UE h 1 1 
E1uE1s 
E1uE/ 
E1uE1s 
E UE t 1 1 
El UE1 u 
E1kElh 
EtkEl s 
E aE f 1 1 E kE t 1 1 
EluEla 
E aE k 1 1 E aE h 1 1 
ElaEls 
E1aEla 
El uE lx 
E1kElx 
Comparison o f ratios of a c ti v ity to 
immunologi c al protein for ge notypic 
vari a nts o f plasma ChE 
Number Ratio 
BTI/2-1 BTI/2-4 
2 0.94 1.15 
7 1. 02 1. 08 
9 0.97 1. 03 
6 1.14 1. 02 
7 0.99 1. 02 
3 0.99 1. 02 
170 1. 02 0.96 
1 0.94 0.95 
7 0.87 0.8 7 
2 0.91 0.87 
5 0.87 0.85 
60 0.88 0.85 
20 0.88 0.83 
5 0.72 0.74 
11 0.69 0.74 
56 0 . 63 0.63 
2 0.40 0.46 
1 0.34 0.34 
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DNA Analysis of Genetic Variants 
Dynamic progress has now been made in the DNA analysis of the 
genotypic variants of plasma ChE. Genotyping methods using the 
polymerase chain reaction amplification method have allowed the 
identification of the mutations responsible for several of the 
variants of cholinesterase (La Du 1989). The aspartate 70 to 
glycine pQint mutation in atypical variants was the first to be 
identified ( McGuire et al., 1989). 
Two different point mutations that give rise to the E1f variant 
have been described (Bartels et al., 19908 ). The first mutation, 
a transition from Thr 243 ACG to ATG (Met) was identified in an 
E1aE/ individual. The mutation was called fluoride-1. The change 
from the threonine residue to another amino acid in this position 
would result in the enzyme subunit having 8 carbohydrate chains 
instead of the usual 9, since Asn-X-Thr or Ser is the sequence 
necessary for glycosylation at the Asn site. A second mutation 
was found at Gly 390, changing GCT to GTT (Val). This mutation 
was called fluoride-2. The entire coding region of an E1jE/ 
individual was sequenced and no other mutations were found. The 
2 types of fluoride variants may explain the 2 sets of 
immunological data obtained when analysing the E1f variant (table 
24). Further activity and immunological analysis of a larger 
number of fluoride-! and fluoride-2 variants are required to 
clarify these results. 
The E1k variant has been shown to be associated with an exon 4 
point mutation changing codon 539 from GCA to ACA resulting in 
Ala being replaced by Thr at this position ( Bartels et al., 
1990b). This mutation has also been shown to be in linkage 
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disequilibrium with the exon 2 mutation responsible for the 
atypical phenotype. 88% of the atypical alleles tested were 
linked with Thr539 which may explain why it was previously only 
possible to diagnose the E1k variant when it was seen in 
combination with the heterozygous atypical ( E18 E1k). 
A frameshift mutation at position 117 changing GGT (Gly) to 
GGAG (Gly + 1 base) was identified in 2 unrelated families 
segregating the E 19 gene ( Nogueira et al., 1990). The extra base 
changes the reading frame from Gly 117 to a new stop codon 
created at position 129, upstream of the active site (Ser 198). 
Thus a protein only 22% of the size of the usual ChE molecule is 
produced which does not possess the catalytic serine. This type 
of mutation probably corresponds to the E19 E19 variant described 
(table 23) where no activity or immunological protein could be 
detected. Examination of the other 'silent' variants for ChE 
( E1t, E1r and E1") using these DNA analysis techniques will prove 
invaluable in elucidating their cause, aiding the 
characterization of each and possibly enabling the identification 
of even more 'silent' alleles. 
A point mutation at position 142 changing GTG (Val) to ATG 
(Met) was found during family pedigree analysis of the E h 1 
variant ( Jensen et al., 1990). The reason why this mu tat ion 
should result in such a drastic reduction in ChE activity remains 
unknown. Similarity between activity and immunological data for 
the E1h and E1t variants (table 28) suggest a great similarity 
between the two variants. Use of the polymerase chain reaction 
technique would prove extremely valuable in proving whether these 
two variants are one and the same. 
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At least 7 specific sites within the ChE gene which determine 
either polymorphisms or rare genetic variants have been 
identified (La Du, 1990). These intra-genetic loci are very close 
to each other and one ChE gene may carry more than one ChE 
mutation. Linkage disequilibrium has been noted between the 
atypical and E1k variant, with one DNA strand carrying both 
mutations. 
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Plasma Cholinesterase during Pregnancy and the Puerperium 
A significant decrease in cholinesterase activity occurs during 
pregnancy (Robertson, 1966). The reduction is rapid during the 
first trimester, but no further decrease occurs during the second 
and third trimester (Evans and Wroe, 1980). Reports have 
indicated that even lower levels of activity occur during the 
first 2 to 3 days postpartum (Hazel and Monier, 1971; Robson et 
al., 1986). This is followed by an increase in activity to 
approximately normal nonpregnant values by the end of the 
puerperium (Robson et al., 1986). 
The interpretation of these observations are confused despite 
several hypotheses being advanced. These include haemodilution, 
altered hepatic function and steroid inhibition of the enzyme, 
but none are entirely satisfactory. 
For the 21 women investigated in this study there is a very 
good correlation between the enzymic activities as measured 
kinetically by the rate of hydrolysis of either benzoylcholine 
or butyrylthiocholine and the amount of cholinesterase present 
as indicated by the binding of the monoclonal antibodies MAb2-
1 and MAb2-4 to the protein molecule at their respective 
epitopes. A fairly wide variation between patients was found not 
onlr for enzymic activities, but also for the binding of the 
monoclonal antibodies to the enzyme molecule. The former 
variation could be predicted from the flat Gaussian distribution 
curve obtained whenever a large healthy population is screened 
for cholinesterase activity (Whittaker, 1986). Therefore the 
measurement of enzymic activity during pregnancy and the 
pueriperium appears to be a function of the number of 
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cholinesterase molecules present. There is no indication of any 
inactive molecules, since the binding ratios for the antibodies 
correlate to the enzymic activity. Other monoclonal antibodies 
binding different epitopes on the cholinesterase molecule may not 
show such a correlation. 
Results with these women show that the maternal cholinesterase 
activity falls to about 67% of the non-pregnant level by the end 
of the first trimester and moreover the binding of either of the 
monoclonals decreases by the same amount (fig.49). These 
decreases ar~ maintained during the second and third trimester 
with a transient increase, probably insignificant, in these 
parameters at about 20 days prior to delivery. Further decreases 
are observed during the puerperium which on average reach a 
minimum at about 2 days for the enzyme activity and for the 
binding of either monoclonal (fig.50). Both activity and 
monoclonal antibody binding ratio steadily increase as the 
puerperium proceed until non-pregnant levels are observed in all 
cases at 6 weeks post partum, but often at 3 weeks and sometimes 
earlier during the puerperium. 
Haemodilution appears to be an attractive hypothesis to 
interpret not only the decrease in enzymic activity, but also the 
lower binding capacity of antibody to the cholinesterase molecule 
during gestation. There is a smooth and progressive rise 
(approximately 50%) in total plasma volume during gestation, 
until a plateau is reached at about the thirty sixth week (Lund 
and Donovan, 1967). This 50% increase in volume is maintained 
until delivery. Thus, haemodilution may be the major factor for 
the observed decrease in cholinesterase activity and monoclonal 
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binding capacity during gestation. However, half of the total 
post-partal fall in mean plasma volume, either by diuresis or 
osmotic processes into the tissues, occurs during the first five 
days after delivery and normal non-pregnant volume is restored 
at about 6 weeks. It is therefore impossible, on the basis of 
haemodilution, to interpret the further decrease in 
cholinesterase activity or antibody binding of MAb2-1 or HAb2-
4 to the enzyme which occurs during the first 2 days post partum. 
The hypothesis of impaired hepatic function may account for a 
decreased protein biosynthesis as indicated by the reduced 
protein binding of the monoclonals and cholinesterase activity 
in this obstetric population. In normal pregnancy the total serum 
protein concentration decreases significantly below the normal 
non-pregnant values (De Alvarez et al., 1961), but if one takes 
into account the 50% increase in plasma volume during gestation 
then it would seem that there is no reduction in total plasma 
protein at term. Some of this protein is pregnancy associated 
protein and additionally there is a pregnancy zone protein. The 
former protein disappears early in the puerperium but the latter 
is detectable for several weeks postpartum (Lin et al., 1976). 
It is unlikely that these observed changes in cholinesterase 
should be inversely proportional to the changes in pregnancy zone 
protein and by such means exert a constant osmotic effect. Serum 
albumin, like cholinesterase, also decreases during early 
gestation to a constant level. The hypoalbuminaemia, which in a 
non-pregnant woman stimulates increased albumin synthesis is 
probably controlled in pregnancy by progesterone or oestrogen. 
Oestrogen has been shown to decrease albumin levels in non 
175 
pregnant women, presumably by inhibiting its biosynthesis 
(Laurel! et al., 1968). These steroids have a similar effect on 
cholinesterase (Redderson, 1973). But, after delivery of the 
placenta, oestrogen is rapidly cleared from the plasma and is not 
usually detectable after the third day. At this time the observed 
decreases in cholinesterase are maximum and it must be concluded 
that oestrogen is not inhibiting cholinesterase and thereby 
blocking both the catalytic active site and epitope. However, 
during the first few days of the puerperium levels of other 
plasma proteins such as coagulation factor VII and X, as well as 
fibrinogen are elevated presumably in preparation for the 
haemostatic challange of placental separation. These proteins, 
like cholinesterase, are synthesized in the liver. These 
coagulant proteins are also elevated during oral contraceptive 
therapy (Amundson and Pilgermann, 1963), while cholinesterase is 
decreased (Whittaker et al., 1971). It would th~s seem plausible 
that an agent, possibly a steroid such as oestrogen, would exert 
an effect on the biosynthesis of a number of proteins produced 
by the liver in response to the demands made on the body during 
delivery. If this hypothesis is true then proteins important to 
delivery are elevated and non-essential proteins are decreased 
in production. The existence of an inhibitor in the plasma is 
discounted by the finding of elevated levels of erythrocyte AChE 
during pregnancy and the puerperium (fig.39- 40). 
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Nature of future work 
Although the ELAT is a reliable method for quantitating 
erythrocyte AChE, it is cumbersome and only a small number of 
tests can be performed per run. An alternative method allowing 
high numbers of samples to be tested reliably and with relative 
ease is required. At present the solid phase technique for 
quantitating erythrocyte AChE is not sensitive enough, but with 
the advent of even more sensitive reagents, for example alkaline 
phosphatase anti -alkaline phosphatase ( APAAP) complexes, the real 
potential of this method will be realised. Further evaluation of 
this technique is required. 
The wider availability of fluorescence activated cell sorters 
(FACS) opens up the possibility of quantitation of AChE using a 
fluorescence conjugated anti-mouse antibody after the initial 
sensitization of the erythrocytes with AE-2. This method would 
involve fewer stages than the ELAT since no substrate stage would 
be required and hence no laborious washing away of inorganic 
phosphate with unbuffered saline. This together with the facility 
of direct linkup to a computer makes for an attractive method of 
quantitation and one which should be explored. Further work using 
a FACS in the monitoring of patients with PNH will provide 
essential data concerning prognosis, while also providing 
information on the average life of the transfused red cells 
required to maintain these patients. Further analysis of 
erythrocytes from leukaemic patients may provide a method of 
diagnosis and monitoring states of remission and relapse. 
Further activity and antigen data from cord erythrocytes is 
necessary to establish whether the low activity is due soley to 
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decreased numbers of AChE molecules, a foetal form of the enzyme 
of lower activty than the adult form or a combination of both. 
A larger survey of erythrocyte AChE from women at delivery and 
during the puerperium is also required to positively identify the 
cause of the increased activity in these patients. 
Although, very elaborate techniques in DNA analysis have now 
-been developed (Arpargus et al., 1990) which can pinpoint the 
mutation responsible for the more common genetic variants of 
plasma cholinesterase, enzyme kinetics and inhibition 
·characteristics will still be required to initially identify 
these variants. In addition, DNA analysis can not as yet provide 
direct information concerning the molar concentration of this 
enzyme, thus immunological quanti tat ion will provide further 
valuable information in defining the overall characterization of 
plasma ChE. Further work in enzyme kinetics, immunological 
characterization and DNA analysis is required with larger numbers 
of genetic variants to substantiate data already presented here 
and to investigate new genetic variants. Additional monoclonal 
antibodies defining different antigenic regions of the molecule 
will also prove valuable in providing further characterization. 
Since steroids are. known to be powerful inhibitors of 
cholinesterase in vitro (Whittaker and Britten, 1980) it would 
also appear worthwhile to establish a steroid profile present in 
plasma during the early puerperium and subsequently ascertain 
whether any of these steroids exert an effect by binding to ChE 
or inhibiting biosynthesis of the protein. 
It is hoped that the future development of techniques will 
establish the role of the cholinesterases not only on the 
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erythrocyte surface bi.J·t also in the plasma,. 
179 
References 
Abernathy M.H., Sellman J.D. and Stephenson E.G. Erythrocyte 
acetylcholinesterase in alcoholics. Ann. Clin. Biochem. 25: 444-
445 (1988). 
Adamson E.D. Acetylcholinesterase in mouse brain, erythrocytes 
and muscle. J. Neurochem. 28: 605-615 (1977). 
Ajmar F., Garre C., Sessarego M., Ravazzolo R., Barresi R., 
Scarra G.B. and Lituania M. Expression of erythroid 
acetylcholinesterase in the K-562 leukaemia cell line. Cancer 
Res. 43: 5560-5563 (1983). 
Alles G.A. and Hawes R.C. Cholinesterase in the blood of man. J. 
Biol. Chem. 133: 375-390 (1940). 
Altland K. and Goedde H.W. Heterogeneity in the Silent Gene 
Phenotype of Pseudocholinesterase of human serum. Biochem. Genet. 
4: 321-338 (1970). 
Altland K., Goedde H.W., Held K., Jensen M., Munsch H. and Solem 
E. New biochemical and immunological data on quantitative and 
qualitative variability of human pseudocholinesterase. Human 
genetik 14: 56-60 (1971). 
Amundson B.A. and Pilgerman L.O. Observations on a relationship 
between steroid metabolism and the concentration of plasma 
fibrinogen. Thromb. et Diath. Haem. 10: 400-405 (1963). 
180 
Archer T.L. and Janowsky E.C. Plasma pseudocholinesterase 
deficiency associated with diethylstilbestrol therapy. Anesth. 
Analg. 57: 726-729 (1978). 
Arias s., Rolo M. and Gonzalez N. Gene dosage effect present in 
trisomy 3q25.2-qter for serum cholinesterase (CHE1) and absent 
for transferrin (TF) and ceruloplasmin (CP). Cytogenet Cell 
Genet. 40: 571 (1985). 
Arpagaus M., Masson P., Vaughan T.A., Chatonnet A., Newton M., 
Taylor P., La Du B.N. and Lockridge 0. Use of the polymerase 
chain reaction for homology probing of butyrylcholinesterase 
(BCHE) in several animal species. Third International Meeting On 
Cholinesterases. Program and Abstracts. 107 (1990). 
Ashton G.C. and Simpson N.E. C5 types of serum cholinesterase in 
a Brazilian population. Amer. J. Hum. Genet. 8: 438-447 (1966). 
Augustinsson K.B. Determination of activity of cholinesterases, 
in: D. Glick {ed.), Methods of Biochem. Anal. 19: 217-273 John 
Wiley and Sons Inc., New York {1971). 
Augustinsson K.B. and Nachmansohn D. Distinction between 
acetylcholinesterase and other choline ester-splitting enzymes. 
Science 110: 98-99 {1949). 
181 
Avrameas S. and Ternynck T. Peroxidase labelled antibody and Fab 
conjugates with enhanced intracellular penetration. Immunochem. 
8: 1175-1179 (1971). 
Avrameas S. and Uriel J. Methode de marquage d' ant igenes et 
d'anticorps avec des enzymes et son application en 
immunodiffusion. Compt. Rend. Acad. Sci.; Paris 262: 2543-2545 
(1966). 
Barnes J.M. and Davies O.R. Blood cholinesterase levels in 
workers exposed to organo-phosphorus insecticides. Br. Med. J. 
ii: 816-819 (1951). 
Barrett A.J., Kembhavi A.A., Brown M.A., Kirschke H., Knight 
C.G., Toman M. and Hanada K. L-trans-epoxysuccinyl-leucylamido 
(4-guanidino) butane (E-64) and its analogues as inhibitors of 
cysteine proteinases including cathepsins B, H and L. Biochem. 
J. 201: 181-198 (1982). 
Barrow M.E.H. and Johnson J.K. A study of the anticholinesterase 
and anticurare effects of some cholinesterase inhibitors. Br. J,· 
Anaesth. 38: 420-431 (1966). 
182 
Bartels C. F. 1 Nogueira C.P. 1 McGuire M.C., Adkins S., Rubinstein 
H.M., Lubrano T., Van der Spek A.F.L., Lightstone H., Lockridge 
0. and La Du B.N. Identification of two different mutations 
associated with human butyrylcholinesterase fluoride resistance 
in serum. Third International Heeting On Cholinesterases. Program 
and Abstracts. 103 (19908 ). 
Bartels C., Van der Spek A. 1 Rubinstein H. 1 Lubrano T., Lockridge 
0 and La Du B.N. DNA coding for the K polymorphism in linkage 
disequilibrium with atypical human butyrylchol~nesterase 
complicates phenotyping. Third International Meeting On 
Cholinesterases. Program and Abstracts. 104 (1990b), 
Beckett A.H. and Al-Badr A.A. A modified structure of the 
acetylcholinesterase receptor. J. Pharm. Pharacol. 27: 855-858 
(1975). 
Bergmann F. and Wurzel M. The structure of the active surface of 
serum cholinesterase. Biochim. Biophys. Acta 13: 251-259 (1954). 
Beveridge D.L. 1 Radna R.J. Structural chemistry of cholinergic 
neural transmission systems. I. A quantum theoretical study of 
the molecular electronic structure of acetylcholine. J. Am. Chem. 
Soc. 93: 3759-3764 (1971). 
Bodley p .o., Halwax K. and Potts L. Low serum 
pseudocholinesterase levels complicating treatment with 
phenelzine. Br. Med. J. 3: 510-512 (1969). 
183 
Boulard C. and Lecroisey A. Specific antisera produced by direct 
immunization with slices of polyacrylamide gel containing small 
amounts of protein. J. Immunol. Methods 50: 221-226 (1982). 
Brimijoin S., Hammond P.I. and Petitt R.M. Paroxysmal nocturnal 
haemoglobinuria: erythrocyte acetylcholinesterase deficit 
analysed by immunoassay and fluorescence-activated sorting. Mayo 
Clin. Proc. 61: 522-529 (1986), 
Brimijoin S., Hammond P. and Rakonczay z. Two-site immunoassay 
for acetylcholinesterase in brain, 
Nellrochem. 49: 555-562 ( 1987). 
nerve and muscle. 
Brimijoin S., Mintz K. and Allay M.C. Production 
J. 
and 
characterization of separate monoclonal antibodies to human 
acetylcholinesterase and butyrylcholinesterase. Mol. pharmacol. 
24: 513-520 (1983). 
Brimijoin S. and Rakonczay z. Immunology and molecular biology 
of the cholinesterases: current results and prospects. Int. Rev. 
Nellrbiol. 28: 363-410 (1986). 
Brimijoin S., Rakonczay and Mintz K. Immunochemistry of mammalian 
cholinesterases. Fed. Proc. 45:2960-2964 (1986). 
Brodsky F. M. , Par ham P. , Barns table C, J. , Crumpton M. J. and 
Bodmer W.F. Monoclonal antibodies for analysis of the HL.-\ system. 
Immunol. Re\', 47: 3-61 (1979). 
184 
Brown S.S., Kalow W., Pilz W., Whittaker M. and Woronick C.L. The 
plasma cholinesterases: A new perspective. Ad"·· Clin. Chem. 22: 
1-123 (1981). 
Burman D. Red cell cholinesterase in infancy and childhood. Arch. 
dis. child. 36: 362-365 ( 1960). 
Burt S.M., Carter T.J.N. and Kricka L. Thermal characteristics 
of microtitre plates used in immunological assays. J. Immunol. 
Hethods 31: 231-236 (1979). 
Canterero L.A., Butler J.E. and Osborne J.W. The ·adsorptive 
characteristics of proteins for polystyrene and their 
significance in solid-phase immunoassays. Anal. Biochem. 105: 
375-382 (1980). 
Changeux J.P. Responses of acetylcholinesterase from Torpedo 
marmorata to salts and curarizing drugs. Mol. Pharmacal. 2: 369-
392 (1966) 
Chhajlani V., Derr D., Earles B., Schmell E. and August T. 
Purification and partial amino acid sequence analysis of human 
erythrocyte acetylcholinesterase. Febs lett. 24 7: 279-282 ( 1989). 
Chow F.L., Telen M.J. and Rosse W.F.: The acetylcholinesterase 
deficit in paroxysmal nocturnal hemoglobinuria: evidence that the 
enzyme is absent from the cell membrane. Blood 66: 940-9-15 
(1985). 
185 
Christensen P., Johansson A. and Nielsen V. Quantitation of 
protein adsorbance to glass and plastics: investigation of a new 
tube with low adherence. J. Immunol. Methods 23: 23-28 (1978). 
Clitherow J.W., Mitchard M. and Harper ~.J. The possible 
biological function of cholinesterase. Nature 199: 1000-1001 
(1963). 
Coates P.M. and Simpson N.E. Genetic variation in human 
erythrocyte acetylcholinesterase. Science 175: 1~66-1467 (1972). 
Dacie J.V. 'The Haemolytic Anaemias: Congenital and Acquired. 
Part H'.' 2nd Ed. New York: Grune and Stratton, 1128-1160 (1967). 
Dacie J.V. and Lewis S.M. Practical Haematology. 6th Ed. New 
York: Churchill Livingstone (1984). 
Dale H.H. The action of certain ethers and esters of choline and 
their relation to muscarine. J. Pharmacal. Exp. Ther. 6: U7-
190 (1914). 
Daniels G. Cromer related antigens - blood group determinants on 
decay-accelerating factor. Vox sang. 56: 205-211 (1989). 
Das P.K. and Liddell J. Value of butyrylthiocholine assay for 
identification of cholinesterase variants. J. Med. Genet. 7: 351-
355 (1970). 
186 
Davies R.O., Martin A.V. and Kalow W. The action of normal and 
atypical cholinesterase of human serum upon a series of esters 
of choline. Can. J, Biochem. 38: 545-551 (1960). 
Dobbins Place J. and Schroeder H.R. The fixation of anti-Hb 5 Ag on 
plastic surfaces. J. Immunol. t"fethods 48: 251-260 (1982). 
De Alvazez R.R., Afonso J.F. and Sherrard D.J. Serum protein 
fractionation in normal pregnancy. Am. J. Obst. Gynec. 82: 1096-
1111 (1961). 
Dockter M.E. and Morrison M. Paroxysmal mocturnal hemoglobinuria 
erythrocytes are of two distinct types: positive or negative for 
acetylchoinesterase. Blood 67: 540-543 (1986). 
Doenicke A., Krumey I., Kugler J. and Klempa J. Experimental 
studies of the breakdown of epontal: determination of propanidid 
in human serum. Br. J. Anaesth. 40: 415-429 (1968). 
Duncan C.J. The molecular properties and e\·olution of excitable 
cells. pp.l12-124 (Pergamon Press, New York 1967). 
Dutta-Choudhury T.A. and Rosenberry T.L. Human erythrocyte 
acetylcholinesterase is an amphipathic protein ~hose short 
membrane binding domain is removed by papain digestion. J. Biol. 
Chem. 259: 5653-5660 ( 1984). 
187 
Eckerson H.W., Oseroff A. Lockeridge 0. and La Du B.N. 
Immunological comparison of the usual and atypical human serum. 
Biochem. Genet. 21: 93-108 (1983). 
Ehrlich P.H., Moyle W.R., Moustafa Z.A. and Canfield R.E. Mixing 
two monoclonal antibodies yields enhanced affinity for antigen. 
J. Immunol. 128: 2709-2713 (1982). 
Eiberg H., Nielsen L.S., Klausen J., Dahlen M., Kristensen M., 
Bissaard M.L., Holler N. and Mohr J. Linkage between serum 
cholinesterase 2 (CHE 2) and gamma-crystallin gene cluster 
(CRYG): assignment to chromosome 2. Clin. Genet. 35: 313-321 
( 1989). 
Ellman G.L., Courtney D., Andres V. Jr. and Featherstone R.M. A 
new and rapid calorimetric determination of acetylcholinesterase 
activity. Biochem. Pharmacal. 7: 88-95 (1961). 
Engvall E. Enzyme Immunoassay ELISA and EMIT. Methods Enzymol. 
70: 419-439 (1980). 
Engvall E. I Jonsson K. and Perlmann p, Enzyme-linked 
immunosorbent assay. II. Quantitative assay of protein antigen, 
immunoglobulin G, by means of enzyme-labelled antigen and 
antibody-coated tubes. Biochim. Biophys. Acta 251: 427-434 
(1971). 
188 
Evans R.T. and Wardell J. On the identification and frequency of 
the J and K cholinesterase phenotypes in a Caucasian population. 
J. Med. Genet. 21: 99-102 (1984). 
Evans R.T. and Wroe J.M. Plasma cholinesterase changes during 
pregnancy. Anaesthesia 35: 651-654 (1980). 
Evans R.T. 1 0 1 Callaghan J. and Norman A. A longitudinal study of 
cholinesterase changes in pregnancy. Clin. Chem. 34: 2249-2252 
(1988). 
Fambrough D. M. I Engel A.G. and Rosenberry T.L. 
Acetylcholinesterase of human erythrocytes and neuromuscular 
junctions: Homologies revealed by monoclonal antibodies. Proc. 
Natl. Acad. Sci. USA 79: 1078-1082 (1982). 
Ferrone s, I Zanella A. and Sirchia G. Red cell 
acetylcholinesterase in ABO haemolytic disease of the newborn. 
Separatum Experienta 24: 495 (1968). 
Foldes F. F. 1 Arari T. 1 Getsch H.H. and Zarda Y. The influence of 
glucocorticoids on plasma cholinesterase. Proc. Soc. Exp. Biol. 
Hed. 146: 918-920 (1974). 
Foldes F.F. and Smith J.C. The interaction of human 
cholinesterases with anticholinesterases used in the therapy of 
myasthenia gravis. Ann. NY Acad. Sci. 135: 287-301 (1966). 
189 
Frenkel E.T., Roelofsen B., Brodbeck U., van Deenen L.L.M. and 
Ott P. Lipid protein interactions of human erythrocyte membrane 
acetylcholinesterase. Eur. J. Biochem. lOG: 377-382 (1980). 
Froman G., Acevedo F. and Hjerten S. A molecular seiving method 
for preparing erythrocyte membranes. Preparati \"e Biochem. 10: 59-
67 (1980). 
Funnell H.S. anct Oliver W.T. Proposed physiological function for 
plasm~ cholinesterase. Nature 208: 689-690 (1965). 
GalPltr 0. and Plattner F. Uber das Schicksal des Acetylcholins 
im Blute. Pflugers Arch. 218: 488-505 ( 1928). 
Garre C., Ravazzolo R., Ajmar F. and Bruzzone G. Electrophoretic 
difference between fetal and adult acetylcholinesterase of human 
red cell membranes. Cell Differ 9:165-168 (1980). 
Garry P.J., Dietz A.A., Lubrano T., Ford P.C., James K. and 
Rubinstein H.M. New allele at cholinesterase locus 1. J. Med. 
Genet. 13: 38-42 (1976). 
Goedde H.W. and Altland K. Evidence for different ''silent genes'' 
in the human serum pseudo-cholinesterase polymorphism. Ann. N. 
1". Acad. Sci. 151: 540-544 (1968). 
190 
Goedde H.W. and Baitsch H. On nomenclature of 
pseudocholinesterase polymorphism. Acta Genet. 14: 
(1964). 
366-369 
Goedde H.W., Gehring D. and Hofmann R.A. On the problem of a 
"silent gene" in pseudocholinesterase polymorphism. Biochim. 
Biophys. Acta 107: 391-393 (1965). 
Goedde H.W., Hirth L., Benkmann H.G., Pellicer A., Pellicer T., 
Stahn M. and Singh S. Population genetic studies of serum protein 
polymorphisms in four Spanish populations. Hum. Hered. 23: 135-
146 (1973). 
Gurari D. and Fuchs S. The interaction of acetylcholinesterase 
with specific inhibitors conjugated to bacteriophage T4 and to 
proteins. Eur. J. Biochem. 42: 269-274 (1974). 
Gutsche B.B., Scott E.M. and Wright R.C. Hereditary deficiency 
of pseudocholinesterase in Eskimos. Nature 215: 322-323 (1967). 
Haas R., Brandt P., Knight J. and Rosenberry T.L. Identification 
of non amino acid components in the hydrophobic membrane-bin.ling 
domain at the C-terminus of human erythrocyte 
acetylcholinesterase. Biochem. 25: 3098-3105 (1986). 
Halbert S.P., Bastomsky C.H. and Anken M. A rapid standardized 
enzyme immunoassay for autoantibodies to thyroglobulin. C 1 in. 
Chim. Acta 127: 69-76 (1983). 
191 
Hall G.~., Hood G.J. and Paterson J.L. Half-life of plasma 
cholinesterase. Br. J. Anaesth. 56: 903-90~ (198~). 
Hangaard J., Sorensen K., Brodbeck V. and Norgaard-Pedersen B. 
Quantitative determination of acetylcholinesterase by enzyme 
antigen immunoassay: methodological aspec·ts and clinical use. 
Scand. J. Clin. Lab. Invest. ~~: 717-724 (1984). 
Harris H., Hopkinson D.A., Robson E. B. and Whittaker M. Genetical 
studies on a new variant of serum cholinesterase detected by 
electrophoresis. Ann. Hum. Genet. 26: 359-382 (1963). 
Harris H. and l~hittaker M. Differential inhibition of human serum 
cholinesterase with fluoride. Recognition of two new phenotypes . 
. Vature 191: 496-498 (1961). 
Hart S.M. and Mitchell J,V, Suxamethonium in the absence of 
pseudocholinesterase. Br. J. Anaesth. 34: 207-209 (1962). 
Haupt H., Heide K., Zwisler 0. and Schwick H.G. Isolierung und 
physikalisch-chemische Charakterisierung der Cholinesterase aus 
Humanserum. Blut 14: 65-75 (1966). 
Hazel B. and Monier D. Human serum cholinesterase: variation 
during pregnancy and postpartum. Can. Anaesth. Soc. J. 18: 272-
277 (1971). 
192 
Heller M. and Hanahan D.J. Human erythrocyte membrane bound 
enzyme acetylcholinesterase. Biochim. Biophys. Acta 255: 251-
272 (1972). 
Hellsing K. and Richter W. Immunochemical quantitation of dextran 
by a polymer enhanced nephelometric procedure. J. Immunol. 
Hethods 5: 147-151 (1974). 
Herz F. and Kaplan E. A review: Human erythrocyte 
acetylcholinesterase. Pediatr. Res. 7: 204-212 (1973). 
Herz F. 1 Kaplan E. and Furuhjelm U. Acetylcholinesterase activity 
in En( a-) red cells. Vox Sang 23: 228-231 ( 1 972b). 
Herz F. 1 Kaplan E. and Scheye E.S. Differences between the red 
cell acetylchlinesterase defects of paroxysmal nocturnal 
haemoglobinuria and of ABO hemolytic disease. Acta Haemat. 39: 
85-90 (1968). 
Herz F. 1 Kaplan E. and Scheye E.S. Red cell acetylcholinesterase 
deficiency in autoimmune haemolytic anaemia and in paroxysmal 
nocturnal haemoglobinuria. Clin. Chim. Acta 38: 301-306 (1972a), 
Herz F. I Kaplan E. and Scheye E.S. Erythrocyte 
acetylcholinesterase and glucose-6-phosphate dehydrogenase in 
newborn infants of low birth weight. Clin. Chim. Acta -!6: 1-t7-
152 (1973). 
193 
Heusser C.H., Stacker J.W. and Gisler R.H. Methods of binding 
cells to plastic: Application to solid phase immunoassays for 
cell surface antigens. Methods Enzymol. 73: 406-418 (1981). 
Hodgkin W.E., Giblett E.R. 1 Levine H., Bauer W, and Motulsky .l..G. 
Complete pseudocholinesterase deficiency: genetic and immunologic 
characterization. J. Clin. Invest. 44: 486-493 (1965). 
Huerre C., Uzan G .. , Greschik K.H., Weil D., Levin M., Hors-Cayla 
M. C., Boue J., Kahn A. and Junien C. The structural gene for 
transferrin TF maps to 3q21-3qter. Ann. Genet. 40: 107-127 
(1984). 
Hunt R. and Taveaux R. de M. On the physiological action of 
certain cholin derivatives and new methods of detecting cholin. 
Br. Yed. J. ii: 1788-1791 (1906). 
Hutchinson A.D. and Widdowson E.M. Cholinesterase activities in 
the serum of healthy British children. Nature 169: 284-285 
(1954). 
Jensen F.S., Bartels C. F. and La Du B.N. A DNA mutation 
associated with the H-variant of human butyrylcholinesterase. 
Third International Meeting On Cholinesterases. Program and 
Abstracts. 101 (1990). 
Johns R.J. Familial Reduction in red cell cholinesterase. ,Ve~<.· 
Eng. J. Med. 267: 1344-1348 (1962). 
194 
-
Kabachnik M.I. 1 Brestkin A.P.I Godovikov N.N. 1 Michelson M.N. 1 
Rozengart E.V. and Rozengart V.I. Hydrophobic areas at the active 
surface of cholinesterase. Pharmacal. Rev. 22: 355-388 (1970). 
Kalow W. and Genest K. A method for the detection of atypical 
forms of human cholinesterase; determination of dibucaine 
numbers. Can. J. Biochem. 35: 339-346 (1957). 
Kalow W. and Gunn D.R. Some statistical data on atypical 
cholinesterase of human serum. Ann. Hum. Genet. 23: 239-250 
(1959). 
Kamber E. 1 Poyiagi A. and Deliconstantinos G. Modifications in 
the activities of membrane-bound enzymes during in-vivo ageing 
of human and rabbit erythrocytes. Comp. Biochem. Physiol. 77B: 
95-99 ( 1984). 
Kaplan E. 1 Herz F. and Hsu K.S. Erythrocyte acetlcholinesterase 
activity in ABO hemolytic disease of the newborn. Pediatrics 33: 
205-211 ( 1964). 
Katz R.L. Modification of the 
succinylcholine and halothane. 
(1971). 
195 
action of pancuronium by 
Anaesthesiology 35: 602-606 
Kedziora J., Bartosz G., Kofe'r M. and Leyko W. Erythrocyte 
membrane acetylcholinesterase in Down's Syndrome. IRCS Hedical 
Science: Anatomy and Human Biology, Biochemistry; Cell and 
Membrane Biology; Clinical Biochemistry; Clinical Medicine; 
Haematology; Pathology 10: 783 (1982). 
Keyhani E. and Maigne J. Acetylcholinesterase in mammalian 
erythroid cells. J, Cell Sci. 52: 327-339 (1981). 
Kjrervig Broe M. and Ingild A. Amplification of immunoprecipitates 
in agarose gels by horseradish peroxidase-labelled antibody. 
Scand. J. Immunol. 17: 255-258 (1983}. 
Kidd K.K. and Gusella J. Report of the committee on the genetic 
constitution of chromosomes 3 and.4. Cytogenet. Cell. Genet. ~0: 
107-127 (1985). 
Kobayashi K., Sakoguchi T. and Matsuoka A. Stimulating effects 
of calcium and magnesium on serum cholinesterase. Clin. Chem. 34: 
173-174 (1988). 
Kohler G. and Milstein C. Continuous cultures of fused cells 
secreting antibody of predefined specificity . .Vature 256: -195-
~97 (1975). 
Kurstak E., Tijssen P. and Kurstak C. ( 1984). In 'Applied 
rirolog;r' (E. Kurstak, ed.}. pp. 479-503, Academic Press, New 
York. 
Kurstak E., Tijssen P. and Kurstak C. (1984). In 'Control of 
Virus Diseases' (E. Kurstak and R. Marusyk, eds. ), pp. 477-500. 
Dekker, New York. 
Kutty K.M. Biological function of cholinesterase. Clin. Biochem. 
13: 239-243 (1980). 
La Du B.N. Plasma esterase activity and the metabolism of drugs 
with ester groups. Ann. N. Y. Acad. Sci. 179: 684-694 (1971). 
La Du B.N. Identification of human serum cholinesterase variants 
using the polymerase chain reaction amplification technique. 
Trends in Pharmacal. Sci. 10: 309-313 (1989). 
La Du B.N., Bartels C. and Lockridge 0. Practical 
of having more than one mutation within 
consequences 
the same 
butyrylcholinesterase gene. Third International Meeting On 
Cholinesterases. Program and Abstracts. 105 (1990). 
Laity J.L.H. and Whittaker M. Neuromuscular activity of 
lignocaine and prilocaine. Proc. Brit. Pharm. Soc. 19: 33-34 
(1971). 
LaMotta R.V., McComb R.B. and Wetstone H.J. Isoenzymes of serum 
chl inesterase. A new polymorphism sequence. Can. J. Pysiol. 
Pharmacol. 43: 313-318 (1965). 
197 
Langone J, J, Protein A of Staphylocoocus aureus and related 
immunoglobulin receptors produced by Streptococci and 
pneomococci. Adv. Immunol. 32: 157-252 (1982), 
Laurell C.B. 1 Kullander s. and Thorell J. Effect of 
administration of a combined oestrogen-progestin contraceptive 
on the level of individual plasma proteins. Scand. J. Clin. Lab. 
Invest. 21: 337-343 (1968). 
Lawson A.A. and Barr R. D. Acetylcholinesterase in red blood 
cells. Amer. J, Haematol. 26: 101-112 (1987). 
Lehmann H. and Liddell J. Human serum cholinesterase. In 
'Progress in Medical Genetics' Vol. III; Steinberg A.G. and Bearn 
A.G. 1 Grune and Stratton 1 New York. p.75 (1965). 
Lehmann H. and Ryan E. The familial incidence of low pseudo-
cholinesterase level. Lancet ii: 124 (1956). 
Lehmann H. and Silk E. Succinylmonocholine. Br. Med. J. i: 76i-
768 (1953). 
Levy H.B. and Sober H.A. A Simple Chromatographic Method for 
Preparation of Gamma Globulin. Proc. Soc. Exptl. Hed. Biol. 103: 
250-252 ( 1960). 
Liddell J. 1 Lehmann H. and Silk E. A silent pseudocholinesterase 
gene. Nature 193: 561-562 (1962). 
198 
Lin T.M., Halbert S.P., Spellacy W.N. and Gall S. Human pregnancy 
associated plasma proteins during the postpartum period. Am. J, 
Obst. Gynec. 124: 382-387 (1976). 
Lockridge 0., Bartels C., Vaughan T., Wong C.K., Norton S.E. and 
Johnson L.L. Complete amino acid sequence of human serum 
cholinesterase. J. Biol. Chem. 262: 549-557 (1987). 
Lockridge 0., Eckerson H.W. and LaDu B.N. Interchain disulphide 
bonds and subunit organization in human serum.cholinesterase. J. 
Biol. Chem. 254: 8324-8330 (1979). 
Lockridge 0. and La Du B.N. Amino acid sequence of the active 
site of human serum cholinesterase from usual, atypical and 
atypical silent genotypes. Biochem. Genet. 24: 485-498 (1986). 
Lovrien E.W., Magenis R.E., Rivas M.L., Lamvik N., Rowe s., Wood 
J. and Hemmerling J. Serum cholinesterase E2 linkage analysis: 
possible evidence for localization to chromosome 16. Cytogenet. 
Cell. Genet. 22: 324-326 (1978). 
Low M.G. Biochemistry of the glycosyl-phosphatidylinositol 
membrane protein anchors. Biochem. J. 244: 1-13 (1987). 
Lund C.J. and Donovan J.C. Blood volume during pregnancy. 
Significance of plasma and red cell volumes, Amer. J, Obstet. 
Gynecol. 98: 393-403 (1967). 
199 
~lalvano R., Boniolo A., Dovis M. and Zannino M. ELISA for 
antibody measurement: Aspects related to data expression. J. 
Immunol. Methods 48: 51-60 (1982). 
~ason D.Y. and Sammons R. J. Alkaline phosphatase and peroxidase 
for double immunoenzymatic labelling of cellular constituents. 
Clin. Pathol. 31: 454-460 (1978). 
~aze M. and Gray G.M. Intestinal brush border 
aminooligopeptidases: Cytosol precursors of the membrane enzyme. 
Biochem. 19: 2351-2358 (1980). 
McArdle B. The serum choline esterase in jaundice and diseases 
of the liver. Quart. J. Med. 9: 107-119 (19~0). 
~lcGavin D. D. M. Depressed levels· of serum-pseudocholinesterase 
~ith ecothiopate iodide eyedrops. Lancet ii: 272-273 (1965). 
McGuire M.C., Nogueira C.P., Bartels C.F., Lightstone H., Hajra 
A., Van der Spek A.F.L., Lockridge 0. and La Du B.N. 
Identification of the structural mutation responsible for the 
dibucaine-resistant (atypical) variant form of human serum 
cholinesterase. Proc. Natl. Acad. Sci. USA 86: 953-957 (1989). 
Mendel B. and Rudney H. Studies on cholinesterase. Cholinesterase 
and pseudocholinesterase. Biochem. J. 37: 59-63 (1943). 
200 
Merry A.H. I Thomson E.E. I Rawlinson V. I. and Stratton F. 
Quantitation of IgG on erythrocytes: correlation of number of IgG 
molecules per cell with the strength of the direct and indirect 
antiglobulin tests. Vox Sang 47: 73-81 (1984). 
Mezincesco M.D. and Ghetie S. La fonction metabolique de la 
butyrylcholinesterase. Biochim. Biophys. Acta 350: 54-60 (1974). 
Michel H.O. An electrometric method for determination of red 
blood cell and plasma cholinesterase activity. J. Clin. Hed. 34: 
1564-1568 (1949). 
Mintz K.P. and Brimijoin S. Two-step immunoaffinity purification 
of acetylcholinesterase from rabbit brain. J, Neurochem. 44: 
225-232 (1985) 
Mosmann T.R. 1 Gallatin M. and Langenecker B.M. Alteration of 
apparent specificity of monoclonal (hybridoma) antibodies 
recognising polymorphic histocompatibility and blood group 
determinants. J. Immunol. 125: 1152-1156 .(1980). 
Motulsky A.G. Pharmacogenetics In 'Progress in Medical Genetics'. 
Vol. III (Steinberg 1 A.G. and Bearn1 A.G. ed). pp. 49-74. Grune 
and Stratton 1 New York (1964). 
Muensch H. 1 Goedde H.W. and Yoshida A. Human serum cholinesterase 
subunits and number of active sites of the major component. Eur. 
J. Biochem. 70: 217-223 (1976). 
201 
Muensch H., Yoshida A., Altland K., Jensen W, and Goedde H.W. 
Structural difference at the active site of dibucaine resistant 
variant of human plasma cholinesterase. Am. J, Hum. Genet. 30: 
302-307 (1978). 
Nachmansohn D. and Rothenberg M.A. Studies on cholinesterase. I 
On the specificity of the enzyme in nerve tissue. J. Biol. Chem. 
158: 653-666 (1945). 
Nakane P.K. and Pierce G. B., Jr. Enzyme-labelled antibodies: 
preparation and application for the localization of antigens. J. 
Histochem. Cytochem. 14: 929-931 (1966). 
Nakane P.K. and Pierce G.B. Enzyme-labelled antibodies for the 
light and electron microscopic localization of tissue antigens. 
J. Cell. Biol. 33: 307-318 (1967). 
Narayanan R. and Balaram P. Fluoresence and NMR studies of the 
bonding of cholinergic fluorescent probes to horse serum 
cholinesterase. Int. J. Peptide Protein Res. 17: 170-180 (1981). 
Neitlich H.W. Increased plasma cholinesterase activity and 
succinylcholine resistance. A genetic variant. J. Clin. Invest. 
45: 289-307 ( 1966). 
202 
Ngiam T.L. and Go M.L. The structure of the acetylcholinesterase 
center and the mode of acetylcholine I acetylcholinesterase 
interaction - a theoretical study. Asia Pacific J. Pharmacal. 
2: 33-41 (1987). 
Niday E., Wang C.S. and Alaupov ic P. Studies on the 
characterization of human erythrocyte acetylcholinesterase and 
its interaction with antibodies. Biochim. Biophys. Acta .t69: 
180-193 (1977). 
Nogueira C.P., McGuire M.C., Bartels C., Arpagaus M., Van der 
Spek A.F.L., Lightstone H., Lockridge 0. and La Du B.N. 
Identification of a frameshift mutatuion responsible for the 
silent phenotype of human butyrylcholinesterase in serum. Third 
International .lfeeting On Cholinestera.ses. Program and Abstracts. 
102 (1990). 
!l:olte H.J., Rosenberry T.L., Neumann E. Effective charge on 
acetylchlinesterase active sites determined from the ionic 
strength dependence of associated rate constants with cationic 
ligands. Biochem. 19: 3705-3711 (1980). 
Ogita Z-I. Genetic control and epigenetic modification of human 
serum cholinesterase. In 'Isozymes II. Physiological function'. 
(~arkert, C.L. ed.) 289-314. Academic Press, ~ew York (1975). 
Okabe H., Sagesli:a K., Nakajima N. and Noma A. New enz~·matic assay 
of cholinesterase activity. Clin. Chim. Acta.. 80: 87-94 (1977). 
203 
Ott P., Lustig A, Brodbeck u. and Rosenbusch J • P. 
Acetylcholinesterase form human erythrocyte membranes: Dimers as 
functional units. Febs lett. 138: 187-189 (1982). 
Panteghini M. and Bonora R. Evaluation of a ne" continuous 
c o 1 or i mat r i c method for det erm ina tion of serum 
pseudocholinesterase catalytic activity and its application to 
a centrifugal fast analyser. J. Clin. Chem. Clin. Biochem. 22: 
671-676 (1984). 
Pantel S. A fluoristatic method for the determination of alkaline 
phosphatase, sorbitol dehydrogenase, peroxidase and 
pseudocholinesterase. Ann. Clin. Acta 129: 231-236 (1981). 
Paul us J. M., Haigne J. and Keyhani E. Mouse megakaryocytes 
secrete acetylcholinesterase. Blood 58: 1100-1106 (1981). 
Postoway N., Nance S.J. and Garratty G. Variables affecting the 
enzyme-linked antiglobulin test when detecting and quantitating 
IgG red cell antibodies. Hed. Lab. Sci. 42: 11-19 (1985). 
Pritchard J .A. and Weismann R. Jr. Erythrocyte cholinesterase 
activity in normal pregnancy and in megaloblastic and other 
anemias of pregnancy and the puerperium. J. Lab. Clin. Med. 47: 
98-107 (1956). 
204 
Propert D.N. and Brackenridge C.J. The relation of sex, age, 
smoking, status, birth rank and parental ages to 
pseudocholinesterase activity and phenotypes in a sample of 
Australian Caucasian adults. Hum. Genet. 32: 181-188 (1976). 
Redderson C.L. Interaction of steroids and serum cholinesterase. 
Int. J. Clin. Pharmacal. 8: 51-57 (1973). 
Richardson M.D., _Turner A., Warnock 0.\V, and Llewellyn P.A. 
Computer-assisted rapid enzyme linked immunosorbent assay ( ELISA) 
in the serological diagnosis of Aspergillosis. J. Immunol. 
Hethods 56: 201-207 (1983). 
Rieger F., Bon S., Massoul ie J. , Chartaud J., Pi card B. and Benda 
P. Torpedo marmorata acetylcholinesterase; a comparison with the 
Electrophorus electricus enzyme: molecular forms, subunits, 
electron microscopy, immunological relationship. Eur. J. Biochem. 
68: 513-521 (1976). 
Roberts W.L. and Rosenberry T.L. Identification of covalently 
attached fatty acids in the hydrophobic membrane binding domain 
of human erythrocyte acetylcholinesterase. Biochem. Bioph;ys. Res. 
Comms 133: 621-627 (1985). 
Robertson G.S. Serum cholinesterase deficiency. II Pregnancy. Br. 
J. Anaesth 38: 361-369 (1966). 
205 
Robson N. 1 Robertson I. and Whittaker M. Plasma cholinesterase 
changes during the puerperium. Anaesthesia 41: 243-249 (1986}. 
Rosenberry T.L. and Scoggin D.M. Structure of human erythrocyte 
acetylcholinesterase. J. Biol. Chem. 259: 5643-5652 (1984). 
Rosse W. F. and Parker C. J.: Paroxysmal nocturnal haemoglobinuria. 
Clin. Haematol. 14: 105-125 (1985). 
Rotoli B. 1 Robledo R. 1 Scarpato N. and Luzzato L. Two populations 
of erythroid cell progenitors in paroxysmal nocturnal 
haemoglobinuria. Blood 64: 847-851 (1984). 
Rubinstein H.M. 1 Dietz A.A. 1 Hodges L.K. I Lubrano T. and Czebotar 
V. Silent Cholinesterase gene: Variations in the properties of 
serum enzyme in apparent homozygotes. J. Clin. Invest. ~9: ~79-
486 ( 1970). 
Rubinstein H.M. 1 Dietz A.A. another 
quantitative variant at cholinesterase locus 1. J. Med. Genet. 
15: 27-29 (1978). 
Rubinstein H.M. 1 Dietz A.A. 1 Lubrano T. and Garry P.J. E1i. A 
quantitative variant at cholinesterase locus 1: Immunological 
evidence. J, Ned. Genet. 13: 43-45 (1976). 
205 
Rubinstein H., Lubrano T., Dainko J., Mat thews H., Lange C., 
Silberman S. and Minowada J. Acetylcholinesterase in cultured 
human leukaemia/lymphoma cell lines. Leuk. Res. 8: 741-744 
(1984). 
Sabine J.C. The clinical significance of erythrocyte 
cholinesterase titers. 1. A method suitable for clinical use and 
the distribution of normal values. Blood 10: 1132-1138 (1955). 
Sabine J.C. Red-cell acetylcholinesterase activity in 
physiological and pathological reticulocytosis. Brit. J. Haemat. 
11: 162-170 (1965). 
Scott E.M. Inheritance of two types of deficiency of human serum 
cholinesterase. Ann. Hum. Genet. Lond. 37: 139-143 (1973). 
Scott E.H. and Powers R.F. Properties of the C5 variant form of 
human serum cholinesterase. Am. J. Hum. Genet. 26: 189-194 
(1974). 
Scott E.M. and Wright R.C. Hereditary deficiency of 
pseudocholinesterase in Eskimos. Nature 215: 322-323 (1967). 
Scott E.M. and Wright R.C. A third type of serum cholinesterase 
deficiency in Eskimos. Am. J. Hum. Genet. 28: 253-256 (1976). 
207 
Scott G.L., Dornhorst A. and Rasbridge M.R. The relationship 
between red cell acetylcholinesterase activity and Ii 
antigenicity in leukaemia. Scand. J. Haemat. II: 230-235 (1973). 
Scott G.L. and Rasbridge M.R. Red cell acetylcholinesterase and 
adenosine-triphosphate activity in patients with a positive 
antiglobulin test. Scand. J. Haemat. 8: 53-62 (1971). 
Shanor S.P., VanHees G.R., Baart N., Erdos E.G. and Foldes F. F. 
The influence of age and sex on human ple,sma and red cell 
cholinesterase. Am. J. Med. Sci. 242: 357-361 (1961). 
Shows T.B., Alper C.A., Bootsma D. et al. International system 
for human gene nomenclature. In 'Human Gene Mapping 5, Edinburgh 
Conference', edited by Evans H.J.; Hamerton J.L.; Klinger I!.P. 
and McKusick V.A. Birth Defects Orig. Art. Ser. XV (II) pp 96-
116 (1979). 
Silk E., King J. and Whittaker M. Assay of cholinesterase in 
clinical chemistry. Ann. Clin. Biochem. 16: 57-75 (1979). 
Simmers N.E., Stupens I. and Sutherland G.R. Localization of the 
human haptoglobin genes distal to the fragile site at 16g22 using 
in situ hybridization. Cytogenet. Cell. Genet. 41: 38-41 (1986). 
Simpson N.E. and Kalow W. The "silent" gene for serum 
cholinesterase, Amm. J. Hum Genet. 16: 180-188 (196~). 
208 
Sirchia G. 1 Ferrone S. 1 Hercuriali F. and Zanelle A. Red cell 
acetylcholinesterase activity in autoimmune haemolytic anaemias. 
Br. J. Haematol. 19: ~11-415 (1970). 
Sorensen K. 1 Brodbeck U. 1 Rasmussen A.G. and Norgaard-Pedersen 
B. ~ormal human serum contains two forms of acetylcholinesterase, 
Clin. Chem. Acta 158: 1-6 (1986). 
Soreq H. and Gnatt A. Nolecular biological search for human g!'!nes 
encs>ding. chol inesterases. Hol. Nellrobiol. 1: 4 7-80 ( 1987). 
Steck T.L. 1 Weinstein R.S. 1 Straus J.H. and Wallach D.F.H. 
Inside-out red cell membrane vesicles: preparation and 
purification. Science 168: 255-257 (1970). 
Stedman E. and Stedman E. The relative choline esterase 
activities of serum and corpuscles from the blood of certain 
species. Biochem. J. 29: 2107-2111 (1935). 
Stedman E. 1 Stedman E. and Easson L.H. Choline-esterase. An 
enzyme present in the blood serum of the horse. Biochem. J. 26: 
2056-2066 (1932). 
209 
Sternberger L.A., Hardy P.H., Jr., Cuculis J,J, and Meyer H.G. 
J, The unlabelled antibody enzyme method of immunohistochemistry. 
Preparation and properties of soluble antigen-antibody complex 
(Horseradish peroxidase-antihorseradish peroxidase) and its use 
in identification of spirochetes. Histochem. Cytochem. 18: 315-
333 (1970). 
Stovner J. Variation in the cholinesterase inhibiting effect of 
succinylcholine. Scand. J. Clin. Lab. Invest. 7: 197-200 (1955). 
Stovner J., Oftedal N. and Holmboe J, The inhibition of 
cholinesterases by pancuronium. Br. J. Anaesth. 47: 949-954 
(1975). 
Stratton F., Rawlinson V.I., Merry A.H. and Thomson E.E. Positive 
direct antiglobulin test in normal individuals. II. Clin. Lab. 
Haemat. 5: 17-21 (1983). 
Streichman S., Klin A., Tatarsky I. and Livne A. Unique profile 
for erythrocyte membrane acetylcholinesterase in hereditary 
spherocytosis. Biochim. Biophys. Acta 757: 168-175 (1983). 
Suhail M. and Rizvi S.I. Erythrocyte acetylcholinesterase in type 
I (insulin dependent) diabetes mellitus. Biochem. J. 259: 879-
899 (1989). 
210 
Szasz G. Cholinesterase Bestimmung im Serum mit Acetyl-und 
Butyrylthiocholin als Substrat. Clin. Chim. Acta 19: 191-204 
(1968). 
Szelenyi J.G., Bartha E. and Hollan S.R. Acetylcholinesterase 
activity of lymphocytes: An enzyme characteristic ofT-cells. Br. 
J. Haematol. 50: 241-245 (1982). 
Thompson J.C. and Whittaker M. Pseudocholinesterase activity in 
thyroid disease. J. Clin. Path. 18: 811-812 (1965). 
Tijssen P. Practice and theory of enzyme immunoassays. (R.H. 
Burden and P.H. van Knippenberg eds. ). Elsevier (1985). 
Topilko A. and Caillou B. Acetylcholinesterase in human thymus 
cells. Blood 66: 891-895 (1985). 
Viby Mogensen J. Cholinesterase and succinylcholine. pp 7-31 
Laegeforeningens forlag (1982). 
Vincent D. I Guinet P. and Poncet J. La cholinesterase serique 
dans les maladies thyroidiennes. J. Med. Lyon 54: 563-573 (1973). 
Walker I.R., Zapf P.W. and Mackay I.R. Cyclophosphamide, 
cholinesterase and anaesthesia. Aust. N. z. J. Hed. 3: 247-251 
(1972). 
211 
Wang R. I. H. and Ross C.A. Prolonged 
succinylcholine in cancer patients 
Anesthesiology 24: 363-367 (1963). 
apnoea 
receiving 
following 
AB-132. 
Weitz M., Bjerrum O.J. and Brodbeck U. Characterization of an 
active hydrophilic erythrocyte membrane acetylcholinesterase 
obtained by limited proteolysis of the purified enzyme. Biochim. 
Biophys. Acta 776: 65-74 (1984). 
Weitz M., Bjerrum O.J., Ott P. and Brodbeck U. Quantitative 
composition and characterization of the proteins in membrane 
vesicles released from erythrocytes b y 
dimyristoylphosphatidylcholine. Membrane system without 
cytoskeleton. J. Cell. Biochem. 19: 179-191 (1982). 
Whittaker M. The pseudocholinesterase variants. Differentiation 
by means of sodium chloride. Acta Gent. (Basel) 18: 556-562 
(1968 8 ), 
Whittaker M. The pseudocholinesterase variants. Differentiation 
by means of alkyl alcohols. Acta. Genet. (Basal) 18: 325-334 
(1968b), 
Whittaker M. Plasma cholinesterase variants and the anaesthetist. 
Anaesthesia 35: 174-197 (1980). 
212 
\{hit taker M. Cholinesterases In 'Methods of Enzymic Analysis'. 
(3rd Ed.) (Bergmeyer H.U. Ed.) pp 52-74. Verlag Chimie, Weinheim 
(1984). 
Whittaker M. Cholinesterase in Beckmann, Monogr. Hum. Genet. 11: 
1-134 (Karger, Basel) 1986. 
Whittaker M. and Britten J.J. Inhibition of the plasma 
cholinesterase variants by pancuronium bromide and some of its 
analogues. Clin. Chem . .-lcta 108: 89-94 (1980). 
Whittaker M. and Britten J.J. Differential inhibition of plasma 
cholinesterase variants using the dibutyrate analogue of 
pancuronium bromide. Hum. Hered. 31: 242-247 (1981). 
whittaker M. and Britten J.J. The plasma cholinesterase variants. 
Family studies of the E1k gene. Hum. Hered. 35: 364-368 ( 1985). 
Whittaker M. and Britten J.J. E1h, a new allele at chromosome 
locus 1. Hum. Hered. 37: 54-58 (1987). 
Whittaker M. and Britten J .J. Segregation of the E 1j gene for 
plasma cholinesterase in famil~· studies. Hum. Hered. 39: 1-6 
(1989). 
Whittaker ~t., Britten J.J. and Wicks R.J. Inhibition of the 
plasma cholinesterase variants by propranolol. Br. J •. 4naes th. 
53: 511-516 (1981). 
213 
Whittaker M., Charlier A.R. and Ramaswamy S. Changes in plasma 
cholinesterase isoenzymes due to oral contraceptives. J, Reprod. 
Fert. 26:373-375 (1971). 
Whittaker M., Wicks R.J. and Britten J.J. Studies on the 
inhibition of propranolol of some erythrocyte membrane enzymes 
and plasma cholinesterase. Clin. Chim. Acta 119:107-114 (1982). 
Williams R.M. Antibodies to acetylcholinesterase. Proc. Natl. 
Acad. Sci. 62: 1175-1180 (1969). 
Wood G.J. and Hall G.M. Plasmapheresis and plasma cholinesterase. 
Br. J. Anaesth. 50: 945-949 (1978). 
Zajicek J. Studies on the histogenesis of blood platelets and 
megakaryocytes. Acta Physiol. Scand. 40: suppl. 138 (1957). 
Zanetta J.P., Rakonczay z., Reeber A., Kasa P. and Vincendon G. 
Antibodies against membrane-bound acetylcholinesterase from adult 
rat brain. FEBS .Lett. 129: 293-296 (1981). 
Zsigmond E.K. and Robins G. The effect of a series of anti-
cancer drugs on plasma cholinesterase. Can. Anaesth. Soc. J. 19: 
i5-82 ( 1972). 
214 
Appendix I 
Solutions 
Phosphate Buffer, 0.01M pH 7.2. 
NaH 2P04 .H20, 0.345gm (0.0025M) 
Na2HP04 .12H20, 2.680gm (0.0075M) 
Distilled water up to 1 litre. 
Phosphate Buffered Saline, PBS 0.01M pH 7.2. 
Phosphate buffer, 0.01M pH 7.2 
NaCl, 8.470gm (0.1450M) per litre 
For PBS/tween add 1ml tween/1 PBS. 
Unbuffered Saline, UBS, pH 7.0. 
NaCl, 8.470gm (0.1450M) 
Distilled water up to 1 litre. 
Low Ionic Strength Solution (LISS), pH 6.7. 
NaCl, 1. 79g/l 
KH 2P04 , 0. 257g/l 
Na2HP04 , 0.158g/l 
Glycine, 18g/l 
PBS/BSA, UBS/BSA and LISS/BSA contained 2g/l BSA. 
Sodium Carbonate Buffer, 0.1M pH 9.6. 
NaHC0 3 , 8. 4g/l 
Na2C0 3 , 10.6g/l 
9ml :-JaHC03 + 1ml Na2C03 • 
i 
Sodium Carbonate buffer, 0.05M pH 9.8 
NaHC03 , 4.2g/l 
Na2C03 , 5.3g/l 
6ml NaHC03 + 4ml Na2C03 • 
contained 0.001 mol/1 MgCl 2 • 
Citric Acid-Phosphate Buffer, 0.1M pH 5.0. 
Citric acid H20, 7.30gm (0.034M) 
Na2HP04 .12H20, 23.87gm (0.0667M) 
Distilled water up to l. litre 
Store at 4'C, stability 2 months. 
Tris-veronal Buffer, pH 8.7. 
Sodium Barbitone, 4.48gm 
Tris (glycine), 8.86gm 
Sodium Azide, 0.20gm 
Distilled water up to 1 litre 
0.05M Acetate/Acetic acid pH 5.0 
(a) CH 3COONa (0.05M) 4.1g/l 
(b) CH 3COOH (0.05H) 2.85ml glacial acetic 
acid made up to 1 litre 
lOOml of (a) is adjusted to pH5.0 by adding 
approximately 50ml of (b). 
ii 
Substrate Solutions 
Acetylcholinesterase Substrate. 
39.6mg 5,5' dithio-bis-2 nitrobenzoic acid 
(DTNB), in lOml phosphate buffer (O.OlM pH7.2) 
15mg sodium bicarbonate. 
108.35mg Acetylthiocholine iodide (ATI), in 
5ml distilled water. 
Cholinesterase Substrate. 
20mg DTNB in lOOml of 0.05M (6.8g/l) 
KH 2P04 pH 7. 0. 
30mg Butyrylthiocholine iodide, BTI in lOml 
distilled water. 
Add lml BTI + 9ml DTNB. 
Cholinesterase Substrate 
0.2mg a-naphthyl acetate (previously 
dissolved in acetone as a 1% solution) 
per ml 0.01M phosphate buffer pH 7.2 
and 0.5mg/ml of Fast Red TR. 
Peroxidase Substrate. 
Orthophenylenediamine, OPD. 
8 mg 1,1-phenylenediamine dihydrochloride in 
12 ml O.lM citric acid-phosphate buffer, pH5.0 
Add 5~1 30% H20 2 • Prepare shortly before use. 
iii 
Peroxidase Substrate. 
3,3' ,5,5'-tetramethylbenzidine (TMBl 0.4g/l 
in an organic base and 
0.02% H20 2 solution in a citric acid buffer 
premade (Kirkegaard and Perry Labs Inc., 
2 Cessna Court, Gaithersburg, Maryland). 
Add togetl1er in ratio 1:1 vol:vol. 
Peroxidase Substrate. 
20mg of 3-amino-9-ethyl carbazole dissolved 
in acetate buffer. To this mixture add 25~1 
of 30% H20 2 • Prepare immediately before use. 
Alkaline Phosphatase Substrate. 
40mg p-Nitrophenylphosphate capsule dissolved 
in 20ml 0.05M carbonate buffer, pH 9.8. 
iv 
Antibodies Used 
Erythrocyte AChE 
Hybridomas AE-1 and AE-2 were donated to the American Type 
Culture Collection {ATCC) by Fambrough et al. (1982). These are 
murine monoclonal antibodies to human erythrocyte AChE. 
Plasma ChE 
In addition to the commercially available rabbit anti-
cholinesterase available from DAKO, a number of other sources of 
antibody were sought. Polyclonal antisera were produced with the 
help of the Immunology Department of Plymouth Polytechnic and the 
'Binding Site' at Birmingham University. 
A pure form of serum cholinesterase was required for production 
of suitable antisera. The BCL human cholinesterase reagent is not 
highly purified, being isolated from Cohn Fraction IV from human 
plasma (Das and Lidell 1970) and is therefore unsuitable for use 
in preparing antibodies. Electrophoresis confirmed this (picture 
3). The 2 banding patterns of the BCL reagent on the right 
showing P1, P2 and a diffuse gamma band. Only the a band was 
absent compared to the normal plasma on the left. Thus, 
prec ipi tat ion techniques were employed to purify the reagent. The 
DAKO anti-cholinesterase and BCL cholinesterase reagents were 
subjected to immunoelectrophoresis (picture 4) on agar gel and 
the coomassie blue stained precipitin arc (rabbit 
IgG/cholinesterase complex) was cut out, solubilised and injected 
into 2 rabbits at Plymouth and a sheep at Birmingham. On day 1 
10pl of complex (corresponding to less than 5pg cholinesterase) 
and on day 30 50pl of complex were injected. On day 37 a trial 
V 
bleed was tested using immunoelectrophoresis of human serum and 
BCL cholinesterase against the antiserum produced . Once the 
presence of anti -cholinesterase was confirmed the animal was 
further bled and the antiserum adsorbed with human IgG. 
Picture 3 Electrophoresis banding pattern of 
normal plasma (left) and BCL reagent (middle and 
right. 
vi 
Picture 4 I mmunoelectrophoresis of BCL 
cholinesterase reagent with DAKO anti-cholinesterase . 
These polyclonals together with a number of monoclonal 
antibodies (table 31) were evaluated in an enzyme linked 
quantitation of plasma cholinesterase. 
vii 
Table 31 Antibodies Used for the Quantitation of the 
Cholinesterases 
Antibody Antigen Source Animal Type 
AE-1 AChE BTS House Monoclonal 
AE-2 AChE BTS Mouse Monoclonal 
A-032 ChE DAKO Rabbit Polyclonal 
B-1 ChE Behring Rabbit Polyclonal 
188 ChE Plymouth Rabbit Polyclonal 
288 ChE Plymouth Rabbit Polyclonal 
B'ham ChE Binding Site Sheep Polyclonal 
SSI ChE SSI Rabbit Polyclonal 
2-1 ChE SSI Mouse Monoclonal 
2-2 ChE SSI Mouse Monoclonal 
2-3 ChE SSI Mouse ~!ono clonal 
2-4 ChE SSI House Monoclonal 
SSI = State Serum Institute 
viii 
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